ANTI-B7-H3 ANTIBODIES

Abstract

Provided are antibodies that specifically recognize B7 homology 3 protein (B7-H3).

Description

INCORPORATION OF SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on May 26, 2020, is named SCT0007-401-PC_Sequence_Listing_ST5.txt, and is 581 kilobytes in size.

BACKGROUND

The B7 homology 3 protein (B7-H3) (also known as CD276 and B7RP-2, referred to herein as “B7-H3”) is a type I transmembrane glycoprotein of the immunoglobulin superfamily. Human B7-H3 contains a putative signal peptide, V-like and C-like Ig domains, a transmembrane region and a cytoplasmic domain. Exon duplication in humans results in the expression of two B7-H3 isoforms having either a single IgV-IgC-like domain (2IgB7-H3 isoform) or an IgV-IgC-IgV-IgC-like domain (4IgB7-H3 isoform) containing several conserved cysteine residues. The predominant B7-H3 isoform in human tissues and cell lines is the 4IgB7-H3 isoform (Steinberger et al., 2004).

B7-H3 has been reported as having both co-stimulatory and co-inhibitory signaling functions (Chapoval et al., 2001; Suh et al., 2003; Prasad et al., 2004; Wang et al., 2005). For example, in vitro studies have shown B7-H3's co-stimulatory function since B7-H3 was able to increase proliferation of cytotoxic T-lymphocytes (CTLs) and upregulate interferon gamma (IFN-7) production in the presence of anti-CD3 antibody to mimic the T cell receptor signal (Chapoval et al., 2001). Moreover, in vivo studies using cardiac allografts in B7-H3 −/− mice showed decreased production of key cytokine, chemokine and chemokine receptor mRNA transcripts {e.g., IL-2, IFN-γ, monocyte chemoattractant protein (MCP-1) and IFN-inducible protein (IP)-10) as compared to wild-type control (Wang et al., 2005). In contrast, B7-H3 co-inhibitory function has been observed, for example, in mice where B7-H3 protein inhibited T-cell activation and effector cytokine production (Suh et al., 2003). Although no ligands have been identified for human B7-H3, murine B7-H3 has been found to bind to the triggering receptor expressed on myeloid cells (TREM-) like transcript 2 (TLT-2), a modulator of adaptive and innate immunity cellular responses. Binding of murine B7-H3 to TLT-2 on CD8+ T-cells enhances T-cell effector functions such as proliferation, cytotoxicity and cytokine production (Hashiguchi et al., 2008).

B7-H3 is not constitutively expressed in many immune cells (e.g., natural killer (NK) cells, T-cells, and antigen-presenting cells (APCs)), however, its expression can be induced. Further, the expression of B7-H3 is not restricted to immune cells. B7-H3 transcripts are expressed in a variety of human tissues including colon, heart, liver, placenta, prostate, small intestine, testis, and uterus, as well as osteoblasts, fibroblasts, epithelial cells, and other cells of non-lymphoid lineage, potentially indicating immunological and non-immunological functions (Nygren et al., 2011). However, protein expression in normal tissue is typically maintained at a low level and thus, may be subject to post-transcriptional regulation.

B7-H3 is also expressed in a variety of human cancers, including prostate cancer, clear cell renal cell carcinoma, glioma, melanoma, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, pancreatic cancer, gastric cancer, acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), ovarian cancer, colorectal cancer, colon cancer, renal cancer, hepatocellular carcinoma, kidney cancer, head and neck cancer, hypopharyngeal squamous cell carcinoma, glioblastoma, neuroblastoma, breast cancer, endometrial cancer, and urothelial cell carcinoma (Chapoval et al., 2001; Saatian et al., 2004; Castriconi et al., 2004; Sun et al., 2002).

Although the role of B7-H3 in cancer cells is unclear, its expression may orchestrate signaling events that may protect cancer cells from innate and adaptive immune responses. For example, B7-H3 is overexpressed in high-grade prostatic intraepithelial neoplasia and adenocarcinomas of the prostate, and high expression levels of B7-H3 in these cancerous cells is associated with an increased risk of cancer progression after surgery (Roth et al., 2007). Further, tumor B7-H3 expression in NSCLC inversely correlated with the number of tumor-infiltrating lymphocytes and significantly correlated with lymph node metastasis (Sun et al., 2006). The level of circulating soluble B7-H3 in NSCLC patients has also been associated with higher tumor stage, tumor size, lymph node metastasis, and distant metastasis (Yamato et al., 2009). These lines of evidence suggest that B7-H3 is exploited by tumors as an immune evasion pathway (Hofmeyer et al., 2008).

B7-H3 may also play an important role in T-cell-mediated antitumor responses in a context dependent manner. For example, gastric cancer tumor cell expression of B7-H3 positively correlated with survival time, infiltration depth, and tissue type (Wu et al., 2006). Further, high expression of B7-H3 in pancreatic tumor cells was associated with patient survival after surgical resection and significantly correlated with the number of tumor-infiltrating CD8+ T-cells (Loos et al., 2009).

Thus, despite all prior advances, a need remains for improved compositions capable of binding to cancer cells and of facilitating or mediating an immune response against cancer cells. Such compositions may be used to diagnose and treat such cancers either by reducing or enhancing the capabilities of B7-H3 to mediate T-cell activation or by recognizing and killing cancer cells that express B7-H3. The present invention is directed to such compositions and to their uses in diagnostics and in the treatment of diseases such as cancer.

SUMMARY

Provided are antibodies that recognize and specifically bind to human B7-B3. In one embodiment, the disclosure provides an antibody that binds to SEQ ID NO:1.

BRIEF DESCRIPTION OF THE SEQUENCES

TABLE 1
SEQ ID NO. Description of sequence
1          Human B7-H3 protein sequence
2          Human B7-H3 (4Ig) His tagged protein sequence
3          Human B7-H3 (4Ig) Human Fc tagged protein sequence
4          SCT-Da001 mature heavy chain variable domain protein sequence
5          SCT-Da002 mature heavy chain variable domain protein sequence
6          SCT-Da003 mature heavy chain variable domain protein sequence
7          SCT-Da004 mature heavy chain variable domain protein sequence
8          SCT-Da005 mature heavy chain variable domain protein sequence
9          SCT-Da006 mature heavy chain variable domain protein sequence
9          SCT-Da007 mature heavy chain variable domain protein sequence
9          SCT-Da008 mature heavy chain variable domain protein sequence
9          SCT-Da009 mature heavy chain variable domain protein sequence
10         SCT-Da010 mature heavy chain variable domain protein sequence
11         SCT-Da011 mature heavy chain variable domain protein sequence
11         SCT-Da012 mature heavy chain variable domain protein sequence
12         SCT-Da013 mature heavy chain variable domain protein sequence
13         SCT-Da014 mature heavy chain variable domain protein sequence
14         SCT-Da015 mature heavy chain variable domain protein sequence
15         SCT-Da016 mature heavy chain variable domain protein sequence
16         SCT-Da017 mature heavy chain variable domain protein sequence
16         SCT-Da018 mature heavy chain variable domain protein sequence
17         SCT-Da019 mature heavy chain variable domain protein sequence
18         SCT-Da020 mature heavy chain variable domain protein sequence
19         SCT-Da021 mature heavy chain variable domain protein sequence
19         SCT-Da022 mature heavy chain variable domain protein sequence
21         SCT-Da023 mature heavy chain variable domain protein sequence
22         SCT-Da024 mature heavy chain variable domain protein sequence
22         SCT-Da025 mature heavy chain variable domain protein sequence
22         SCT-Da026 mature heavy chain variable domain protein sequence
22         SCT-Da027 mature heavy chain variable domain protein sequence
23         SCT-Da028 mature heavy chain variable domain protein sequence
24         SCT-Da029 mature heavy chain variable domain protein sequence
25         SCT-Da030 mature heavy chain variable domain protein sequence
26         SCT-Da031 mature heavy chain variable domain protein sequence
27         SCT-Da032 mature heavy chain variable domain protein sequence
28         SCT-Da033 mature heavy chain variable domain protein sequence
29         SCT-Da034 mature heavy chain variable domain protein sequence
30         SCT-Da035 mature heavy chain variable domain protein sequence
31         SCT-Da036 mature heavy chain variable domain protein sequence
32         SCT-Da037 mature heavy chain variable domain protein sequence
33         SCT-Da038 mature heavy chain variable domain protein sequence
34         SCT-Da039 mature heavy chain variable domain protein sequence
35         SCT-Da040 mature heavy chain variable domain protein sequence
36         SCT-Da041 mature heavy chain variable domain protein sequence
37         SCT-Da042 mature heavy chain variable domain protein sequence
38         SCT-Da043 mature heavy chain variable domain protein sequence
39         SCT-Da044 mature heavy chain variable domain protein sequence
39         SCT-Da045 mature heavy chain variable domain protein sequence
40         SCT-Da046 mature heavy chain variable domain protein sequence
41         SCT-Da047 mature heavy chain variable domain protein sequence
41         SCT-Da048 mature heavy chain variable domain protein sequence
42         SCT-Da049 mature heavy chain variable domain protein sequence
43         SCT-Da050 mature heavy chain variable domain protein sequence
44         SCT-Da051 mature heavy chain variable domain protein sequence
45         SCT-Da052 mature heavy chain variable domain protein sequence
46         SCT-Da053 mature heavy chain variable domain protein sequence
47         SCT-Da054 mature heavy chain variable domain protein sequence
48         SCT-Da055 mature heavy chain variable domain protein sequence
49         SCT-Da056 mature heavy chain variable domain protein sequence
50         SCT-Da057 mature heavy chain variable domain protein sequence
51         SCT-Da058 mature heavy chain variable domain protein sequence
52         SCT-Da059 mature heavy chain variable domain protein sequence
53         SCT-Da060 mature heavy chain variable domain protein sequence
54         SCT-Da061 mature heavy chain variable domain protein sequence
55         SCT-Da062 mature heavy chain variable domain protein sequence
56         SCT-Da063 mature heavy chain variable domain protein sequence
57         SCT-Da064 mature heavy chain variable domain protein sequence
57         SCT-Da065 mature heavy chain variable domain protein sequence
58         SCT-Da066 mature heavy chain variable domain protein sequence
59         SCT-Da067 mature heavy chain variable domain protein sequence
59         SCT-Da068 mature heavy chain variable domain protein sequence
60         SCT-Da069 mature heavy chain variable domain protein sequence
60         SCT-Da070 mature heavy chain variable domain protein sequence
60         SCT-Da071 mature heavy chain variable domain protein sequence
60         SCT-Da072 mature heavy chain variable domain protein sequence
61         SCT-Da073 mature heavy chain variable domain protein sequence
62         SCT-Da074 mature heavy chain variable domain protein sequence
62         SCT-Da075 mature heavy chain variable domain protein sequence
62         SCT-Da076 mature heavy chain variable domain protein sequence
63         SCT-Da077 mature heavy chain variable domain protein sequence
63         SCT-Da078 mature heavy chain variable domain protein sequence
64         SCT-Da079 mature heavy chain variable domain protein sequence
65         SCT-Da080 mature heavy chain variable domain protein sequence
66         SCT-Da081 mature heavy chain variable domain protein sequence
67         SCT-Da082 mature heavy chain variable domain protein sequence
68         SCT-Da083 mature heavy chain variable domain protein sequence
68         SCT-Da084 mature heavy chain variable domain protein sequence
69         SCT-Da085 mature heavy chain variable domain protein sequence
70         SCT-Da086 mature heavy chain variable domain protein sequence
71         SCT-Da087 mature heavy chain variable domain protein sequence
72         SCT-Da088 mature heavy chain variable domain protein sequence
72         SCT-Da089 mature heavy chain variable domain protein sequence
72         SCT-Da090 mature heavy chain variable domain protein sequence
73         SCT-Da091 mature heavy chain variable domain protein sequence
74         SCT-Da092 mature heavy chain variable domain protein sequence
75         SCT-Da093 mature heavy chain variable domain protein sequence
75         SCT-Da094 mature heavy chain variable domain protein sequence
75         SCT-Da095 mature heavy chain variable domain protein sequence
76         SCT-Da096 mature heavy chain variable domain protein sequence
77         SCT-Da097 mature heavy chain variable domain protein sequence
77         SCT-Da098 mature heavy chain variable domain protein sequence
77         SCT-Da099 mature heavy chain variable domain protein sequence
77         SCT-Da100 mature heavy chain variable domain protein sequence
78         SCT-Da101 mature heavy chain variable domain protein sequence
79         SCT-Da102 mature heavy chain variable domain protein sequence
80         SCT-Da103 mature heavy chain variable domain protein sequence
80         SCT-Da104 mature heavy chain variable domain protein sequence
80         SCT-Da105 mature heavy chain variable domain protein sequence
81         SCT-Da106 mature heavy chain variable domain protein sequence
82         SCT-Da107 mature heavy chain variable domain protein sequence
82         SCT-Da108 mature heavy chain variable domain protein sequence
82         SCT-Da109 mature heavy chain variable domain protein sequence
82         SCT-Da110 mature heavy chain variable domain protein sequence
83         SCT-Da111 mature heavy chain variable domain protein sequence
83         SCT-Da112 mature heavy chain variable domain protein sequence
83         SCT-Da113 mature heavy chain variable domain protein sequence
83         SCT-Da114 mature heavy chain variable domain protein sequence
84         SCT-Da115 mature heavy chain variable domain protein sequence
85         SCT-Da116 mature heavy chain variable domain protein sequence
85         SCT-Da117 mature heavy chain variable domain protein sequence
85         SCT-Da118 mature heavy chain variable domain protein sequence
85         SCT-Da119 mature heavy chain variable domain protein sequence
86         SCT-Da120 mature heavy chain variable domain protein sequence
87         SCT-Da121 mature heavy chain variable domain protein sequence
87         SCT-Da122 mature heavy chain variable domain protein sequence
87         SCT-Da123 mature heavy chain variable domain protein sequence
87         SCT-Da124 mature heavy chain variable domain protein sequence
87         SCT-Da125 mature heavy chain variable domain protein sequence
87         SCT-Da126 mature heavy chain variable domain protein sequence
87         SCT-Da127 mature heavy chain variable domain protein sequence
87         SCT-Da128 mature heavy chain variable domain protein sequence
88         SCT-Da129 mature heavy chain variable domain protein sequence
89         SCT-Da130 mature heavy chain variable domain protein sequence
89         SCT-Da131 mature heavy chain variable domain protein sequence
90         SCT-Da132 mature heavy chain variable domain protein sequence
91         SCT-Da133 mature heavy chain variable domain protein sequence
91         SCT-Da134 mature heavy chain variable domain protein sequence
91         SCT-Da135 mature heavy chain variable domain protein sequence
91         SCT-Da136 mature heavy chain variable domain protein sequence
92         SCT-Da137 mature heavy chain variable domain protein sequence
92         SCT-Da138 mature heavy chain variable domain protein sequence
92         SCT-Da139 mature heavy chain variable domain protein sequence
93         SCT-Da140 mature heavy chain variable domain protein sequence
94         SCT-Da141 mature heavy chain variable domain protein sequence
95         SCT-Da142 mature heavy chain variable domain protein sequence
96         SCT-Da143 mature heavy chain variable domain protein sequence
97         SCT-Da144 mature heavy chain variable domain protein sequence
98         SCT-Da145 mature heavy chain variable domain protein sequence
99         SCT-Da146 mature heavy chain variable domain protein sequence
99         SCT-Da147 mature heavy chain variable domain protein sequence
99         SCT-Da148 mature heavy chain variable domain protein sequence
99         SCT-Da149 mature heavy chain variable domain protein sequence
99         SCT-Da150 mature heavy chain variable domain protein sequence
99         SCT-Da151 mature heavy chain variable domain protein sequence
99         SCT-Da152 mature heavy chain variable domain protein sequence
99         SCT-Da153 mature heavy chain variable domain protein sequence
99         SCT-Da154 mature heavy chain variable domain protein sequence
100        SCT-Da155 mature heavy chain variable domain protein sequence
101        SCT-Da156 mature heavy chain variable domain protein sequence
101        SCT-Da157 mature heavy chain variable domain protein sequence
101        SCT-Da158 mature heavy chain variable domain protein sequence
101        SCT-Da159 mature heavy chain variable domain protein sequence
102        SCT-Da160 mature heavy chain variable domain protein sequence
103        SCT-Da161 mature heavy chain variable domain protein sequence
104        SCT-Da162 mature heavy chain variable domain protein sequence
105        SCT-Da163 mature heavy chain variable domain protein sequence
105        SCT-Da164 mature heavy chain variable domain protein sequence
105        SCT-Da165 mature heavy chain variable domain protein sequence
105        SCT-Da166 mature heavy chain variable domain protein sequence
106        SCT-Da167 mature heavy chain variable domain protein sequence
106        SCT-Da168 mature heavy chain variable domain protein sequence
106        SCT-Da169 mature heavy chain variable domain protein sequence
106        SCT-Da170 mature heavy chain variable domain protein sequence
106        SCT-Da171 mature heavy chain variable domain protein sequence
106        SCT-Da172 mature heavy chain variable domain protein sequence
106        SCT-Da173 mature heavy chain variable domain protein sequence
106        SCT-Da174 mature heavy chain variable domain protein sequence
107        SCT-Da175 mature heavy chain variable domain protein sequence
108        SCT-Da176 mature heavy chain variable domain protein sequence
108        SCT-Da177 mature heavy chain variable domain protein sequence
108        SCT-Da178 mature heavy chain variable domain protein sequence
109        SCT-Da179 mature heavy chain variable domain protein sequence
110        SCT-Da180 mature heavy chain variable domain protein sequence
111        SCT-Da181 mature heavy chain variable domain protein sequence
112        SCT-Da182 mature heavy chain variable domain protein sequence
113        SCT-Da183 mature heavy chain variable domain protein sequence
114        SCT-Da184 mature heavy chain variable domain protein sequence
115        SCT-Da185 mature heavy chain variable domain protein sequence
116        SCT-Da186 mature heavy chain variable domain protein sequence
117        SCT-Da187 mature heavy chain variable domain protein sequence
118        SCT-Da188 mature heavy chain variable domain protein sequence
119        SCT-Da189 mature heavy chain variable domain protein sequence
120        SCT-Da190 mature heavy chain variable domain protein sequence
121        SCT-Da191 mature heavy chain variable domain protein sequence
121        SCT-Da192 mature heavy chain variable domain protein sequence
122        SCT-Da193 mature heavy chain variable domain protein sequence
123        SCT-Da194 mature heavy chain variable domain protein sequence
124        SCT-Da195 mature heavy chain variable domain protein sequence
124        SCT-Da196 mature heavy chain variable domain protein sequence
125        SCT-Da197 mature heavy chain variable domain protein sequence
126        SCT-Da198 mature heavy chain variable domain protein sequence
126        SCT-Da199 mature heavy chain variable domain protein sequence
126        SCT-Da200 mature heavy chain variable domain protein sequence
127        SCT-Da201 mature heavy chain variable domain protein sequence
128        SCT-Da202 mature heavy chain variable domain protein sequence
128        SCT-Da203 mature heavy chain variable domain protein sequence
128        SCT-Da204 mature heavy chain variable domain protein sequence
128        SCT-Da205 mature heavy chain variable domain protein sequence
129        SCT-Da206 mature heavy chain variable domain protein sequence
130        SCT-Da207 mature heavy chain variable domain protein sequence
131        SCT-Da208 mature heavy chain variable domain protein sequence
132        SCT-Da209 mature heavy chain variable domain protein sequence
133        SCT-Da210 mature heavy chain variable domain protein sequence
134        SCT-Da211 mature heavy chain variable domain protein sequence
135        SCT-Da212 mature heavy chain variable domain protein sequence
136        SCT-Da213 mature heavy chain variable domain protein sequence
137        SCT-Da214 mature heavy chain variable domain protein sequence
138        SCT-Da215 mature heavy chain variable domain protein sequence
139        SCT-Da216 mature heavy chain variable domain protein sequence
139        SCT-Da217 mature heavy chain variable domain protein sequence
140        SCT-Da218 mature heavy chain variable domain protein sequence
141        SCT-Da219 mature heavy chain variable domain protein sequence
142        SCT-Da220 mature heavy chain variable domain protein sequence
143        SCT-Da221 mature heavy chain variable domain protein sequence
144        SCT-Da222 mature heavy chain variable domain protein sequence
144        SCT-Da223 mature heavy chain variable domain protein sequence
145        SCT-Da224 mature heavy chain variable domain protein sequence
146        SCT-Da225 mature heavy chain variable domain protein sequence
147        SCT-Da226 mature heavy chain variable domain protein sequence
148        SCT-Da227 mature heavy chain variable domain protein sequence
149        SCT-Da228 mature heavy chain variable domain protein sequence
150        SCT-Da229 mature heavy chain variable domain protein sequence
151        SCT-Da230 mature heavy chain variable domain protein sequence
152        SCT-Da231 mature heavy chain variable domain protein sequence
153        SCT-Da232 mature heavy chain variable domain protein sequence
154        SCT-Da233 mature heavy chain variable domain protein sequence
155        SCT-Da234 mature heavy chain variable domain protein sequence
156        SCT-Da235 mature heavy chain variable domain protein sequence
157        SCT-Da236 mature heavy chain variable domain protein sequence
157        SCT-Da237 mature heavy chain variable domain protein sequence
158        SCT-Da238 mature heavy chain variable domain protein sequence
159        SCT-Da239 mature heavy chain variable domain protein sequence
160        SCT-Da240 mature heavy chain variable domain protein sequence
161        SCT-Da241 mature heavy chain variable domain protein sequence
162        SCT-Da242 mature heavy chain variable domain protein sequence
163        SCT-Da243 mature heavy chain variable domain protein sequence
164        SCT-Da244 mature heavy chain variable domain protein sequence
165        SCT-Da245 mature heavy chain variable domain protein sequence
165        SCT-Da246 mature heavy chain variable domain protein sequence
166        SCT-Da247 mature heavy chain variable domain protein sequence
167        SCT-Da248 mature heavy chain variable domain protein sequence
168        SCT-Da249 mature heavy chain variable domain protein sequence
169        SCT-Da250 mature heavy chain variable domain protein sequence
170        SCT-Da251 mature heavy chain variable domain protein sequence
171        SCT-Da252 mature heavy chain variable domain protein sequence
172        SCT-Da253 mature heavy chain variable domain protein sequence
173        SCT-Da254 mature heavy chain variable domain protein sequence
173        SCT-Da255 mature heavy chain variable domain protein sequence
174        SCT-Da256 mature heavy chain variable domain protein sequence
175        SCT-Da257 mature heavy chain variable domain protein sequence
176        SCT-Da258 mature heavy chain variable domain protein sequence
177        SCT-Da259 mature heavy chain variable domain protein sequence
178        SCT-Da260 mature heavy chain variable domain protein sequence
179        SCT-Da261 mature heavy chain variable domain protein sequence
180        SCT-Da262 mature heavy chain variable domain protein sequence
181        SCT-Da263 mature heavy chain variable domain protein sequence
182        SCT-Da264 mature heavy chain variable domain protein sequence
183        SCT-Da265 mature heavy chain variable domain protein sequence
184        SCT-Da266 mature heavy chain variable domain protein sequence
185        SCT-Da267 mature heavy chain variable domain protein sequence
186        SCT-Da268 mature heavy chain variable domain protein sequence
187        SCT-Da269 mature heavy chain variable domain protein sequence
188        SCT-Da270 mature heavy chain variable domain protein sequence
188        SCT-Da271 mature heavy chain variable domain protein sequence
189        SCT-Da272 mature heavy chain variable domain protein sequence
190        SCT-Da273 mature heavy chain variable domain protein sequence
190        SCT-Da274 mature heavy chain variable domain protein sequence
191        SCT-Da275 mature heavy chain variable domain protein sequence
192        SCT-Da276 mature heavy chain variable domain protein sequence
193        SCT-Da277 mature heavy chain variable domain protein sequence
194        SCT-Da278 mature heavy chain variable domain protein sequence
194        SCT-Da279 mature heavy chain variable domain protein sequence
196        SCT-Da280 mature heavy chain variable domain protein sequence
197        SCT-Da281 mature heavy chain variable domain protein sequence
198        SCT-Da282 mature heavy chain variable domain protein sequence
199        SCT-Da283 mature heavy chain variable domain protein sequence
199        SCT-Da284 mature heavy chain variable domain protein sequence
199        SCT-Da285 mature heavy chain variable domain protein sequence
199        SCT-Da286 mature heavy chain variable domain protein sequence
199        SCT-Da287 mature heavy chain variable domain protein sequence
199        SCT-Da288 mature heavy chain variable domain protein sequence
199        SCT-Da289 mature heavy chain variable domain protein sequence
199        SCT-Da290 mature heavy chain variable domain protein sequence
199        SCT-Da291 mature heavy chain variable domain protein sequence
199        SCT-Da292 mature heavy chain variable domain protein sequence
199        SCT-Da293 mature heavy chain variable domain protein sequence
200        SCT-Da294 mature heavy chain variable domain protein sequence
200        SCT-Da295 mature heavy chain variable domain protein sequence
200        SCT-Da296 mature heavy chain variable domain protein sequence
200        SCT-Da297 mature heavy chain variable domain protein sequence
200        SCT-Da298 mature heavy chain variable domain protein sequence
200        SCT-Da299 mature heavy chain variable domain protein sequence
200        SCT-Da300 mature heavy chain variable domain protein sequence
200        SCT-Da301 mature heavy chain variable domain protein sequence
200        SCT-Da302 mature heavy chain variable domain protein sequence
200        SCT-Da303 mature heavy chain variable domain protein sequence
201        SCT-Da304 mature heavy chain variable domain protein sequence
202        SCT-Da305 mature heavy chain variable domain protein sequence
203        SCT-Da306 mature heavy chain variable domain protein sequence
204        SCT-Da307 mature heavy chain variable domain protein sequence
204        SCT-Da308 mature heavy chain variable domain protein sequence
205        SCT-Da309 mature heavy chain variable domain protein sequence
205        SCT-Da310 mature heavy chain variable domain protein sequence
206        SCT-Da311 mature heavy chain variable domain protein sequence
207        SCT-Da312 mature heavy chain variable domain protein sequence
208        SCT-Da313 mature heavy chain variable domain protein sequence
209        SCT-Da314 mature heavy chain variable domain protein sequence
210        SCT-Da315 mature heavy chain variable domain protein sequence
211        SCT-Da316 mature heavy chain variable domain protein sequence
212        SCT-Da317 mature heavy chain variable domain protein sequence
213        SCT-Da318 mature heavy chain variable domain protein sequence
214        SCT-Da319 mature heavy chain variable domain protein sequence
215        SCT-Da320 mature heavy chain variable domain protein sequence
215        SCT-Da321 mature heavy chain variable domain protein sequence
216        SCT-Da322 mature heavy chain variable domain protein sequence
217        SCT-Da323 mature heavy chain variable domain protein sequence
218        SCT-Da324 mature heavy chain variable domain protein sequence
219        SCT-Da325 mature heavy chain variable domain protein sequence
220        SCT-Da326 mature heavy chain variable domain protein sequence
221        SCT-Da327 mature heavy chain variable domain protein sequence
222        SCT-Da328 mature heavy chain variable domain protein sequence
222        SCT-Da329 mature heavy chain variable domain protein sequence
222        SCT-Da330 mature heavy chain variable domain protein sequence
223        SCT-Da331 mature heavy chain variable domain protein sequence
224        SCT-Da332 mature heavy chain variable domain protein sequence
225        SCT-Da333 mature heavy chain variable domain protein sequence
225        SCT-Da334 mature heavy chain variable domain protein sequence
225        SCT-Da335 mature heavy chain variable domain protein sequence
226        SCT-Da336 mature heavy chain variable domain protein sequence
227        SCT-Da337 mature heavy chain variable domain protein sequence
228        SCT-Da338 mature heavy chain variable domain protein sequence
229        SCT-Da339 mature heavy chain variable domain protein sequence
230        SCT-Da340 mature heavy chain variable domain protein sequence
231        SCT-Da341 mature heavy chain variable domain protein sequence
232        SCT-Da342 mature heavy chain variable domain protein sequence
233        SCT-Da343 mature heavy chain variable domain protein sequence
234        SCT-Da344 mature heavy chain variable domain protein sequence
235        SCT-Da345 mature heavy chain variable domain protein sequence
236        SCT-Da346 mature heavy chain variable domain protein sequence
237        SCT-Da347 mature heavy chain variable domain protein sequence
238        SCT-Da348 mature heavy chain variable domain protein sequence
239        SCT-Da349 mature heavy chain variable domain protein sequence
239        SCT-Da350 mature heavy chain variable domain protein sequence
239        SCT-Da351 mature heavy chain variable domain protein sequence
240        SCT-Da352 mature heavy chain variable domain protein sequence
241        SCT-Da353 mature heavy chain variable domain protein sequence
242        SCT-Da354 mature heavy chain variable domain protein sequence
242        SCT-Da355 mature heavy chain variable domain protein sequence
242        SCT-Da356 mature heavy chain variable domain protein sequence
242        SCT-Da357 mature heavy chain variable domain protein sequence
243        SCT-Da358 mature heavy chain variable domain protein sequence
244        SCT-Da359 mature heavy chain variable domain protein sequence
245        SCT-Da360 mature heavy chain variable domain protein sequence
246        SCT-Da361 mature heavy chain variable domain protein sequence
246        SCT-Da362 mature heavy chain variable domain protein sequence
247        SCT-Da001 mature light chain variable domain protein sequence
248        SCT-Da002 mature light chain variable domain protein sequence
249        SCT-Da003 mature light chain variable domain protein sequence
249        SCT-Da071 mature light chain variable domain protein sequence
249        SCT-Da073 mature light chain variable domain protein sequence
249        SCT-Da076 mature light chain variable domain protein sequence
250        SCT-Da004 mature light chain variable domain protein sequence
250        SCT-Da021 mature light chain variable domain protein sequence
250        SCT-Da022 mature light chain variable domain protein sequence
250        SCT-Da025 mature light chain variable domain protein sequence
251        SCT-Da005 mature light chain variable domain protein sequence
252        SCT-Da006 mature light chain variable domain protein sequence
252        SCT-Da283 mature light chain variable domain protein sequence
253        SCT-Da007 mature light chain variable domain protein sequence
254        SCT-Da008 mature light chain variable domain protein sequence
254        SCT-Da011 mature light chain variable domain protein sequence
254        SCT-Da013 mature light chain variable domain protein sequence
255        SCT-Da009 mature light chain variable domain protein sequence
256        SCT-Da010 mature light chain variable domain protein sequence
256        SCT-Da012 mature light chain variable domain protein sequence
257        SCT-Da014 mature light chain variable domain protein sequence
257        SCT-Da019 mature light chain variable domain protein sequence
257        SCT-Da080 mature light chain variable domain protein sequence
258        SCT-Da015 mature light chain variable domain protein sequence
259        SCT-Da016 mature light chain variable domain protein sequence
260        SCT-Da017 mature light chain variable domain protein sequence
261        SCT-Da018 mature light chain variable domain protein sequence
261        SCT-Da164 mature light chain variable domain protein sequence
262        SCT-Da020 mature light chain variable domain protein sequence
262        SCT-Da175 mature light chain variable domain protein sequence
263        SCT-Da023 mature light chain variable domain protein sequence
263        SCT-Da024 mature light chain variable domain protein sequence
264        SCT-Da026 mature light chain variable domain protein sequence
264        SCT-Da063 mature light chain variable domain protein sequence
264        SCT-Da068 mature light chain variable domain protein sequence
264        SCT-Da077 mature light chain variable domain protein sequence
264        SCT-Da285 mature light chain variable domain protein sequence
264        SCT-Da296 mature light chain variable domain protein sequence
265        SCT-Da027 mature light chain variable domain protein sequence
265        SCT-Da303 mature light chain variable domain protein sequence
265        SCT-Da357 mature light chain variable domain protein sequence
266        SCT-Da028 mature light chain variable domain protein sequence
266        SCT-Da034 mature light chain variable domain protein sequence
267        SCT-Da029 mature light chain variable domain protein sequence
267        SCT-Da163 mature light chain variable domain protein sequence
268        SCT-Da030 mature light chain variable domain protein sequence
269        SCT-Da031 mature light chain variable domain protein sequence
270        SCT-Da032 mature light chain variable domain protein sequence
271        SCT-Da033 mature light chain variable domain protein sequence
272        SCT-Da035 mature light chain variable domain protein sequence
273        SCT-Da036 mature light chain variable domain protein sequence
274        SCT-Da037 mature light chain variable domain protein sequence
275        SCT-Da038 mature light chain variable domain protein sequence
276        SCT-Da039 mature light chain variable domain protein sequence
277        SCT-Da040 mature light chain variable domain protein sequence
278        SCT-Da041 mature light chain variable domain protein sequence
279        SCT-Da042 mature light chain variable domain protein sequence
280        SCT-Da043 mature light chain variable domain protein sequence
281        SCT-Da044 mature light chain variable domain protein sequence
282        SCT-Da045 mature light chain variable domain protein sequence
283        SCT-Da046 mature light chain variable domain protein sequence
283        SCT-Da083 mature light chain variable domain protein sequence
283        SCT-Da176 mature light chain variable domain protein sequence
284        SCT-Da047 mature light chain variable domain protein sequence
284        SCT-Da146 mature light chain variable domain protein sequence
285        SCT-Da048 mature light chain variable domain protein sequence
286        SCT-Da049 mature light chain variable domain protein sequence
287        SCT-Da050 mature light chain variable domain protein sequence
287        SCT-Da053 mature light chain variable domain protein sequence
288        SCT-Da051 mature light chain variable domain protein sequence
289        SCT-Da052 mature light chain variable domain protein sequence
290        SCT-Da054 mature light chain variable domain protein sequence
291        SCT-Da055 mature light chain variable domain protein sequence
292        SCT-Da056 mature light chain variable domain protein sequence
293        SCT-Da057 mature light chain variable domain protein sequence
293        SCT-Da086 mature light chain variable domain protein sequence
293        SCT-Da090 mature light chain variable domain protein sequence
293        SCT-Da286 mature light chain variable domain protein sequence
294        SCT-Da058 mature light chain variable domain protein sequence
294        SCT-Da059 mature light chain variable domain protein sequence
294        SCT-Da134 mature light chain variable domain protein sequence
294        SCT-Da198 mature light chain variable domain protein sequence
294        SCT-Da202 mature light chain variable domain protein sequence
294        SCT-Da288 mature light chain variable domain protein sequence
295        SCT-Da060 mature light chain variable domain protein sequence
296        SCT-Da061 mature light chain variable domain protein sequence
296        SCT-Da147 mature light chain variable domain protein sequence
297        SCT-Da062 mature light chain variable domain protein sequence
298        SCT-Da064 mature light chain variable domain protein sequence
299        SCT-Da065 mature light chain variable domain protein sequence
300        SCT-Da066 mature light chain variable domain protein sequence
301        SCT-Da067 mature light chain variable domain protein sequence
301        SCT-Da284 mature light chain variable domain protein sequence
302        SCT-Da069 mature light chain variable domain protein sequence
303        SCT-Da070 mature light chain variable domain protein sequence
304        SCT-Da072 mature light chain variable domain protein sequence
304        SCT-Da116 mature light chain variable domain protein sequence
304        SCT-Da145 mature light chain variable domain protein sequence
304        SCT-Da148 mature light chain variable domain protein sequence
304        SCT-Da157 mature light chain variable domain protein sequence
304        SCT-Da299 mature light chain variable domain protein sequence
304        SCT-Da349 mature light chain variable domain protein sequence
305        SCT-Da074 mature light chain variable domain protein sequence
305        SCT-Da089 mature light chain variable domain protein sequence
305        SCT-Da247 mature light chain variable domain protein sequence
306        SCT-Da075 mature light chain variable domain protein sequence
307        SCT-Da078 mature light chain variable domain protein sequence
308        SCT-Da079 mature light chain variable domain protein sequence
309        SCT-Da081 mature light chain variable domain protein sequence
310        SCT-Da082 mature light chain variable domain protein sequence
311        SCT-Da084 mature light chain variable domain protein sequence
312        SCT-Da085 mature light chain variable domain protein sequence
312        SCT-Da172 mature light chain variable domain protein sequence
312        SCT-Da291 mature light chain variable domain protein sequence
313        SCT-Da087 mature light chain variable domain protein sequence
313        SCT-Da131 mature light chain variable domain protein sequence
314        SCT-Da088 mature light chain variable domain protein sequence
314        SCT-Da156 mature light chain variable domain protein sequence
315        SCT-Da091 mature light chain variable domain protein sequence
316        SCT-Da092 mature light chain variable domain protein sequence
316        SCT-Da140 mature light chain variable domain protein sequence
317        SCT-Da093 mature light chain variable domain protein sequence
317        SCT-Da209 mature light chain variable domain protein sequence
317        SCT-Da211 mature light chain variable domain protein sequence
318        SCT-Da094 mature light chain variable domain protein sequence
318        SCT-Da101 mature light chain variable domain protein sequence
318        SCT-Da105 mature light chain variable domain protein sequence
318        SCT-Da106 mature light chain variable domain protein sequence
318        SCT-Da112 mature light chain variable domain protein sequence
318        SCT-Da118 mature light chain variable domain protein sequence
318        SCT-Da129 mature light chain variable domain protein sequence
318        SCT-Da151 mature light chain variable domain protein sequence
318        SCT-Da289 mature light chain variable domain protein sequence
318        SCT-Da300 mature light chain variable domain protein sequence
319        SCT-Da095 mature light chain variable domain protein sequence
320        SCT-Da096 mature light chain variable domain protein sequence
321        SCT-Da097 mature light chain variable domain protein sequence
321        SCT-Da102 mature light chain variable domain protein sequence
322        SCT-Da098 mature light chain variable domain protein sequence
322        SCT-Da159 mature light chain variable domain protein sequence
323        SCT-Da099 mature light chain variable domain protein sequence
324        SCT-Da100 mature light chain variable domain protein sequence
324        SCT-Da301 mature light chain variable domain protein sequence
325        SCT-Da103 mature light chain variable domain protein sequence
326        SCT-Da104 mature light chain variable domain protein sequence
326        SCT-Da117 mature light chain variable domain protein sequence
326        SCT-Da123 mature light chain variable domain protein sequence
327        SCT-Da107 mature light chain variable domain protein sequence
328        SCT-Da108 mature light chain variable domain protein sequence
328        SCT-Da295 mature light chain variable domain protein sequence
329        SCT-Da109 mature light chain variable domain protein sequence
329        SCT-Da133 mature light chain variable domain protein sequence
329        SCT-Da191 mature light chain variable domain protein sequence
329        SCT-Da222 mature light chain variable domain protein sequence
330        SCT-Da110 mature light chain variable domain protein sequence
331        SCT-Da111 mature light chain variable domain protein sequence
331        SCT-Da327 mature light chain variable domain protein sequence
332        SCT-Da113 mature light chain variable domain protein sequence
332        SCT-Da119 mature light chain variable domain protein sequence
332        SCT-Da158 mature light chain variable domain protein sequence
333        SCT-Da114 mature light chain variable domain protein sequence
333        SCT-Da128 mature light chain variable domain protein sequence
333        SCT-Da135 mature light chain variable domain protein sequence
333        SCT-Da181 mature light chain variable domain protein sequence
333        SCT-Da183 mature light chain variable domain protein sequence
333        SCT-Da188 mature light chain variable domain protein sequence
333        SCT-Da189 mature light chain variable domain protein sequence
333        SCT-Da192 mature light chain variable domain protein sequence
333        SCT-Da200 mature light chain variable domain protein sequence
333        SCT-Da201 mature light chain variable domain protein sequence
333        SCT-Da205 mature light chain variable domain protein sequence
333        SCT-Da206 mature light chain variable domain protein sequence
333        SCT-Da207 mature light chain variable domain protein sequence
333        SCT-Da216 mature light chain variable domain protein sequence
333        SCT-Da220 mature light chain variable domain protein sequence
333        SCT-Da223 mature light chain variable domain protein sequence
333        SCT-Da255 mature light chain variable domain protein sequence
333        SCT-Da302 mature light chain variable domain protein sequence
333        SCT-Da321 mature light chain variable domain protein sequence
333        SCT-Da362 mature light chain variable domain protein sequence
334        SCT-Da115 mature light chain variable domain protein sequence
335        SCT-Da120 mature light chain variable domain protein sequence
336        SCT-Da121 mature light chain variable domain protein sequence
337        SCT-Da122 mature light chain variable domain protein sequence
337        SCT-Da287 mature light chain variable domain protein sequence
338        SCT-Da124 mature light chain variable domain protein sequence
339        SCT-Da125 mature light chain variable domain protein sequence
340        SCT-Da126 mature light chain variable domain protein sequence
341        SCT-Da127 mature light chain variable domain protein sequence
342        SCT-Da130 mature light chain variable domain protein sequence
342        SCT-Da132 mature light chain variable domain protein sequence
342        SCT-Da144 mature light chain variable domain protein sequence
343        SCT-Da136 mature light chain variable domain protein sequence
344        SCT-Da137 mature light chain variable domain protein sequence
345        SCT-Da138 mature light chain variable domain protein sequence
346        SCT-Da139 mature light chain variable domain protein sequence
347        SCT-Da141 mature light chain variable domain protein sequence
348        SCT-Da142 mature light chain variable domain protein sequence
349        SCT-Da143 mature light chain variable domain protein sequence
349        SCT-Da226 mature light chain variable domain protein sequence
350        SCT-Da149 mature light chain variable domain protein sequence
351        SCT-Da150 mature light chain variable domain protein sequence
352        SCT-Da152 mature light chain variable domain protein sequence
353        SCT-Da153 mature light chain variable domain protein sequence
354        SCT-Da154 mature light chain variable domain protein sequence
354        SCT-Da350 mature light chain variable domain protein sequence
355        SCT-Da155 mature light chain variable domain protein sequence
356        SCT-Da160 mature light chain variable domain protein sequence
356        SCT-Da161 mature light chain variable domain protein sequence
357        SCT-Da162 mature light chain variable domain protein sequence
358        SCT-Da165 mature light chain variable domain protein sequence
358        SCT-Da290 mature light chain variable domain protein sequence
359        SCT-Da166 mature light chain variable domain protein sequence
359        SCT-Da177 mature light chain variable domain protein sequence
359        SCT-Da203 mature light chain variable domain protein sequence
360        SCT-Da167 mature light chain variable domain protein sequence
361        SCT-Da168 mature light chain variable domain protein sequence
362        SCT-Da169 mature light chain variable domain protein sequence
363        SCT-Da170 mature light chain variable domain protein sequence
364        SCT-Da171 mature light chain variable domain protein sequence
365        SCT-Da173 mature light chain variable domain protein sequence
366        SCT-Da174 mature light chain variable domain protein sequence
366        SCT-Da293 mature light chain variable domain protein sequence
366        SCT-Da330 mature light chain variable domain protein sequence
367        SCT-Da178 mature light chain variable domain protein sequence
368        SCT-Da179 mature light chain variable domain protein sequence
368        SCT-Da180 mature light chain variable domain protein sequence
369        SCT-Da182 mature light chain variable domain protein sequence
370        SCT-Da184 mature light chain variable domain protein sequence
371        SCT-Da185 mature light chain variable domain protein sequence
371        SCT-Da292 mature light chain variable domain protein sequence
372        SCT-Da186 mature light chain variable domain protein sequence
373        SCT-Da187 mature light chain variable domain protein sequence
374        SCT-Da190 mature light chain variable domain protein sequence
375        SCT-Da193 mature light chain variable domain protein sequence
376        SCT-Da194 mature light chain variable domain protein sequence
377        SCT-Da195 mature light chain variable domain protein sequence
377        SCT-Da199 mature light chain variable domain protein sequence
378        SCT-Da196 mature light chain variable domain protein sequence
379        SCT-Da197 mature light chain variable domain protein sequence
380        SCT-Da204 mature light chain variable domain protein sequence
381        SCT-Da208 mature light chain variable domain protein sequence
382        SCT-Da210 mature light chain variable domain protein sequence
383        SCT-Da212 mature light chain variable domain protein sequence
384        SCT-Da213 mature light chain variable domain protein sequence
385        SCT-Da214 mature light chain variable domain protein sequence
386        SCT-Da215 mature light chain variable domain protein sequence
386        SCT-Da217 mature light chain variable domain protein sequence
387        SCT-Da218 mature light chain variable domain protein sequence
387        SCT-Da274 mature light chain variable domain protein sequence
388        SCT-Da219 mature light chain variable domain protein sequence
389        SCT-Da221 mature light chain variable domain protein sequence
390        SCT-Da224 mature light chain variable domain protein sequence
391        SCT-Da225 mature light chain variable domain protein sequence
392        SCT-Da227 mature light chain variable domain protein sequence
393        SCT-Da228 mature light chain variable domain protein sequence
394        SCT-Da229 mature light chain variable domain protein sequence
395        SCT-Da230 mature light chain variable domain protein sequence
396        SCT-Da231 mature light chain variable domain protein sequence
397        SCT-Da232 mature light chain variable domain protein sequence
397        SCT-Da244 mature light chain variable domain protein sequence
397        SCT-Da246 mature light chain variable domain protein sequence
397        SCT-Da248 mature light chain variable domain protein sequence
398        SCT-Da233 mature light chain variable domain protein sequence
399        SCT-Da234 mature light chain variable domain protein sequence
400        SCT-Da235 mature light chain variable domain protein sequence
400        SCT-Da333 mature light chain variable domain protein sequence
401        SCT-Da236 mature light chain variable domain protein sequence
402        SCT-Da237 mature light chain variable domain protein sequence
403        SCT-Da238 mature light chain variable domain protein sequence
404        SCT-Da239 mature light chain variable domain protein sequence
405        SCT-Da240 mature light chain variable domain protein sequence
406        SCT-Da241 mature light chain variable domain protein sequence
407        SCT-Da242 mature light chain variable domain protein sequence
408        SCT-Da243 mature light chain variable domain protein sequence
409        SCT-Da245 mature light chain variable domain protein sequence
410        SCT-Da249 mature light chain variable domain protein sequence
410        SCT-Da319 mature light chain variable domain protein sequence
411        SCT-Da250 mature light chain variable domain protein sequence
411        SCT-Da297 mature light chain variable domain protein sequence
412        SCT-Da251 mature light chain variable domain protein sequence
413        SCT-Da252 mature light chain variable domain protein sequence
413        SCT-Da298 mature light chain variable domain protein sequence
414        SCT-Da253 mature light chain variable domain protein sequence
415        SCT-Da254 mature light chain variable domain protein sequence
416        SCT-Da256 mature light chain variable domain protein sequence
417        SCT-Da257 mature light chain variable domain protein sequence
418        SCT-Da258 mature light chain variable domain protein sequence
419        SCT-Da259 mature light chain variable domain protein sequence
419        SCT-Da260 mature light chain variable domain protein sequence
420        SCT-Da261 mature light chain variable domain protein sequence
421        SCT-Da262 mature light chain variable domain protein sequence
422        SCT-Da263 mature light chain variable domain protein sequence
423        SCT-Da264 mature light chain variable domain protein sequence
424        SCT-Da265 mature light chain variable domain protein sequence
425        SCT-Da266 mature light chain variable domain protein sequence
426        SCT-Da267 mature light chain variable domain protein sequence
427        SCT-Da268 mature light chain variable domain protein sequence
428        SCT-Da269 mature light chain variable domain protein sequence
429        SCT-Da270 mature light chain variable domain protein sequence
429        SCT-Da273 mature light chain variable domain protein sequence
429        SCT-Da280 mature light chain variable domain protein sequence
429        SCT-Da304 mature light chain variable domain protein sequence
430        SCT-Da271 mature light chain variable domain protein sequence
430        SCT-Da275 mature light chain variable domain protein sequence
430        SCT-Da294 mature light chain variable domain protein sequence
431        SCT-Da272 mature light chain variable domain protein sequence
432        SCT-Da276 mature light chain variable domain protein sequence
433        SCT-Da277 mature light chain variable domain protein sequence
434        SCT-Da278 mature light chain variable domain protein sequence
434        SCT-Da279 mature light chain variable domain protein sequence
434        SCT-Da281 mature light chain variable domain protein sequence
435        SCT-Da282 mature light chain variable domain protein sequence
436        SCT-Da305 mature light chain variable domain protein sequence
437        SCT-Da306 mature light chain variable domain protein sequence
438        SCT-Da307 mature light chain variable domain protein sequence
438        SCT-Da310 mature light chain variable domain protein sequence
438        SCT-Da331 mature light chain variable domain protein sequence
439        SCT-Da308 mature light chain variable domain protein sequence
440        SCT-Da309 mature light chain variable domain protein sequence
441        SCT-Da311 mature light chain variable domain protein sequence
442        SCT-Da312 mature light chain variable domain protein sequence
443        SCT-Da313 mature light chain variable domain protein sequence
443        SCT-Da314 mature light chain variable domain protein sequence
444        SCT-Da315 mature light chain variable domain protein sequence
445        SCT-Da316 mature light chain variable domain protein sequence
446        SCT-Da317 mature light chain variable domain protein sequence
447        SCT-Da318 mature light chain variable domain protein sequence
448        SCT-Da320 mature light chain variable domain protein sequence
449        SCT-Da322 mature light chain variable domain protein sequence
450        SCT-Da323 mature light chain variable domain protein sequence
451        SCT-Da324 mature light chain variable domain protein sequence
452        SCT-Da325 mature light chain variable domain protein sequence
453        SCT-Da326 mature light chain variable domain protein sequence
454        SCT-Da328 mature light chain variable domain protein sequence
455        SCT-Da329 mature light chain variable domain protein sequence
456        SCT-Da332 mature light chain variable domain protein sequence
456        SCT-Da336 mature light chain variable domain protein sequence
457        SCT-Da334 mature light chain variable domain protein sequence
457        SCT-Da338 mature light chain variable domain protein sequence
458        SCT-Da335 mature light chain variable domain protein sequence
459        SCT-Da337 mature light chain variable domain protein sequence
460        SCT-Da339 mature light chain variable domain protein sequence
461        SCT-Da340 mature light chain variable domain protein sequence
462        SCT-Da341 mature light chain variable domain protein sequence
463        SCT-Da342 mature light chain variable domain protein sequence
464        SCT-Da343 mature light chain variable domain protein sequence
465        SCT-Da344 mature light chain variable domain protein sequence
466        SCT-Da345 mature light chain variable domain protein sequence
467        SCT-Da346 mature light chain variable domain protein sequence
468        SCT-Da347 mature light chain variable domain protein sequence
468        SCT-Da359 mature light chain variable domain protein sequence
469        SCT-Da348 mature light chain variable domain protein sequence
470        SCT-Da351 mature light chain variable domain protein sequence
471        SCT-Da352 mature light chain variable domain protein sequence
472        SCT-Da353 mature light chain variable domain protein sequence
473        SCT-Da354 mature light chain variable domain protein sequence
474        SCT-Da355 mature light chain variable domain protein sequence
475        SCT-Da356 mature light chain variable domain protein sequence
476        SCT-Da358 mature light chain variable domain protein sequence
477        SCT-Da360 mature light chain variable domain protein sequence
478        SCT-Da361 mature light chain variable domain protein sequence
973        SCT-Da363 mature heavy chain variable domain protein sequence
973        SCT-Da364 mature heavy chain variable domain protein sequence
974        SCT-Da363 mature light chain variable domain protein sequence
975        SCT-Da364 mature light chain variable domain protein sequence
976        SCT-Da365 mature heavy chain variable domain protein sequence
976        SCT-Da366 mature heavy chain variable domain protein sequence
976        SCT-Da367 mature heavy chain variable domain protein sequence
977        SCT-Da365 mature light chain variable domain protein sequence
977        SCT-Da368 mature light chain variable domain protein sequence
978        SCT-Da366 mature light chain variable domain protein sequence
978        SCT-Da369 mature light chain variable domain protein sequence
979        SCT-Da367 mature light chain variable domain protein sequence
979        SCT-Da370 mature light chain variable domain protein sequence
980        SCT-Da368 mature heavy chain variable domain protein sequence
980        SCT-Da369 mature heavy chain variable domain protein sequence
980        SCT-Da370 mature heavy chain variable domain protein sequence
981        SCT-Da371 mature heavy chain variable domain protein sequence
981        SCT-Da372 mature heavy chain variable domain protein sequence
982        SCT-Da371 mature light chain variable domain protein sequence
982        SCT-Da373 mature light chain variable domain protein sequence
983        SCT-Da372 mature light chain variable domain protein sequence
983        SCT-Da374 mature light chain variable domain protein sequence
984        SCT-Da373 mature heavy chain variable domain protein sequence
984        SCT-Da374 mature heavy chain variable domain protein sequence

DETAILED DESCRIPTION

The disclosure provides antibodies that bind to B7-H3. In one embodiment, the disclosure provides an isolated antibody that binds to SEQ ID NO:1.

Antibodies

The disclosure provides antibodies that bind specifically to SEQ ID NO:1. The term “antibody” as used herein, includes both full-length immunoglobulins and antibody fragments that bind to the same antigens. The antibodies can be, e.g., a monoclonal, polyclonal, chimeric, humanized, or single chain antibody. As used herein, the terms “antigen binding fragment,” “fragment,” and “antibody fragment” are used interchangeably to refer to any fragment that comprises a portion of a full-length antibody, generally at least the antigen binding portion or the variable region thereof. Examples of antibody fragments include, but are not limited to, diabodies, single-chain antibody molecules, multi-specific antibodies, Fab, Fab′, F(ab′)₂, Fv or scFv.

The phrase “therapeutically effective” is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.

The term “therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.

The terms “treating,” “treatment,” and the like, as used herein, mean ameliorating a disease, so as to reduce, ameliorate, or eliminate its cause, its progression, its severity, or one or more of its symptoms, or otherwise beneficially alter the disease in a subject. Reference to “treating,” or “treatment” of a patient is intended to include prophylaxis. Treatment may also be preemptive in nature, i.e., it may include prevention of disease in a subject exposed to or at risk for the disease. Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.

The terms “subject” and “patient” are used interchangeably herein to mean all mammals including humans. Examples of subjects include, but are not limited to, humans, monkeys, dogs, cats, horses, cows, goats, sheep, pigs, and rabbits. In one embodiment, the subject or patient is a human.

In certain embodiments, the cancer treated with the anti-B7-H3 antibody molecule, alone or in combination, includes but is not limited to, a solid tumor, a hematological cancer (e.g., leukemia, lymphoma, myeloma), and a metastatic lesion thereof. In one embodiment, the cancer is a solid tumor. Examples of solid tumors include malignancies, e.g., sarcomas and carcinomas (e.g., adenocarcinomas), of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal or colorectal, genitals and genitourinary tract (e.g., renal, urothelial, bladder cells), pharynx, CNS (e.g., brain, neural or glial cells), skin (e.g., melanoma), head and neck (e.g., head and neck squamous cell carcinoma (HNCC)), and pancreas. For example, melanoma, colon cancers, gastric cancer, rectal cancer, renal-cell carcinoma, breast cancer (e.g., a breast cancer that does not express one, two or all of estrogen receptor, progesterone receptor, or Her2/neu, e.g., a triple negative breast cancer), liver cancer, a lung cancer (e.g., a non-small cell lung cancer (NSCLC) (e.g., a NSCLC with squamous and/or non-squamous histology) or small cell lung cancer), prostate cancer, cancer of head or neck (e.g., HPV+ squamous cell carcinoma), cancer of the small intestine and cancer of the esophagus. Examples of hematological cancer include, but is not limited to, leukemia (e.g., a myeloid leukemia, lymphoid leukemia, or chronic lymphocytic leukemia (CLL)), lymphoma (e.g., Hogdkin lymphoma (HL), non-Hogdkin lymphoma (NHL), Diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, or mantle cell lymphoma (MCL)), and myeloma, e.g., multiple myeloma. The cancer may be at an early, intermediate, late stage or metastatic cancer. For discovering and developing antibody therapeutics to B7-H3 generally known in the art, please see U.S. Pat. No. 9,207,238, which is incorporated in its entirety by reference.

The provided antibodies disclosed herein can be used to treat, prevent and/or diagnose cancerous or malignant disorders (e.g., cancers such melanoma, e.g., advanced stage melanoma; pancreatic cancer, e.g., advanced pancreatic cancer; solid tumors; breast cancer, e.g., metastatic breast carcinoma; renal cell carcinoma, e.g., advanced or metastatic renal cell carcinoma (MRCC) or clear cell renal cell carcinoma), as well as infectious diseases (e.g., hepatitis, e.g., hepatitis B; influenza).

The disclosure provides the antibodies SCT-Da001, SCT-Da002, SCT-Da003, SCT-Da004, SCT-Da005, SCT-Da006, SCT-Da007, SCT-Da008, SCT-Da009, SCT-Da010, SCT-Da011, SCT-Da012, SCT-Da013, SCT-Da014, SCT-Da015, SCT-Da016, SCT-Da017, SCT-Da018, SCT-Da019, SCT-Da020, SCT-Da021, SCT-Da022, SCT-Da023, SCT-Da024, SCT-Da025, SCT-Da026, SCT-Da027, SCT-Da028, SCT-Da029, SCT-Da030, SCT-Da031, SCT-Da032, SCT-Da033, SCT-Da034, SCT-Da035, SCT-Da036, SCT-Da037, SCT-Da038, SCT-Da039, SCT-Da040, SCT-Da041, SCT-Da042, SCT-Da043, SCT-Da044, SCT-Da045, SCT-Da046, SCT-Da047, SCT-Da048, SCT-Da049, SCT-Da050, SCT-Da051, SCT-Da052, SCT-Da053, SCT-Da054, SCT-Da055, SCT-Da056, SCT-Da057, SCT-Da058, SCT-Da059, SCT-Da060, SCT-Da061, SCT-Da062, SCT-Da063, SCT-Da064, SCT-Da065, SCT-Da066, SCT-Da067, SCT-Da068, SCT-Da069, SCT-Da070, SCT-Da071, SCT-Da072, SCT-Da073, SCT-Da074, SCT-Da075, SCT-Da076, SCT-Da077, SCT-Da078, SCT-Da079, SCT-Da080, SCT-Da081, SCT-Da082, SCT-Da083, SCT-Da084, SCT-Da085, SCT-Da086, SCT-Da087, SCT-Da088, SCT-Da089, SCT-Da090, SCT-Da091, SCT-Da092, SCT-Da093, SCT-Da094, SCT-Da095, SCT-Da096, SCT-Da097, SCT-Da098, SCT-Da099, SCT-Da100, SCT-Da101, SCT-Da102, SCT-Da103, SCT-Da104, SCT-Da105, SCT-Da106, SCT-Da107, SCT-Da108, SCT-Da109, SCT-Da110, SCT-Da111, SCT-Da112, SCT-Da113, SCT-Da114, SCT-Da115, SCT-Da116, SCT-Da117, SCT-Da118, SCT-Da119, SCT-Da120, SCT-Da121, SCT-Da122, SCT-Da123, SCT-Da124, SCT-Da125, SCT-Da126, SCT-Da127, SCT-Da128, SCT-Da129, SCT-Da130, SCT-Da131, SCT-Da132, SCT-Da133, SCT-Da134, SCT-Da135, SCT-Da136, SCT-Da137, SCT-Da138, SCT-Da139, SCT-Da140, SCT-Da141, SCT-Da142, SCT-Da143, SCT-Da144, SCT-Da145, SCT-Da146, SCT-Da147, SCT-Da148, SCT-Da149, SCT-Da150, SCT-Da151, SCT-Da152, SCT-Da153, SCT-Da154, SCT-Da155, SCT-Da156, SCT-Da157, SCT-Da158, SCT-Da159, SCT-Da160, SCT-Da161, SCT-Da162, SCT-Da163, SCT-Da164, SCT-Da165, SCT-Da166, SCT-Da167, SCT-Da168, SCT-Da169, SCT-Da170, SCT-Da171, SCT-Da172, SCT-Da173, SCT-Da174, SCT-Da175, SCT-Da176, SCT-Da177, SCT-Da178, SCT-Da179, SCT-Da180, SCT-Da181, SCT-Da182, SCT-Da183, SCT-Da184, SCT-Da185, SCT-Da186, SCT-Da187, SCT-Da188, SCT-Da189, SCT-Da190, SCT-Da191, SCT-Da192, SCT-Da193, SCT-Da194, SCT-Da195, SCT-Da196, SCT-Da197, SCT-Da198, SCT-Da199, SCT-Da200, SCT-Da201, SCT-Da202, SCT-Da203, SCT-Da204, SCT-Da205, SCT-Da206, SCT-Da207, SCT-Da208, SCT-Da209, SCT-Da210, SCT-Da211, SCT-Da212, SCT-Da213, SCT-Da214, SCT-Da215, SCT-Da216, SCT-Da217, SCT-Da218, SCT-Da219, SCT-Da220, SCT-Da221, SCT-Da222, SCT-Da223, SCT-Da224, SCT-Da225, SCT-Da226, SCT-Da227, SCT-Da228, SCT-Da229, SCT-Da230, SCT-Da231, SCT-Da232, SCT-Da233, SCT-Da234, SCT-Da235, SCT-Da236, SCT-Da237, SCT-Da238, SCT-Da239, SCT-Da240, SCT-Da241, SCT-Da242, SCT-Da243, SCT-Da244, SCT-Da245, SCT-Da246, SCT-Da247, SCT-Da248, SCT-Da249, SCT-Da250, SCT-Da251, SCT-Da252, SCT-Da253, SCT-Da254, SCT-Da255, SCT-Da256, SCT-Da257, SCT-Da258, SCT-Da259, SCT-Da260, SCT-Da261, SCT-Da262, SCT-Da263, SCT-Da264, SCT-Da265, SCT-Da266, SCT-Da267, SCT-Da268, SCT-Da269, SCT-Da270, SCT-Da271, SCT-Da272, SCT-Da273, SCT-Da274, SCT-Da275, SCT-Da276, SCT-Da277, SCT-Da278, SCT-Da279, SCT-Da280, SCT-Da281, SCT-Da282, SCT-Da283, SCT-Da284, SCT-Da285, SCT-Da286, SCT-Da287, SCT-Da288, SCT-Da289, SCT-Da290, SCT-Da291, SCT-Da292, SCT-Da293, SCT-Da294, SCT-Da295, SCT-Da296, SCT-Da297, SCT-Da298, SCT-Da299, SCT-Da300, SCT-Da301, SCT-Da302, SCT-Da303, SCT-Da304, SCT-Da305, SCT-Da306, SCT-Da307, SCT-Da308, SCT-Da309, SCT-Da310, SCT-Da311, SCT-Da312, SCT-Da313, SCT-Da314, SCT-Da315, SCT-Da316, SCT-Da317, SCT-Da318, SCT-Da319, SCT-Da320, SCT-Da321, SCT-Da322, SCT-Da323, SCT-Da324, SCT-Da325, SCT-Da326, SCT-Da327, SCT-Da328, SCT-Da329, SCT-Da330, SCT-Da331, SCT-Da332, SCT-Da333, SCT-Da334, SCT-Da335, SCT-Da336, SCT-Da337, SCT-Da338, SCT-Da339, SCT-Da340, SCT-Da341, SCT-Da342, SCT-Da343, SCT-Da344, SCT-Da345, SCT-Da346, SCT-Da347, SCT-Da348, SCT-Da349, SCT-Da350, SCT-Da351, SCT-Da352, SCT-Da353, SCT-Da354, SCT-Da355, SCT-Da356, SCT-Da357, SCT-Da358, SCT-Da359, SCT-Da360, SCT-Da361, and SCT-Da362. Each of these is a murine monoclonal antibody. In addition, the disclosure provides the antibodies SCT-Da363, SCT-Da364, SCT-Da365, SCT-Da366, SCT-Da367, SCT-Da368, SCT-Da369, SCT-Da370, SCT-Da371, SCT-Da372, SCT-Da373, and SCT-Da374. Each of these is a humanized monoclonal antibody.

Additionally, recombinant anti-B7-H3 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the disclosure. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques such as, for example, the methods described in U.S. Pat. No. 7,112,421; Better et al. (1988) Science 240:1041-1043; or Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443.

Antibody Variable Domain Sequence

The antibodies of the disclosure may comprise the heavy chain variable domain sequences of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:973, SEQ ID NO:976, SEQ ID NO:980, SEQ ID NO:981, or SEQ ID NO:984. The heavy chain variable domain sequences may consist essentially of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:973, SEQ ID NO:976, SEQ ID NO:980, SEQ ID NO:981, or SEQ ID NO:984.

The antibodies of the disclosure may comprise the light chain variable domain sequences of SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:283, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:370, SEQ ID NO:371, SEQ ID NO:372, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:391, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:394, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:398, SEQ ID NO:399, SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:404, SEQ ID NO:405, SEQ ID NO:406, SEQ ID NO:407, SEQ ID NO:408, SEQ ID NO:409, SEQ ID NO:410, SEQ ID NO:411, SEQ ID NO:412, SEQ ID NO:413, SEQ ID NO:414, SEQ ID NO:415, SEQ ID NO:416, SEQ ID NO:417, SEQ ID NO:418, SEQ ID NO:419, SEQ ID NO:420, SEQ ID NO:421, SEQ ID NO:422, SEQ ID NO:423, SEQ ID NO:424, SEQ ID NO:425, SEQ ID NO:426, SEQ ID NO:427, SEQ ID NO:428, SEQ ID NO:429, SEQ ID NO:430, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:433, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:438, SEQ ID NO:439, SEQ ID NO:440, SEQ ID NO:441, SEQ ID NO:442, SEQ ID NO:443, SEQ ID NO:444, SEQ ID NO:445, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:449, SEQ ID NO:450, SEQ ID NO:451, SEQ ID NO:452, SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:455, SEQ ID NO:456, SEQ ID NO:457, SEQ ID NO:458, SEQ ID NO:459, SEQ ID NO:460, SEQ ID NO:461, SEQ ID NO:462, SEQ ID NO:463, SEQ ID NO:464, SEQ ID NO:465, SEQ ID NO:466, SEQ ID NO:467, SEQ ID NO:468, SEQ ID NO:469, SEQ ID NO:470, SEQ ID NO:471, SEQ ID NO:472, SEQ ID NO:473, SEQ ID NO:474, SEQ ID NO:475, SEQ ID NO:476, SEQ ID NO:477, SEQ ID NO:478, SEQ ID NO:974, SEQ ID NO:975, SEQ ID NO:977, SEQ ID NO:978, SEQ ID NO:979, SEQ ID NO:982, or SEQ ID NO:983. The light chain variable domain sequences may consist essentially of SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:283, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:370, SEQ ID NO:371, SEQ ID NO:372, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:391, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:394, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:398, SEQ ID NO:399, SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:404, SEQ ID NO:405, SEQ ID NO:406, SEQ ID NO:407, SEQ ID NO:408, SEQ ID NO:409, SEQ ID NO:410, SEQ ID NO:411, SEQ ID NO:412, SEQ ID NO:413, SEQ ID NO:414, SEQ ID NO:415, SEQ ID NO:416, SEQ ID NO:417, SEQ ID NO:418, SEQ ID NO:419, SEQ ID NO:420, SEQ ID NO:421, SEQ ID NO:422, SEQ ID NO:423, SEQ ID NO:424, SEQ ID NO:425, SEQ ID NO:426, SEQ ID NO:427, SEQ ID NO:428, SEQ ID NO:429, SEQ ID NO:430, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:433, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:438, SEQ ID NO:439, SEQ ID NO:440, SEQ ID NO:441, SEQ ID NO:442, SEQ ID NO:443, SEQ ID NO:444, SEQ ID NO:445, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:449, SEQ ID NO:450, SEQ ID NO:451, SEQ ID NO:452, SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:455, SEQ ID NO:456, SEQ ID NO:457, SEQ ID NO:458, SEQ ID NO:459, SEQ ID NO:460, SEQ ID NO:461, SEQ ID NO:462, SEQ ID NO:463, SEQ ID NO:464, SEQ ID NO:465, SEQ ID NO:466, SEQ ID NO:467, SEQ ID NO:468, SEQ ID NO:469, SEQ ID NO:470, SEQ ID NO:471, SEQ ID NO:472, SEQ ID NO:473, SEQ ID NO:474, SEQ ID NO:475, SEQ ID NO:476, SEQ ID NO:477, SEQ ID NO:478, SEQ ID NO:974, SEQ ID NO:975, SEQ ID NO:977, SEQ ID NO:978, SEQ ID NO:979, SEQ ID NO:982, or SEQ ID NO:983.

The disclosure also provides a variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to a sequence selected from SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, SEQ ID NO:158, SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, SEQ ID NO:162, SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, SEQ ID NO:228, SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:973, SEQ ID NO:976, SEQ ID NO:980, SEQ ID NO:981, or SEQ ID NO:984. The disclosure also provides a variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to a sequence selected from SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:283, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:287, SEQ ID NO:288, SEQ ID NO:289, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, SEQ ID NO:317, SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, SEQ ID NO:341, SEQ ID NO:342, SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:349, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, SEQ ID NO:369, SEQ ID NO:370, SEQ ID NO:371, SEQ ID NO:372, SEQ ID NO:373, SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:391, SEQ ID NO:392, SEQ ID NO:393, SEQ ID NO:394, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:398, SEQ ID NO:399, SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:402, SEQ ID NO:403, SEQ ID NO:404, SEQ ID NO:405, SEQ ID NO:406, SEQ ID NO:407, SEQ ID NO:408, SEQ ID NO:409, SEQ ID NO:410, SEQ ID NO:411, SEQ ID NO:412, SEQ ID NO:413, SEQ ID NO:414, SEQ ID NO:415, SEQ ID NO:416, SEQ ID NO:417, SEQ ID NO:418, SEQ ID NO:419, SEQ ID NO:420, SEQ ID NO:421, SEQ ID NO:422, SEQ ID NO:423, SEQ ID NO:424, SEQ ID NO:425, SEQ ID NO:426, SEQ ID NO:427, SEQ ID NO:428, SEQ ID NO:429, SEQ ID NO:430, SEQ ID NO:431, SEQ ID NO:432, SEQ ID NO:433, SEQ ID NO:434, SEQ ID NO:435, SEQ ID NO:436, SEQ ID NO:437, SEQ ID NO:438, SEQ ID NO:439, SEQ ID NO:440, SEQ ID NO:441, SEQ ID NO:442, SEQ ID NO:443, SEQ ID NO:444, SEQ ID NO:445, SEQ ID NO:446, SEQ ID NO:447, SEQ ID NO:448, SEQ ID NO:449, SEQ ID NO:450, SEQ ID NO:451, SEQ ID NO:452, SEQ ID NO:453, SEQ ID NO:454, SEQ ID NO:455, SEQ ID NO:456, SEQ ID NO:457, SEQ ID NO:458, SEQ ID NO:459, SEQ ID NO:460, SEQ ID NO:461, SEQ ID NO:462, SEQ ID NO:463, SEQ ID NO:464, SEQ ID NO:465, SEQ ID NO:466, SEQ ID NO:467, SEQ ID NO:468, SEQ ID NO:469, SEQ ID NO:470, SEQ ID NO:471, SEQ ID NO:472, SEQ ID NO:473, SEQ ID NO:474, SEQ ID NO:475, SEQ ID NO:476, SEQ ID NO:477, SEQ ID NO:478, SEQ ID NO:974, SEQ ID NO:975, SEQ ID NO:977, SEQ ID NO:978, SEQ ID NO:979, SEQ ID NO:982, or SEQ ID NO:983. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:4 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:247. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:248. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:6 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:249. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:250. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:8 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:251. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:252. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:253. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:254. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:255. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:10 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:256. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:11 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:254. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:11 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:256. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:12 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:254. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:13 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:257. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:14 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:258. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:15 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:259. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:260. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:261. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:17 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:257. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:18 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:262. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:19 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:250. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:19 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:250. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:263. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:22 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:263. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:22 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:250. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:22 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:264. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:22 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:265. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:266. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:24 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:267. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:25 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:268. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:26 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:269. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:27 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:270. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:28 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:271. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:29 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:266. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:30 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:272. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:31 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:273. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:32 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:274. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:33 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:275. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:34 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:276. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:35 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:277. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:36 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:278. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:37 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:279. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:38 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:280. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:39 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:281. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:39 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:282. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:40 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:283. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:41 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:284. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:41 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:285. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:42 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:286. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:43 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:287. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:44 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:288. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:45 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:289. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:46 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:287. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:47 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:290. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:48 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:291. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:49 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:292. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:50 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:293. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:51 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:294. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:52 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:294. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:53 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:295. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:54 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:296. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:55 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:297. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:56 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:264. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:57 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:298. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:57 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:299. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:58 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:300. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:59 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:301. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:59 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:264. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:60 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:302. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:60 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:303. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:60 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:249. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:60 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:304. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:61 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:249. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:62 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:305. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:62 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:306. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:62 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:249. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:63 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:264. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:63 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:307. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:308. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:65 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:257. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:66 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:309. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:67 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:310. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:68 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:283. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:68 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:311. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:69 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:312. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:70 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:293. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:71 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:313. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:72 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:314. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:72 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:305. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:72 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:293. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:73 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:315. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:74 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:316. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:75 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:317. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:75 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:75 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:319. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:76 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:320. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:77 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:321. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:77 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:322. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:77 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:323. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:77 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:324. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:78 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:79 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:321. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:80 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:325. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:80 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:326. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:80 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:81 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:82 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:327. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:82 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:328. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:82 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:329. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:82 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:330. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:331. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:332. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:84 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:334. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:85 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:304. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:85 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:326. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:85 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:85 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:332. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:86 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:335. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:336. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:337. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:326. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:338. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:339. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:340. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:341. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:88 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:89 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:342. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:89 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:313. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:90 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:342. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:91 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:329. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:91 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:294. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:91 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:91 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:343. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:92 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:344. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:92 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:345. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:92 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:346. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:93 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:316. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:94 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:347. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:95 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:348. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:96 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:349. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:97 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:342. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:98 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:304. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:284. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:296. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:304. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:350. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:351. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:352. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:353. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:354. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:100 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:355. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:101 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:314. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:101 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:304. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:101 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:332. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:101 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:322. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:102 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:356. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:103 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:356. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:104 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:357. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:105 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:267. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:105 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:261. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:105 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:358. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:105 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:359. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:360. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:361. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:362. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:363. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:364. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:312. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:365. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:366. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:107 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:262. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:108 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:283. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:108 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:359. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:108 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:367. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:109 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:368. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:110 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:368. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:111 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:112 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:369. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:113 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:114 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:370. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:115 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:371. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:116 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:372. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:117 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:373. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:118 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:119 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:120 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:374. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:121 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:329. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:121 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:122 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:375. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:123 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:376. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:124 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:377. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:124 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:378. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:125 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:379. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:126 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:294. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:126 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:377. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:126 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:127 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:128 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:294. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:128 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:359. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:128 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:380. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:128 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:129 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:130 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:131 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:381. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:132 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:317. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:133 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:382. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:134 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:317. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:135 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:383. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:136 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:384. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:137 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:385. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:138 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:386. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:139 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:139 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:386. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:140 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:387. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:141 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:388. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:142 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:143 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:389. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:144 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:329. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:144 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:145 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:390. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:146 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:391. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:147 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:349. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:148 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:392. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:149 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:393. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:150 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:394. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:151 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:395. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:152 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:396. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:153 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:397. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:154 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:398. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:155 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:399. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:156 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:400. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:157 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:401. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:157 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:402. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:158 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:403. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:159 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:404. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:160 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:405. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:161 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:406. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:162 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:407. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:163 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:408. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:164 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:397. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:165 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:409. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:165 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:397. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:166 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:305. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:167 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:397. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:168 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:410. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:169 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:411. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:170 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:412. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:171 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:413. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:172 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:414. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:173 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:415. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:173 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:174 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:416. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:175 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:417. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:176 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:418. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:177 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:419. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:178 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:419. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:179 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:420. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:180 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:421. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:181 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:422. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:182 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:423. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:183 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:424. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:184 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:425. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:185 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:426. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:186 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:427. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:187 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:428. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:188 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:429. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:188 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:430. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:189 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:431. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:190 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:429. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:190 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:387. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:191 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:430. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:192 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:432. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:193 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:433. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:194 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:434. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:194 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:434. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:196 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:429. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:197 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:434. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:198 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:435. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:252. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:301. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:264. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:293. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:337. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:294. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:358. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:312. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:371. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:199 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:366. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:430. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:328. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:264. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:411. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:413. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:304. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:318. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:324. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:200 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:265. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:201 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:429. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:202 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:436. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:203 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:437. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:204 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:438. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:204 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:439. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:205 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:440. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:205 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:438. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:206 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:441. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:207 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:442. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:208 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:443. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:209 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:443. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:210 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:444. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:211 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:445. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:212 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:446. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:213 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:447. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:214 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:410. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:215 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:448. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:215 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:216 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:449. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:217 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:450. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:218 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:451. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:219 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:452. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:220 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:453. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:221 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:331. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:222 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:454. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:222 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:455. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:222 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:366. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:223 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:438. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:224 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:456. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:225 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:400. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:225 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:457. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:225 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:458. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:226 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:456. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:227 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:459. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:228 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:457. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:229 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:460. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:230 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:461. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:231 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:462. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:232 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:463. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:233 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:464. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:234 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:465. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:235 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:466. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:236 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:467. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:237 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:468. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:238 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:469. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:239 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:304. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:239 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:354. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:239 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:470. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:240 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:471. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:241 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:472. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:242 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:473. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:242 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:474. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:242 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:475. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:242 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:265. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:243 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:476. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:244 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:468. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:245 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:477. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:246 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:478. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:246 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:333. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:973 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:974. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:973 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:975. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:976 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:977. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:976 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:978. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:976 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:979. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:980 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:977. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:980 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:978. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:980 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:979. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:981 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:982. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:981 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:983. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:984 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:982. The disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:984 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:983.

Table 1 provides a summary of the B7-H3-specific antibodies described herein:

Pharmaceutical Compositions

Pharmaceutical compositions comprising the antibodies or antibody fragments of the present disclosure are also contemplated and can be used in the methods disclosed herein. Pharmaceutical compositions can comprise one or more of the antibodies or antibody fragments described herein and a pharmaceutically acceptable carrier or excipient. Although the carrier or excipient may facilitate administration, it should not itself induce the production of antibodies harmful to the subject or individual receiving the composition; nor should it be toxic. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles, and are known to one of skill in the art.

The antibodies or an antigen binding fragments described herein, or the pharmaceutical compositions disclosed herein, may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intraperitoneal, intrathecal, intraventricular, transdermal, transcutaneous, topical, subcutaneous, intranasal, enteral, sublingual, intravaginal or rectal routes. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

In one embodiment, the antibody, or an antigen binding fragment thereof, or pharmaceutical composition is administered intravenously. In another embodiment, the antibody, or an antigen binding fragment thereof, or pharmaceutical composition is administered by intravenous infusion.

Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule. Known antibody-based pharmaceuticals provide guidance relating to frequency of administration e.g., whether a pharmaceutical should be delivered daily, weekly, monthly, etc. Frequency and dosage may also depend on the severity of symptoms.

It will be appreciated that the active ingredient in the composition will be an antibody molecule, an antibody fragment or variants and derivatives thereof. As such, it will be susceptible to degradation in the gastrointestinal tract. Thus, if the composition is to be administered by a route using the gastrointestinal tract, the composition will need to contain agents which protect the antibody from degradation, but which release the antibody once it has been absorbed from the gastrointestinal tract.

The methods of the present invention can use an antibody, or an antigen binding fragment thereof, as described above, alone or in combination with other pharmaceutically active compounds, to treat conditions such as those disclosed hereinabove. The additional pharmaceutically active compound(s) can be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially. Accordingly, in one embodiment, the present invention comprises methods for treating a condition by administering to the subject a therapeutically effective amount of an antibody, or an antigen binding fragment thereof, of the present invention and one or more additional pharmaceutically active compounds.

In some embodiments, the antibody, or an antigen binding fragment thereof, of the present invention is used in combination with existing LAG-3-related disease therapies.

EXAMPLES

The following example is put forth so as to provide those of ordinary skill in the art with a complete description of how to make and use the present disclosure, and is not intended to limit the scope of what the inventors regard as their disclosure nor is it intended to represent that the experiment below is all or the only experiment that could be performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

Example 1: Isolation of Murine Anti-Human B7-113 Antibodies

Immunization, & Single Cell Suspension Generation

Recombinant human B7-H3 (4Ig) His tagged, catalog no: B7B-H52E7, ACROBiosystems, Beijing, China, SEQ ID NO:2) was used to immunize young C57/BL6 mice each with 80 μg of the protein in Sigma Adjuvant System® (Sigma-Aldrich, St. Louis, Mo.) over a period of 35 days using a rapid immunization protocol of Antibody Solutions (Sunnyvale, Calif.). The lymph nodes were harvested on day 35. Single cell suspension of the lymph node was generated, and the suspension was filtered through a 70 μm mesh (BD Bioscience) to remove clumps.

Plasma Cell Isolation, Antibody Capture, and Antigen Interrogation

The filtered lymphocyte suspension was enriched for plasma cells actively secreting IgGs using a kit based on cell surface expression of CD138 (Miltenyi, Auburn, Calif.). Using a method described in U.S. Pat. No. 9,328,172, freshly enriched plasma cells were deposited on a PDMS device to allow a single cell settled in the microwells on the device. Antibody secreted from each plasma cell was captured on a derivatized microscope slide. Antigen-specific antibody secreting cells were identified by interrogating the antibody capture slide with varying concentrations of fluorescently labeled B7-H3 (4Ig) protein tagged with human Fc (ACROBiosystems, Beijing, China, catalog no: B7B-H5258, SEQ ID NO:3). Labeling was done using a kit (AnaSpec, Fremont, Calif., AS-72046, AnaTag™ HiLyte™ Fluor 555 Microscale Protein Labeling Kit *Ultra Convenient*).

mRNA Capture

After antibody capture, the medium was removed, and replaced with lysis buffer followed by prompt closure of the top of the microwells with a custom oligonucleotide microarray (Agilent, Santa Clara, Calif.). This procedure was previously described in U.S. Pat. No. 9,328,172. The custom oligonucleotide microarray is prepared such that each feature contains not only a unique tag specifying its coordinate but also capture probes for all subclasses (1, 2a, 2b, and 3) of murine IgG heavy chain, murine Ig kappa light chain.

cDNA Synthesis, PCR Amplification, and Next Generation Sequencing

Captured mRNA on the custom microarray was further processed to synthesize cDNA of each mRNA incorporating the unique tag originally on each feature. The cDNA is then amplify using a Taq polymerase (Promega, Madison, Wis.) and appropriate set of primers to allow amplification of the following genes: variable domain of IgG heavy chain subclasses and variable domain of Ig kappa light chain. Though now released from cells, these fragments of each gene are now labeled with the unique tag from the custom oligonucleotide microarray manifesting their originating locations. The amplicons were further manipulated to have appropriate sequence attached at both ends to enable sequencing on an Illumina MiSeq instrument using 2×250 bp chemistry at SeqMatic LLC (Fremont, Calif.).

Bioinformatic Analysis of Images and DNA Sequences

Sequencing reads from MiSeq were processed and the embedded tag in each read was identified and converted into coordinates. The coordinates were plotted to yield a synthetic map of the mRNA recovered. Most of the coordinates form clusters that designate the location of the originating cell for the recovered mRNA sequences. Next, CDR3 motif present in each read with the coordinates was identified and collated according to the clusters that matched the location of an antibody spot visualized by an appropriate fluorescently labeled secondary antibody. Identical or nearly identical CDR3s for a given antibody spot were organized and form consistent pair of V_H and V_L sequences. The remaining part of V_H or V_L sequence containing the identified CDR3s was identified and the associated sequencing reads were assembled into full-length cDNA sequences for V_H and V_L. The pair of full-length cDNA was correlated with the affinity measurements associated with each of the antigen-specific antibody spot.

Example 2: Molecular Reconstruction and Recombinant Expression of Anti-B7-H3 Antibodies

The paired V_H and V_L anti-B7-H3 antibody sequences were used to synthesize corresponding gene fragments by a service provider according to the known art. The resulting gene fragments were cloned into an appropriate plasmid vector and transfected into an appropriate mammalian host, such as HEK293, for recombinant expression to produce an antibody preparation in full-IgG format. The antibody preparations were characterized by measurements at OD280 to assess the amount produced and by gel electrophoresis on PAGE to assess the size of the antibody chains produced.

Example 3: Characterization of Recombinant Anti-B7-H3 Antibodies

The recombinantly expressed antibodies were used to assess binding activity to B7-H3 by conventional ELISA according to the known art. Recombinant human B7-H3 and cyno B7-H3 were coated onto ELISA plates to detect binding at serially diluted concentrations of the anti-B7-H3 antibody preparations. The EC50s based on ELISA is shown in table 2. The binding affinity of select anti-B7-H3 antibodies were measured on a surface plasmon resonance (SPR) instrument, such as a Biacore T200™, against human B7-H3 (table 3) and cyno B7-H3 (table 4). Cell lines expressing B7-H3, A498 and SK-MES-1, were used to assess binding by anti-B7-H3 antibodies on the native protein on the cell surface by flow cytometry according to the known art. The EC50s for these binding to these 2 cell lines are displayed in table 2 under the heading “FACS” and FIGS. 1A and 1B. In addition, the antibody-dependent cellular cytotoxicity (ADCC) activity of select anti-B7-H3 antibodies were assessed using an engineered surrogate effector cell line, kit reagents, and a luminometer (Promega, Madison, Wis.) on A498 and SK-MES-1 as target cells in table 2 under the heading “ADCC (reporter) and FIGS. 1C and 1D. Finally, specificity of each of the antibodies examined thus far were assessed by interacting with proteins from the B7 family (human B7-1, B7-2, PD-L2, PD-L1, B7-H2, B7-H4, B7-H5, B7-H6, B7-H7) against B7-H3 using ELISA. The data were plotted for each antibody on FIGS. 3A through 3E.

Antibodies recovered from the antibody campaign described above are listed herein. The CDR sequences and the V_H and V_L sequences for the anti-B7-H3 antibodies described herein are depicted in Tables 5 and 6, respectively.

	TABLE 2
			ADCC
	ELISA	FACS	(reporter)	ADCC
	Human	Cyno		SK-			SK-	(PBMC)
	B7-H3	B7-H3	A498	MES-1	Raji	A498	MES-1	A549
	EC50	EC50	EC50	EC50	EC50	EC50	EC50	EC50
Anti-B7-H3 mAb	(pM)	(pM)	(nM)	(nM)	(nM)	(nM)	(nM)	(nM)
SCT-Da148	7.60	11.43	1.60	1.49	>100	3.6	4.2	0.75
SCT-Da182	10.46	8.82	3.70	4.09	>100	4.5	4.6	ND
SCT-Da192	10.86	17.64	2.62	2.32	>100	1.1	0.9	0.21
SCT-Da250	22.55	23.74	1.43	1.46	>100	2.4	2.4	0.20
SCT-Da333	8.33	3048.00	3.29	1.94	>100	23.3	32.8	ND
SCT-Da364	ND	ND	ND	ND	ND	ND	ND	0.18
SCT-Da369	ND	ND	ND	ND	ND	ND	ND	8.05
ND: Not determined.

TABLE 3
Anti-B7-H3 mAb	Ka (1/Ms)	Kd (1/s)	KD (M)	Rmax (RU)
SCT-Da148	3.66E+05	2.34E−03	6.41E−09	50.4
SCT-Da182	9.27E+04	1.01E−03	1.09E−08	39.2
SCT-Da192	8.51E+04	2.03E−03	2.38E−08	118.2
SCT-Da250	4.02E+05	1.10E−03	2.75E−09	71.3
SCT-Da333	1.35E+05	5.12E−02	3.80E−07	51.0

TABLE 4
Anti-B7-H3 mAb	Ka (1/Ms)	Kd (1/s)	KD (M)	Rmax (RU)
SCT-Da148	7.31E+05	3.68E−04	5.03E−10	138.1
SCT-Da182	2.32E+05	2.83E−04	1.22E−09	206.1
SCT-Da192	3.07E+05	5.05E−04	1.64E−09	132.2
SCT-Da250	9.05E+05	3.61E−04	3.98E−10	171.0
SCT-Da333	No binding

TABLE 5
CDR sequences of mAbs generated against human B7-H3
(SEQ ID Nos for each listed sequence are provided in parenthesis)
mAb AA ID	HCDR1	HCDR2	HCDR3	LCDR1	LCDR2	LCDR3
SCT-Da001	GYSITSNYN	IHYSDDT	ARWSYYYGGPYYYSMDY	QDINSY	RAN	LQYDEFPPT
	(479)	(480)	(481)	(763)	(764)	(765)
SCT-Da002	GYSITSGYN	IHYSGGT	GRWSYYYGSPYYYSMDY	QDINTY	RAN	LQYDEFPPT
	(482)	(483)	(484)	(766)	(764)	(765)
SCT-Da003	GFSITSGYY	ISYDGSN	ARDYYGYPAWFTY	QSVDYDGDSY	AAS	QQSNEDPRT
	(485)	(486)	(487)	(857)	(794)	(837)
SCT-Da004	GYSITDGYF	LNYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNALPWT
	(488)	(489)	(490)	(773)	(771)	(807)
SCT-Da005	GYSITSAYF	INYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGKSLPWT
	(491)	(492)	(490)	(773)	(771)	(814)
SCT-Da006	GYSITSAYF	INFDGSS	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(491)	(493)	(490)	(773)	(771)	(772)
SCT-Da007	GYSITSAYF	INFDGSS	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(491)	(493)	(490)	(773)	(771)	(772)
SCT-Da008	GYSITSAYF	INFDGSS	ARRKGWLYAMDY	QDINNY	YTS	QQGNTLPWT
	(491)	(493)	(490)	(770)	(771)	(772)
SCT-Da009	GYSITSAYF	INFDGSS	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(491)	(493)	(490)	(773)	(771)	(772)
SCT-Da010	GYSITSAYF	INYDGTN	ARRKGWLYAMDY	QDISNY	YTS	QQGKSLPWT
	(491)	(494)	(490)	(773)	(771)	(814)
SCT-Da011	GYSITSAYF	INYDGTN	ARRKGWLYAMDY	QDINNY	YTS	QQGNTLPWT
	(491)	(494)	(490)	(770)	(771)	(772)
SCT-Da012	GYSITSAYF	INYDGTN	ARRKGWLYAMDY	QDISNY	YTS	QQGKSLPWT
	(491)	(494)	(490)	(773)	(771)	(814)
SCT-Da013	GYSITSDSF	ISYDGSN	ARRKGWLYAMDY	QDINNY	YTS	QQGNTLPWT
	(495)	(486)	(490)	(770)	(771)	(772)
SCT-Da014	GYSITSDYF	ISYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(496)	(486)	(490)	(773)	(771)	(772)
SCT-Da015	GYSITSDYF	ISYDGSN	ARRKGWLYAMDY	QDISNF	YTS	QQGKTLPWT
	(496)	(486)	(490)	(812)	(771)	(813)
SCT-Da016	GYSITSGYF	INYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(497)	(492)	(490)	(773)	(771)	(772)
SCT-Da017	GYSITSGYF	INYDGSD	ARRKGWLYAMDS	QDINNY	YTS	QQGNTLPWT
	(497)	(498)	(499)	(770)	(771)	(772)
SCT-Da018	GYSITSGYF	INYDGSD	ARRKGWLYAMDS	HDIHNY	YTS	QQGNTLPWT
	(497)	(498)	(499)	(811)	(771)	(772)
SCT-Da019	GYSITSGYF	INYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(497)	(492)	(490)	(773)	(771)	(772)
SCT-Da020	GYSITSGYF	INYDGSS	ARRKGWLYAMDY	SSISSNY	RTS	QQGSSIPRT
	(497)	(500)	(490)	(928)	(929)	(932)
SCT-Da021	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNALPWT
	(497)	(489)	(490)	(773)	(771)	(807)
SCT-Da022	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNALPWT
	(497)	(489)	(490)	(773)	(771)	(807)
SCT-Da023	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGIALPWT
	(497)	(489)	(490)	(773)	(771)	(808)
SCT-Da024	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGIALPWT
	(497)	(489)	(490)	(773)	(771)	(808)
SCT-Da025	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNALPWT
	(497)	(489)	(490)	(773)	(771)	(807)
SCT-Da026	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	ESVDSYGNSF	IAS	QQSNEDPRT
	(497)	(489)	(490)	(846)	(842)	(837)
SCT-Da027	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	QSVTND	YAS	QQDYNSPYT
	(497)	(489)	(490)	(970)	(818)	(962)
SCT-Da028	GYSITSGYF	LNYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(497)	(489)	(490)	(773)	(771)	(772)
SCT-Da029	GYSITSGYF	LNYDGSS	ARRKGWLYAMDY	QDISNY	YTS	QQGNALPWT
	(497)	(501)	(490)	(773)	(771)	(807)
SCT-Da030	GYSITSGYF	INYDGSN	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(497)	(492)	(490)	(773)	(771)	(772)
SCT-Da031	GYSITSGYY	ISYDGSN	AREGDYGSY	QDVGTA	WAS	QQYSSYPYT
	(502)	(486)	(503)	(879)	(866)	(881)
SCT-Da032	GYSITSGYY	ISYDGSN	TRRKGWLYAMDY	QDISNY	YTS	QQGNALPWT
	(502)	(486)	(504)	(773)	(771)	(807)
SCT-Da033	GYSITSDYA	ISYSGST	ASGYYGIHYYAMDY	QDVNTA	SAS	QQHYSTPFT
	(505)	(506)	(507)	(876)	(882)	(883)
SCT-Da034	GYSITSGYF	INYDGSS	ARRKGWLYAMDY	QDISNY	YTS	QQGNTLPWT
	(497)	(500)	(490)	(773)	(771)	(772)
SCT-Da035	GYSFTAYI	INPYYGST	ARGPPYYYGSSRDYALDY	QSIVHTNGNTY	KVS	FQGSHVPYT
	(508)	(509)	(510)	(906)	(907)	(908)
SCT-Da036	GYSFTDYI	INPYYDTT	ATYDGFAY	QSLVHSNGNTY	KVS	SQSTHGPWT
	(511)	(512)	(513)	(919)	(907)	(921)
SCT-Da037	GYSFTDYI	INPYYGTT	ATYDGFAY	QSLVHSYGNTY	KVS	SQSTHGPWT
	(511)	(514)	(513)	(923)	(907)	(921)
SCT-Da038	GYSFTDYI	INPYYYTT	ATYDGFAY	QSLVHSNGNTY	KVS	SQSTHGPWT
	(511)	(515)	(513)	(919)	(907)	(921)
SCT-Da039	GFNIKDYY	IDPENGNT	TIGVRRDYFDY	SSISSNY	RTS	QQGSSLPRT
	(516)	(517)	(518)	(928)	(929)	(930)
SCT-Da040	GFTFSNYW	IRLKFNNY	IKFGGMDY	SSVNY	STS	QQRSTYPRT
	(519)	(520)	(521)	(949)	(877)	(950)
SCT-Da041	GFAFNSYD	ISDGGSFT	ARHQITTLRMDY	QGISSN	HGT	VQYAQFPYT
	(522)	(523)	(524)	(767)	(768)	(769)
SCT-Da042	GFAFSSYD	ISDGGSYT	ARHRVTTVRMDY	QGISSN	HGT	VQYAQFPYT
	(525)	(526)	(527)	(767)	(768)	(769)
SCT-Da043	GFAFSSYD	ISDGGSYT	ARHRVTTVRMDY	QGISSN	HGT	VQYAQFPYT
	(525)	(526)	(527)	(767)	(768)	(769)
SCT-Da044	GFAFSDYD	ISDGGSYT	ARHLITTLRMDY	QGISSN	HGT	VQYAQFPYT
	(528)	(526)	(529)	(767)	(768)	(769)
SCT-Da045	GFAFSDYD	ISDGGSYT	ARHLITTLRMDY	QGISSN	HGT	VQYAQFPYT
	(528)	(526)	(529)	(767)	(768)	(769)
SCT-Da046	GFAFSDYD	ISDGGSYT	ARHLITTLRMDY	QGISSN	HGT	VQYAQFPYT
	(528)	(526)	(529)	(767)	(768)	(769)
SCT-Da047	GFAFSDYD	ISNDGSYT	ARHLITTLRMDY	QGISSN	HGT	VQYAQFPYT
	(528)	(530)	(529)	(767)	(768)	(769)
SCT-Da048	GFAFSDYD	ISNDGSYT	ARHLITTLRMDY	QGISSN	HGT	VQYAQFPYT
	(528)	(530)	(529)	(767)	(768)	(769)
SCT-Da049	GFTFSSYT	IISGGGDI	ARWYSAGYFDV	KSVSTSAYSY	LAS	QHSRELLT
	(531)	(532)	(533)	(852)	(829)	(853)
SCT-Da050	GFTFSSYT	ISGGGVTY	ARWYSVGYFDV	KSVSTSAYSY	LAS	QHSRELLT
	(531)	(534)	(535)	(852)	(829)	(853)
SCT-Da051	GFTFSSYT	ITGGGDTY	ARWYSVGYFDV	KSVSTSAYSY	LAS	QHSRELLT
	(531)	(536)	(535)	(852)	(829)	(853)
SCT-Da052	GFTFSSYT	ITSGGGDT	ARWYSAGYFDV	KSVSTSAYSY	LAS	QHSRELLT
	(531)	(537)	(533)	(852)	(829)	(853)
SCT-Da053	GFTFSSYT	ISGGGVTY	ARWYSVGYFDV	KSVSTSAYSY	LAS	QHSRELLT
	(531)	(534)	(535)	(852)	(829)	(853)
SCT-Da054	GFTFSSYA	IFFGSSVT	ARQGTSPWFAY	KSVSTSNYSY	LAS	QHSRELPT
	(538)	(539)	(540)	(855)	(829)	(856)
SCT-Da055	GFTFSSYT	IISGGGNT	ARWYSAGYFDV	KSVSTSGYSY	LAS	QHSRELLT
	(531)	(541)	(533)	(828)	(829)	(853)
SCT-Da056	GFTFSSYT	ISGGVGDT	ARQGGFPWFAY	KSVSTSGYSY	LAS	QHSRELPYT
	(531)	(542)	(543)	(828)	(829)	(830)
SCT-Da057	GFNIEDTY	IDPANGNT	ARDGYYAPGY	QNVDTN	SGS	QQYNTYPYT
	(544)	(545)	(546)	(873)	(874)	(875)
SCT-Da058	GFNIEDTY	IDPANGNT	ARDGYYAPGY	QNVDTN	SAS	QQYNSYPYT
	(544)	(545)	(546)	(873)	(882)	(902)
SCT-Da059	GFNIEDTY	IDPANGYT	ARDGYYAPGY	QNVDTN	SAS	QQYNSYPYT
	(544)	(547)	(546)	(873)	(882)	(902)
SCT-Da060	GYTFTDYN	INPNYDST	ARSGFDGYYYAMDY	ETVDSYGSSF	RAS	QQSNEDPFT
	(548)	(549)	(550)	(864)	(844)	(845)
SCT-Da061	DYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	QGISNY	YTS	QQYSKLPLT
	(551)	(552)	(553)	(815)	(771)	(816)
SCT-Da062	GYTFTDYN	INPNGDFT	ARRHYGNYFYAMDY	ESVDSYGNSF	IAS	QQSNEDPRT
	(548)	(554)	(553)	(846)	(842)	(837)
SCT-Da063	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	ESVDSYGNSF	IAS	QQSNEDPRT
	(548)	(552)	(553)	(846)	(842)	(837)
SCT-Da064	GYTFTDYN	INPNDDST	ARRHYGNYFYAMDY	DHINNW	GAT	QQYWSTPT
	(548)	(555)	(553)	(799)	(800)	(804)
SCT-Da065	GYTFTDYN	INPNDDST	ARRHYGNYFYAMDY	ESVDSFGHSF	LAS	QQSNEDPRT
	(548)	(555)	(553)	(841)	(829)	(837)
SCT-Da066	GYTFTDYN	INPNDDST	ARRHYGNYFYAMDY	ESVDSFGNSF	IAS	QQSNEDPRT
	(548)	(555)	(553)	(836)	(842)	(837)
SCT-Da067	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	ESVDNFGNSF	LAS	QQSNEDPRT
	(548)	(552)	(553)	(838)	(829)	(837)
SCT-Da068	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	ESVDSYGNSF	IAS	QQSNEDPRT
	(548)	(552)	(553)	(846)	(842)	(837)
SCT-Da069	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	ESVDSFGNSF	LAS	QQSNEDPRT
	(548)	(552)	(553)	(836)	(829)	(837)
SCT-Da070	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	ESVDSYGNSF	LAS	QQSNEDPRT
	(548)	(552)	(553)	(846)	(829)	(837)
SCT-Da071	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	QSVDYDGDSY	AAS	QQSNEDPRT
	(548)	(552)	(553)	(857)	(794)	(837)
SCT-Da072	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	QNVGTD	SAS	QQYNSYPYT
	(548)	(552)	(553)	(904)	(882)	(902)
SCT-Da073	GYTFTDYN	INPNNGGT	ARRHYGNYFYAMDY	QSVDYDGDSY	AAS	QQSNEDPRT
	(548)	(552)	(553)	(857)	(794)	(837)
SCT-Da074	GYTFTDYN	INPNYDST	ARRHYGNYFYAMDY	DHINNW	GAT	QQYWSIPYT
	(548)	(549)	(553)	(799)	(800)	(802)
SCT-Da075	GYTFTDYN	INPNYDST	ARRHYGNYFYAMDY	ESVDSFGNSF	IAS	QQSNEDPRT
	(548)	(549)	(553)	(836)	(842)	(837)
SCT-Da076	GYTFTDYN	INPNYDST	ARRHYGNYFYAMDY	QSVDYDGDSY	AAS	QQSNEDPRT
	(548)	(549)	(553)	(857)	(794)	(837)
SCT-Da077	GYTFTDYN	ISPNYEST	ARRHYGNYFYAMDY	ESVDSYGNSF	IAS	QQSNEDPRT
	(548)	(556)	(553)	(846)	(842)	(837)
SCT-Da078	GYTFTDYN	ISPNYEST	ARRHYGNYFYAMDY	ESVDSFGHSF	LAS	QQSNEDPRT
	(548)	(556)	(553)	(841)	(829)	(837)
SCT-Da079	GYTFTDYN	INPNDDST	ARRHYGNYFYAMDY	ESVDSFGNSF	LAS	QQSNEDPRT
	(548)	(555)	(553)	(836)	(829)	(837)
SCT-Da080	GYTFTDYN	INPNYDST	ARGGFYGNFFDY	QDISNY	YTS	QQGNTLPWT
	(548)	(549)	(557)	(773)	(771)	(772)
SCT-Da081	GYTFTDYN	INPNYDST	ARGGFYGNFFDY	ESVDSSGNSF	RAS	QQSNEDPFT
	(548)	(549)	(557)	(843)	(844)	(845)
SCT-Da082	GFNIKDYY	IDPENGNT	SIGVRRDYFAY	SSISSNY	RTS	QQGSSLPRT
	(516)	(517)	(558)	(928)	(929)	(930)
SCT-Da083	GFNIKDYY	IDPENGNT	TIGVRRDYFDY	QGISSN	HGT	VQYAQFPYT
	(516)	(517)	(518)	(767)	(768)	(769)
SCT-Da084	GFNIKDYY	IDPENGNT	TIGVRRDYFDY	SSISSNY	RTS	QQGSSIPRT
	(516)	(517)	(518)	(928)	(929)	(932)
SCT-Da085	GFNIEDTY	IDPANGNP	ARDGYYAPGY	SSISSNY	RTS	QQGSSIPRT
	(544)	(559)	(546)	(928)	(929)	(932)
SCT-Da086	GFNIEDTY	IDPANGNP	ARDGYYAPGY	QNVDTN	SGS	QQYNTYPYT
	(544)	(559)	(546)	(873)	(874)	(875)
SCT-Da087	GFNIEDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(544)	(560)	(546)	(899)	(882)	(902)
SCT-Da088	GFNIEDTY	IDPANGNT	ARDGYYAPGY	QDINKY	YTS	LQYDNLRT
	(544)	(545)	(546)	(796)	(771)	(797)
SCT-Da089	GFNIEDTY	IDPANGNT	ARDGYYAPGY	DHINNW	GAT	QQYWSIPYT
	(544)	(545)	(546)	(799)	(800)	(802)
SCT-Da090	GFNIEDTY	IDPANGNT	ARDGYYAPGY	QNVDTN	SGS	QQYNTYPYT
	(544)	(545)	(546)	(873)	(874)	(875)
SCT-Da091	GFNIEDTY	NDPANGNT	ASLWVDY	KSLLHSNGNTF	RMS	MQHLEFPYT
	(544)	(561)	(562)	(868)	(869)	(870)
SCT-Da092	GFNIKDTY	IDPANANT	AHDGYYAPGY	QNVGTN	SAS	QQYNNYPYT
	(563)	(564)	(565)	(899)	(882)	(900)
SCT-Da093	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTD	SAS	QQYNIYPYT
	(563)	(545)	(565)	(904)	(882)	(903)
SCT-Da094	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(545)	(565)	(904)	(882)	(902)
SCT-Da095	GFNIKDTY	IDPANGNT	AHDGYYAPGY	TDIDDD	EGN	LQSDNLPFT
	(563)	(545)	(565)	(939)	(940)	(941)
SCT-Da096	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(545)	(565)	(899)	(882)	(902)
SCT-Da097	GFNIKDTY	IDPANGNS	AHDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(566)	(565)	(904)	(882)	(902)
SCT-Da098	GFNIKDTY	IDPANGNS	AHDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(566)	(565)	(899)	(882)	(902)
SCT-Da099	GFNIKDTY	IDPANGNS	AHDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(566)	(565)	(899)	(882)	(902)
SCT-Da100	GFNIKDTY	IDPANGNS	AHDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(566)	(565)	(899)	(882)	(902)
SCT-Da101	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(545)	(565)	(904)	(882)	(902)
SCT-Da102	GFNIKDTY	IDPANGNT	AHDGYYAPGN	QNVGTD	SAS	QQYNSYPYT
	(563)	(545)	(567)	(904)	(882)	(902)
SCT-Da103	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QGISNY	YTS	QQYSKLPYT
	(563)	(545)	(565)	(815)	(771)	(810)
SCT-Da104	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(545)	(565)	(904)	(882)	(902)
SCT-Da105	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(545)	(565)	(904)	(882)	(902)
SCT-Da106	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(545)	(565)	(904)	(882)	(902)
SCT-Da107	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QGISSN	HGT	VQYAQFPYT
	(563)	(560)	(546)	(767)	(768)	(769)
SCT-Da108	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QSVDYDGDNY	AAS	QQSYEDPWT
	(563)	(560)	(546)	(831)	(794)	(832)
SCT-Da109	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVDSN	SAS	QQYNSYPYT
	(563)	(560)	(546)	(901)	(882)	(902)
SCT-Da110	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNTYPYT
	(563)	(560)	(546)	(899)	(882)	(875)
SCT-Da111	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QSISDY	YVS	QNGHSFPFT
	(563)	(560)	(546)	(888)	(897)	(889)
SCT-Da112	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(546)	(904)	(882)	(902)
SCT-Da113	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(546)	(904)	(882)	(902)
SCT-Da114	GFNIKDTY	IDPANGNR	ARDGYYAPGY	SSVSY	LTS	QQWSSNPLT
	(563)	(560)	(546)	(944)	(957)	(947)
SCT-Da115	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(560)	(546)	(899)	(882)	(902)
SCT-Da116	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(568)	(904)	(882)	(902)
SCT-Da117	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(568)	(904)	(882)	(902)
SCT-Da118	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(568)	(904)	(882)	(902)
SCT-Da119	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(568)	(904)	(882)	(902)
SCT-Da120	GFNIKDTY	IDPANGNR	ARDGYSAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(569)	(904)	(882)	(902)
SCT-Da121	GFNIKDTY	IDPANGNR	ARDGYYAPGY	ESVESNGNSF	RAS	QQTDEDPFT
	(563)	(560)	(546)	(848)	(844)	(849)
SCT-Da122	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QRISDY	YAS	QNGHSFPFT
	(563)	(560)	(546)	(893)	(818)	(889)
SCT-Da123	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(546)	(904)	(882)	(902)
SCT-Da124	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(546)	(904)	(882)	(902)
SCT-Da125	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(546)	(904)	(882)	(902)
SCT-Da126	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNTYPYT
	(563)	(560)	(546)	(904)	(882)	(875)
SCT-Da127	GFNIKDTY	IDPANGNR	ARDGYYAPGY	KSISKY	SGS	QQHNEYPLT
	(563)	(560)	(546)	(909)	(874)	(910)
SCT-Da128	GFNIKDTY	IDPANGNR	ARDGYYAPGY	SSVSY	LTS	QQWSSNPLT
	(563)	(560)	(546)	(944)	(957)	(947)
SCT-Da129	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(546)	(904)	(882)	(902)
SCT-Da130	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(560)	(546)	(899)	(882)	(902)
SCT-Da131	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(560)	(546)	(899)	(882)	(902)
SCT-Da132	GFNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(563)	(560)	(546)	(899)	(882)	(902)
SCT-Da133	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVDSN	SAS	QQYNSYPYT
	(563)	(545)	(565)	(901)	(882)	(902)
SCT-Da134	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVDTN	SAS	QQYNSYPYT
	(563)	(545)	(565)	(873)	(882)	(902)
SCT-Da135	GFNIKDTY	IDPANGNT	AHDGYYAPGY	SSVSY	LTS	QQWSSNPLT
	(563)	(545)	(565)	(944)	(957)	(947)
SCT-Da136	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QSVSND	YAS	QQDYSSPWT
	(563)	(545)	(565)	(966)	(818)	(968)
SCT-Da137	GFNIKDTY	IDPANGNT	THDGYYAPGY	QNVDTN	SAS	QQYNIYPYT
	(563)	(545)	(570)	(873)	(882)	(903)
SCT-Da138	GFNIKDTY	IDPANGNT	THDGYYAPGY	QNVDTN	SAS	QQYNSYPYT
	(563)	(545)	(570)	(873)	(882)	(902)
SCT-Da139	GFNIKDTY	IDPANGNT	THDGYYAPGY	QSLVHSNGNTY	KVS	SQSTHAPWT
	(563)	(545)	(570)	(919)	(907)	(920)
SCT-Da140	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTN	SAS	QQYNNYPYT
	(563)	(545)	(565)	(899)	(882)	(900)
SCT-Da141	GFNIKDTY	IDPANGNT	AHDGYYAPGY	QNVGTN	SAS	QQYNNYPYT
	(563)	(545)	(565)	(899)	(882)	(900)
SCT-Da142	GFNIKDTY	IDPANGNT	AHDGYYAPGF	QNVGTN	SAS	QQYNSYPFT
	(563)	(545)	(571)	(899)	(882)	(905)
SCT-Da143	GFNIKDTY	IDPANGNT	APFSYGTLAY	SSIISNY	RTS	QQGSSLPRT
	(563)	(545)	(572)	(935)	(929)	(930)
SCT-Da144	GLNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(573)	(560)	(546)	(899)	(882)	(902)
SCT-Da145	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da146	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QGISSN	HGT	VQYAQFPYT
	(574)	(560)	(546)	(767)	(768)	(769)
SCT-Da147	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QGISNY	YTS	QQYSKLPLT
	(574)	(560)	(546)	(815)	(771)	(816)
SCT-Da148	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da149	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da150	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da151	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da152	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(574)	(560)	(546)	(899)	(882)	(902)
SCT-Da153	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTN	SAS	QQYNSYPYT
	(574)	(560)	(546)	(899)	(882)	(902)
SCT-Da154	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVDNY	YAS	QQDYSSPYT
	(574)	(560)	(546)	(959)	(818)	(960)
SCT-Da155	GFNIKDTY	IDPANFNT	ASLWVDY	KSLLHSNGNTF	RMS	MQHLEYPYT
	(563)	(575)	(562)	(868)	(869)	(871)
SCT-Da156	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QDINKY	YTS	LQYDNLRT
	(563)	(560)	(568)	(796)	(771)	(797)
SCT-Da157	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(568)	(904)	(882)	(902)
SCT-Da158	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QNVGTD	SAS	QQYNSYPYT
	(563)	(560)	(568)	(904)	(882)	(902)
SCT-Da159	GFNIKDTY	IDPANGNR	ARDGYYAPGH	QNVGTN	SAS	QQYNSYPYT
	(563)	(560)	(568)	(899)	(882)	(902)
SCT-Da160	GCNIKDYY	IDPENGNT	TIGVRRDYFAY	SSISSNY	RTS	QQGSSIPRT
	(576)	(517)	(577)	(928)	(929)	(932)
SCT-Da161	GCNIKDYY	IDPENGNT	AIGVRRDYFAY	SSISSNY	RTS	QQGSSIPRT
	(576)	(517)	(578)	(928)	(929)	(932)
SCT-Da162	GFNIKDFY	IDPENGNT	AIGVRRDYFGY	SIISSNY	RTS	QQGSSIPRT
	(579)	(517)	(580)	(934)	(929)	(932)
SCT-Da163	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	QDISNY	YTS	QQGNALPWT
	(516)	(517)	(578)	(773)	(771)	(807)
SCT-Da164	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	HDIHNY	YTS	QQGNTLPWT
	(516)	(517)	(578)	(811)	(771)	(772)
SCT-Da165	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SSISSNY	RTS	QQGSSLPRT
	(516)	(517)	(578)	(928)	(929)	(930)
SCT-Da166	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SNISSNY	RTS	QQGSSIPRT
	(516)	(517)	(578)	(931)	(929)	(932)
SCT-Da167	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	QDIKSY	YAT	LQHGESPFT
	(516)	(517)	(578)	(760)	(761)	(762)
SCT-Da168	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	KSVSSSGYNY	LAS	QHSGELPLT
	(516)	(517)	(578)	(850)	(829)	(851)
SCT-Da169	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	QSISDY	YAS	QNGHSFPPFT
	(516)	(517)	(578)	(888)	(818)	(895)
SCT-Da170	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	QSLVHSDGNTY	KVS	SQSTHVPWT
	(516)	(517)	(578)	(918)	(907)	(916)
SCT-Da171	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SSINSNY	RTS	QQGSSIPRT
	(516)	(517)	(578)	(933)	(929)	(932)
SCT-Da172	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SSISSNY	RTS	QQGSSIPRT
	(516)	(517)	(578)	(928)	(929)	(932)
SCT-Da173	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SSISSNY	RTS	QQGSSIPRT
	(516)	(517)	(578)	(928)	(929)	(932)
SCT-Da174	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SSISY	GTS	QQWSSYPLT
	(516)	(517)	(578)	(954)	(955)	(956)
SCT-Da175	GFNIKDYY	IDPENGNT	AIGVRRDYFDY	SSISSNY	RTS	QQGSSIPRT
	(516)	(517)	(581)	(928)	(929)	(932)
SCT-Da176	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	QGISSN	HGT	VQYAQFPYT
	(516)	(517)	(578)	(767)	(768)	(769)
SCT-Da177	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SNISSNY	RTS	QQGSSIPRT
	(516)	(517)	(578)	(931)	(929)	(932)
SCT-Da178	GFNIKDYY	IDPENGNT	AIGVRRDYFAY	SSISSNY	RTS	QQGSSIPRT
	(516)	(517)	(578)	(928)	(929)	(932)
SCT-Da179	GFNIKDYY	IDPENGNT	AIGVRRDYFDY	SSISSNH	RTS	QQGSSIPRT
	(516)	(517)	(581)	(936)	(929)	(932)
SCT-Da180	GFNIKDYY	IDPENGNT	AIGVRRDYFDY	SSISSNH	RTS	QQGSSIPRT
	(516)	(517)	(581)	(936)	(929)	(932)
SCT-Da181	GYTFTEYT	INPNSGGT	TRPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(584)	(944)	(957)	(947)
SCT-Da182	GFSFTGYT	INTYNGGT	ARSPGRYSMDY	QSVDYNGYSY	PAS	QQSKEDPYT
	(585)	(586)	(587)	(833)	(834)	(835)
SCT-Da183	GYTFTEYT	INPSTGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(588)	(589)	(944)	(957)	(947)
SCT-Da184	GYTFAEYT	INPNNGGT	TRPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(590)	(552)	(584)	(944)	(957)	(947)
SCT-Da185	GYTFTEYP	INPNNGGT	ALYGNYWYFDV	SSVSY	DTS	QQWSSNPLT
	(591)	(552)	(592)	(944)	(953)	(947)
SCT-Da186	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da187	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da188	GYTFTEYTM	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(593)	(552)	(589)	(944)	(957)	(947)
SCT-Da189	GYTFTEYT	VNPNTGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(594)	(589)	(944)	(957)	(947)
SCT-Da190	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	HQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(958)
SCT-Da191	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	QNVDSN	SAS	QQYNSYPYT
	(582)	(552)	(589)	(901)	(882)	(902)
SCT-Da192	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da193	GYTFTEYT	INPNNGGT	TRPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(584)	(944)	(957)	(947)
SCT-Da194	GYTFTEYT	INPNSGGT	TRPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(584)	(944)	(957)	(947)
SCT-Da195	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da196	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	HQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(958)
SCT-Da197	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da198	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	QNVDTN	SAS	QQYNSYPYT
	(582)	(583)	(589)	(873)	(882)	(902)
SCT-Da199	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da200	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da201	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da202	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	QNVDTN	SAS	QQYNSYPYT
	(582)	(583)	(589)	(873)	(882)	(902)
SCT-Da203	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SNISSNY	RTS	QQGSSIPRT
	(582)	(583)	(589)	(931)	(929)	(932)
SCT-Da204	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	ATS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(945)	(947)
SCT-Da205	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da206	GYTFTEYT	INPNTGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(595)	(589)	(944)	(957)	(947)
SCT-Da207	GYTFTEYT	INPNTGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(595)	(589)	(944)	(957)	(947)
SCT-Da208	GYTFTEYT	VNLNTGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(596)	(589)	(944)	(957)	(947)
SCT-Da209	GYTFTSYV	INPYHDGT	ARSRTVIGFDY	QNVGTD	SAS	QQYNIYPYT
	(597)	(598)	(599)	(904)	(882)	(903)
SCT-Da210	GYTFTSYV	INPYHDGT	ARSRTVIGFDY	QSISDY	YAS	QSGHSFPLT
	(597)	(598)	(599)	(888)	(818)	(896)
SCT-Da211	GYTFTSYV	INPYHDGT	ARSRTVIGFDY	QNVGTD	SAS	QQYNIYPYT
	(597)	(598)	(599)	(904)	(882)	(903)
SCT-Da212	GYTFTSYV	INPYNDAT	ARGVRLLDY	ENIYSY	NAK	QHHYVIPPT
	(597)	(600)	(601)	(774)	(775)	(785)
SCT-Da213	GYTFTSYV	INPYTDGT	AKSRTVIGFDY	QNISDY	YAS	QNGHSFPLT
	(597)	(602)	(603)	(890)	(818)	(891)
SCT-Da214	GYTFTSYV	INPYNDGT	ARSRTVVGFDY	QNISDY	YAS	QNAHSFPLT
	(597)	(604)	(605)	(890)	(818)	(892)
SCT-Da215	GYTFTTYV	INPYNDGS	ARWVYYDFGGSMDY	SSVSY	LTS	QQWSSNPLT
	(606)	(607)	(608)	(944)	(957)	(947)
SCT-Da216	GYTFTTYV	INPYNDGS	ARWVYYDFGGSMDY	SSVSY	LTS	QQWSSNPLT
	(606)	(607)	(608)	(944)	(957)	(947)
SCT-Da217	GYTFTTYV	INPYNDGS	ARWVYYDFGGSMDY	SSVSY	LTS	QQWSSNPLT
	(606)	(607)	(608)	(944)	(957)	(947)
SCT-Da218	GYTFTEYT	VNPNTGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(594)	(589)	(944)	(957)	(947)
SCT-Da219	GYTFTSYV	INPYHDGT	ARSRTVIGFDY	QSISDY	YAS	QNGHSFPLT
	(597)	(598)	(599)	(888)	(818)	(891)
SCT-Da220	GYTFTEYT	INPNSGGT	TRPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(584)	(944)	(957)	(947)
SCT-Da221	GYTFTEYT	INPNSGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(583)	(589)	(944)	(957)	(947)
SCT-Da222	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	QNVDSN	SAS	QQYNSYPYT
	(582)	(552)	(589)	(901)	(882)	(902)
SCT-Da223	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da224	GFTLSRYG	SSGGGIYT	ARHDGVPMDY	ENIYSY	NAK	QHHYGIPPWT
	(609)	(610)	(611)	(774)	(775)	(776)
SCT-Da225	GFTFSSYG	IFSGDSNT	SRQGHRSWFAY	KSVSTSGYSY	LAS	QHSRELPYT
	(612)	(613)	(614)	(828)	(829)	(830)
SCT-Da226	GFTFSTYG	ISGGGIYT	VRMITTYFDH	SSIISNY	RTS	QQGSSLPRT
	(615)	(616)	(617)	(935)	(929)	(930)
SCT-Da227	GFTFSSYG	IFSGDSYT	ARQGHRSWFAY	KSVSTSGYSY	LAS	QHSRELPST
	(612)	(618)	(619)	(828)	(829)	(860)
SCT-Da228	GFTFSSYA	ISSGGSYT	ARHEDTTYYYAMDY	ENIYSY	YAK	QHHYGTPLT
	(538)	(620)	(621)	(774)	(786)	(787)
SCT-Da229	GFTFNTYA	IRIKSNNY	VRQAYGNSYFFAMDY	SSVSSSH	STS	HQWSSYPYT
	(622)	(623)	(624)	(951)	(877)	(952)
SCT-Da230	GFTFNTNA	IRSKSNNY	TAMDY	QSLVYSNGNTY	KVS	SQSTHVPYT
	(625)	(626)	(627)	(924)	(907)	(925)
SCT-Da231	GYIFITYW	IFPASGST	ASYDGYYSWFAY	SSVSY	RTS	QQYHSFPRT
	(628)	(629)	(630)	(944)	(929)	(948)
SCT-Da232	GFTFSHSY	IYAGTGGT	ARHETYGSSPDY	DHINNW	GAT	QQYWSIPYT
	(631)	(632)	(633)	(799)	(800)	(802)
SCT-Da233	GFTFSSFY	IDAGTGGT	ARHVGRLRGYFDV	QDVNTA	STS	QQHYSSPWT
	(634)	(635)	(636)	(876)	(877)	(878)
SCT-Da234	GFTFSSNY	IYAGTGST	ASHDGHDAMDY	QSISST	YAS	HQSYSWPHT
	(637)	(638)	(639)	(826)	(818)	(827)
SCT-Da235	GFTFSSNY	IDAGTGGS	ARHVGRLRGYFDV	QDVSTA	SAS	QQHYSTPWT
	(637)	(640)	(636)	(884)	(882)	(885)
SCT-Da236	GFTFSSRY	IYAGTGGT	ASHDGHDAMDY	QSISNT	YAS	QQSNDWPHT
	(641)	(632)	(639)	(821)	(818)	(822)
SCT-Da237	GFTFSSRY	IYAGTGGT	ASHDGHDAMDY	QSISNT	YAS	QQSYDWPHT
	(641)	(632)	(639)	(821)	(818)	(824)
SCT-Da238	GFTFSSRY	IYAGTGGS	ASHDGHDAMDY	QSISNT	YAS	QQSYNWPHT
	(641)	(642)	(639)	(821)	(818)	(825)
SCT-Da239	GFTFSSSY	IYAGTGDT	ASPTGINWYFDV	ENIYSF	NAR	QHHYGPPFT
	(643)	(644)	(645)	(782)	(783)	(784)
SCT-Da240	GFTFSSSY	IYAGTGDT	ASPTGVNWYFDV	ENIYSF	NAR	QHHYGPPFT
	(643)	(644)	(646)	(782)	(783)	(784)
SCT-Da241	GFTFSSSY	IYAGTGGT	ARPNGYGYGMDY	DHISNW	GAT	QQYWSLPYT
	(643)	(632)	(647)	(805)	(800)	(806)
SCT-Da242	GFTFSSSY	IYAGTGGT	ARQDSYGRGPDC	DHINNW	GAT	QQYWTIPYT
	(643)	(632)	(648)	(799)	(800)	(803)
SCT-Da243	GFTFSSSY	IYAGTGGT	ARQDSYGRSPDY	DHINNW	GAT	QQYWSIPYT
	(643)	(632)	(649)	(799)	(800)	(802)
SCT-Da244	GFTFSSSY	IYAGTGGT	ARHETYGSGPDY	DHINNW	GAT	QQYWSIPYT
	(643)	(632)	(650)	(799)	(800)	(802)
SCT-Da245	GFTFSSSY	IYAGTGGT	ARHETYGSSPDY	GNIHNY	NAK	QHFWSTPWT
	(643)	(632)	(633)	(788)	(775)	(789)
SCT-Da246	GFTFSSSY	IYAGTGGT	ARHETYGSSPDY	DHINNW	GAT	QQYWSIPYT
	(643)	(632)	(633)	(799)	(800)	(802)
SCT-Da247	GFTFSSSY	IYAGTGGT	ARQDSYGRSPDY	DHINNW	GAT	QQYWSIPYT
	(643)	(632)	(649)	(799)	(800)	(802)
SCT-Da248	GFTFSSSY	IYAGTGGT	ARQDSYGRSPDY	DHINNW	GAT	QQYWSIPYT
	(643)	(632)	(649)	(799)	(800)	(802)
SCT-Da249	GFTFSSRY	IYAGTGGT	ASHDGLDAMDY	QSINNY	YAS	QQSNSWPLT
	(641)	(632)	(651)	(820)	(818)	(819)
SCT-Da250	GFTFSSFY	IYAGPGYT	ARHVGRQRGYFDV	QDVSTA	SAS	QQHYSTPWT
	(634)	(652)	(653)	(884)	(882)	(885)
SCT-Da251	GFTFSSSY	IYAGTGGT	GRHNGYGIGMDY	DHINNW	GAT	QQYWSLPYM
	(643)	(632)	(654)	(799)	(800)	(801)
SCT-Da252	GLTFSSSY	IDAGTGGT	ARHVGRLRGYFDV	QDVTTA	SAS	QQHYSAPWT
	(655)	(635)	(636)	(886)	(882)	(887)
SCT-Da253	GFTFSSNY	IYAGTGGT	ASHDGHDAMDY	QSISNT	YAS	QQSNSWPHT
	(637)	(632)	(639)	(821)	(818)	(823)
SCT-Da254	GYTFTDYP	IITYYGDA	ASHRGKGYFDV	KSVSTSGYSY	LAS	QHSRELYT
	(656)	(657)	(658)	(828)	(829)	(854)
SCT-Da255	GYTFTDYP	IITYYGDA	ASHRGKGYFDV	SSVSY	LTS	QQWSSNPLT
	(656)	(657)	(658)	(944)	(957)	(947)
SCT-Da256	GYTFTDYF	IYPGNINT	AGGNYALDY	QSISNY	YAS	QQSNSWPLT
	(659)	(660)	(661)	(863)	(818)	(819)
SCT-Da257	GYTFTDYY	IYPGNDNS	AGGNYAMDY	QSISNY	YAS	QQSNSWPLT
	(662)	(663)	(664)	(863)	(818)	(819)
SCT-Da258	GYTFTAYY	IYPGNDNT	AGGNYAMDY	QSISNY	YAS	QQSNSWPLT
	(665)	(666)	(664)	(863)	(818)	(819)
SCT-Da259	GYTFTNSG	INTYTGEP	APTIQVRRLFDY	SSVSY	ATS	QQWSSTPPT
	(667)	(668)	(669)	(944)	(945)	(946)
SCT-Da260	GYTFTNSG	INTYTGEP	APTIQVRRLVDY	SSVSY	ATS	QQWSSTPPT
	(667)	(668)	(670)	(944)	(945)	(946)
SCT-Da261	GYTFTNYG	INTNTGEP	ARRGYYGRGDY	ESVDSYGNSF	RAS	QQSNEDPYT
	(671)	(672)	(673)	(846)	(844)	(847)
SCT-Da262	GFSLTSYD	IWTGGGT	VRWGDDYDWFAY	QSVSND	YAS	QQDYSSPPT
	(674)	(675)	(676)	(966)	(818)	(967)
SCT-Da263	GFSLTTYG	IWRGGGTD	AIYSDHDTYALDY	LSLLYSSNQKNY	WAS	QQYYSYPLT
	(677)	(678)	(679)	(865)	(866)	(867)
SCT-Da264	GYTFTDYA	ISNYNGDV	ARRHGNRAMDY	QDVGTA	RAS	QQYSTYYT
	(680)	(681)	(682)	(879)	(844)	(880)
SCT-Da265	GYSFTSYY	INPSNGGT	TREGNYGYSWYAY	QDVSTA	SAS	QQHYSTPWT
	(683)	(684)	(685)	(884)	(882)	(885)
SCT-Da266	GYTFTSYW	IDPSDSYT	AGGIHFDY	QSLLDSDGKTY	LVS	WQGTHFPFT
	(686)	(687)	(688)	(926)	(912)	(927)
SCT-Da267	GYTFTSYN	IYPGKDDT	ARVYYGNYGGFDY	ESVDSYGYSF	LAS	QQNNEDPFT
	(689)	(690)	(691)	(858)	(829)	(859)
SCT-Da268	GYTFTSYW	IYPGSGSV	TRGGIGVRSPFDV	QSLVHSNGNTY	KVS	SQSTHVWT
	(686)	(692)	(693)	(919)	(907)	(922)
SCT-Da269	GYTFTSSW	IHPNSGNT	VRLGLFDF	DHINNW	GAT	QQYWSIPYT
	(694)	(695)	(696)	(799)	(800)	(802)
SCT-Da270	GYTFTNYW	ISPRTGNT	TRGEAY	ENIYYS	NAN	KQSYDVPYT
	(697)	(698)	(699)	(780)	(778)	(781)
SCT-Da271	GYTFTNYW	ISPRTGNT	TRGEAY	ENIYYS	NAN	KQSYDVPYT
	(697)	(698)	(699)	(780)	(778)	(781)
SCT-Da272	GYTFTNYW	ISPRTGNT	TRGEAY	ENIYYS	NAN	KQSYDVPYT
	(697)	(698)	(699)	(780)	(778)	(781)
SCT-Da273	GYTFTNYW	ISPRTGNT	TRGEAY	ENIYYS	NAN	KQSYDVPYT
	(697)	(698)	(699)	(780)	(778)	(781)
SCT-Da274	GYTFTNYW	ISPRTGNT	TRGEAY	SSVSY	LTS	QQWSSNPLT
	(697)	(698)	(699)	(944)	(957)	(947)
SCT-Da275	GYTFTNYW	ISPRTGNT	ARGEAY	ENIYYS	NAN	KQSYDVPYT
	(697)	(698)	(700)	(780)	(778)	(781)
SCT-Da276	GYTFTNYW	ISPRTGNT	TRGEAY	ENIYYS	NAN	KQSYDVPYT
	(697)	(698)	(699)	(780)	(778)	(781)
SCT-Da277	GYTFTNYW	ISPRTGNT	TRGEAY	ENIYYS	NAK	KQSYDVPYT
	(697)	(698)	(699)	(780)	(775)	(781)
SCT-Da278	GYTFTNYW	ISPRTGNT	ARGEAY	ENIYYS	NAN	KQAYDVPYT
	(697)	(698)	(700)	(780)	(778)	(779)
SCT-Da279	GYTFTNYW	ISPRTGNT	ARGEAY	ENIYYS	NAN	KQAYDVPYT
	(697)	(698)	(700)	(780)	(778)	(779)
SCT-Da280	GYTFTNYW	ISPRTGNT	TRGEAY	ENIYYS	NAN	KQSYDVPYT
	(697)	(698)	(699)	(780)	(778)	(781)
SCT-Da281	GYTFTNYW	ISPRTGNT	ARGEAY	ENIYYS	NAN	KQAYDVPYT
	(697)	(698)	(700)	(780)	(778)	(779)
SCT-Da282	GYTFTNYW	ISPRTTYT	TRGEAY	ENIYYT	NAN	KQAYDVPYT
	(697)	(701)	(699)	(777)	(778)	(779)
SCT-Da283	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	QDISNY	YTS	QQGNTLPWT
	(702)	(703)	(704)	(773)	(771)	(772)
SCT-Da284	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	ESVDNFGNSF	LAS	QQSNEDPRT
	(702)	(703)	(704)	(838)	(829)	(837)
SCT-Da285	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	ESVDSYGNSF	IAS	QQSNEDPRT
	(702)	(703)	(704)	(846)	(842)	(837)
SCT-Da286	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	QNVDTN	SGS	QQYNTYPYT
	(702)	(703)	(704)	(873)	(874)	(875)
SCT-Da287	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	QRISDY	YAS	QNGHSFPFT
	(702)	(703)	(704)	(893)	(818)	(889)
SCT-Da288	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	QNVDTN	SAS	QQYNSYPYT
	(702)	(703)	(704)	(873)	(882)	(902)
SCT-Da289	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	QNVGTD	SAS	QQYNSYPYT
	(702)	(703)	(704)	(904)	(882)	(902)
SCT-Da290	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	SSISSNY	RTS	QQGSSLPRT
	(702)	(703)	(704)	(928)	(929)	(930)
SCT-Da291	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	SSISSNY	RTS	QQGSSIPRT
	(702)	(703)	(704)	(928)	(929)	(932)
SCT-Da292	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	SSVSY	DTS	QQWSSNPLT
	(702)	(703)	(704)	(944)	(953)	(947)
SCT-Da293	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	SSISY	GTS	QQWSSYPLT
	(702)	(703)	(704)	(954)	(955)	(956)
SCT-Da294	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	ENIYYS	NAN	KQSYDVPYT
	(686)	(705)	(706)	(780)	(778)	(781)
SCT-Da295	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	QSVDYDGDNY	AAS	QQSYEDPWT
	(686)	(705)	(706)	(831)	(794)	(832)
SCT-Da296	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	ESVDSYGNSF	IAS	QQSNEDPRT
	(686)	(705)	(706)	(846)	(842)	(837)
SCT-Da297	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	QDVSTA	SAS	QQHYSTPWT
	(686)	(705)	(706)	(884)	(882)	(885)
SCT-Da298	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	QDVTTA	SAS	QQHYSAPWT
	(686)	(705)	(706)	(886)	(882)	(887)
SCT-Da299	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	QNVGTD	SAS	QQYNSYPYT
	(686)	(705)	(706)	(904)	(882)	(902)
SCT-Da300	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	QNVGTD	SAS	QQYNSYPYT
	(686)	(705)	(706)	(904)	(882)	(902)
SCT-Da301	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	QNVGTN	SAS	QQYNSYPYT
	(686)	(705)	(706)	(899)	(882)	(902)
SCT-Da302	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	SSVSY	LTS	QQWSSNPLT
	(686)	(705)	(706)	(944)	(957)	(947)
SCT-Da303	GYTFTSYW	IYPGDGDT	ARVEADDLWYFDV	QSVTND	YAS	QQDYNSPYT
	(686)	(705)	(706)	(970)	(818)	(962)
SCT-Da304	GYTFTTYW	INPSTGYT	ASYYGTSQAWFAY	ENIYYS	NAN	KQSYDVPYT
	(702)	(703)	(704)	(780)	(778)	(781)
SCT-Da305	GYAFTNYL	INPGSGGP	ASDNYGNYDVLDY	QEISGY	AAS	LQSASYPPT
	(707)	(708)	(709)	(793)	(794)	(795)
SCT-Da306	GYAFTNYL	INPGSGGT	DREDAY	KSLLHSNGNTY	RMS	MQHLEYPYT
	(707)	(710)	(711)	(872)	(869)	(871)
SCT-Da307	GYTFTDYA	INTYSSNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(712)	(713)	(888)	(818)	(889)
SCT-Da308	GYTFTDYA	INTYSSNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(712)	(713)	(888)	(818)	(889)
SCT-Da309	GYTFTDYA	INTYSSNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(712)	(713)	(888)	(818)	(889)
SCT-Da310	GYTFTDYA	INTYSSNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(712)	(713)	(888)	(818)	(889)
SCT-Da311	GYTFTDYV	IYPGGNRT	ARFNDWAMDH	QSLVHSNGITY	KVF	SQSTHVPWT
	(714)	(715)	(716)	(914)	(915)	(916)
SCT-Da312	GYTFTDYV	IYPGGNST	ARFNDWSMDY	QSLVHSNGITY	KVS	SQSTHVPWT
	(714)	(717)	(718)	(914)	(907)	(916)
SCT-Da313	GYTFTDYV	IYPGGSSI	ARFNDWAMDY	QSLVHSNGITY	KVS	SQSTHFPWT
	(714)	(719)	(720)	(914)	(907)	(917)
SCT-Da314	GYTFTDYV	IYPGGSSI	ARFNDWAMDY	QSLVHSNGITY	KVS	SQSTHFPWT
	(714)	(719)	(720)	(914)	(907)	(917)
SCT-Da315	GYTFTSYF	IYPGNVNT	ARDYAMDY	QSINNY	YAS	QQSSTWPLT
	(721)	(722)	(723)	(820)	(818)	(862)
SCT-Da316	GYTFTTYF	IYPGNVNV	SRDYAMDY	QGINNY	YAS	QQSNSWPLT
	(724)	(725)	(726)	(817)	(818)	(819)
SCT-Da317	GYTFTTYY	IYPGNVNT	TRDYAMDY	QSINNY	YAS	QQSNSWPLT
	(727)	(722)	(728)	(820)	(818)	(819)
SCT-Da318	GYTFTTYY	IYPGNVNV	TRDYAMDY	QSINNY	YAS	QQSNSWPLT
	(727)	(725)	(728)	(820)	(818)	(819)
SCT-Da319	GYTFTTYY	IYPGNVNV	TRDYAMDY	QSINNY	YAS	QQSNSWPLT
	(727)	(725)	(728)	(820)	(818)	(819)
SCT-Da320	GYTFTTYY	IYPGNVNT	ARDYAMDY	QSINNY	YAS	QQSNSWPLT
	(727)	(722)	(723)	(820)	(818)	(819)
SCT-Da321	GYTFTTYY	IYPGNVNT	ARDYAMDY	SSVSY	LTS	QQWSSNPLT
	(727)	(722)	(723)	(944)	(957)	(947)
SCT-Da322	GYTFTTYY	IYPGNVNV	SRDYAMDY	QRINSY	YAS	QQSNSWPLT
	(727)	(725)	(726)	(861)	(818)	(819)
SCT-Da323	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QSISDY	SAS	QNGHSFPFT
	(680)	(729)	(713)	(888)	(882)	(889)
SCT-Da324	GYTFTDYA	INTHSDNT	ARPNYDGHWYFDV	QSLLDSDGETY	LVS	WEGTHFWP
	(680)	(730)	(731)	(911)	(912)	(913)
SCT-Da325	GYTFTDYA	INTYSGNT	ARRRGIHRDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(729)	(732)	(888)	(818)	(889)
SCT-Da326	GYTFTDYA	INSYSGNT	ARWAITTGVYYAMDY	SSVSSSY	STS	QQYSGYPLT
	(680)	(733)	(734)	(937)	(877)	(938)
SCT-Da327	GYTFTDYA	INTYSANT	ARRRGSHRDAYFDY	QSISDY	YVS	QNGHSFPFT
	(680)	(735)	(713)	(888)	(897)	(889)
SCT-Da328	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	ESVDNYGISF	AAS	QQSKEVPT
	(680)	(729)	(713)	(839)	(794)	(840)
SCT-Da329	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(729)	(713)	(888)	(818)	(889)
SCT-Da330	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	SSISY	GTS	QQWSSYPLT
	(680)	(729)	(713)	(954)	(955)	(956)
SCT-Da331	GYTFTDYA	INTYSGNT	ARRRGSHQDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(729)	(736)	(888)	(818)	(889)
SCT-Da332	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNSHSFPFT
	(680)	(729)	(713)	(888)	(818)	(894)
SCT-Da333	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QDVSTA	SAS	QQHYSTPWT
	(680)	(729)	(713)	(884)	(882)	(885)
SCT-Da334	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNSHSFPFT
	(680)	(729)	(713)	(888)	(818)	(894)
SCT-Da335	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QTISDY	YAS	QNSHSFPFT
	(680)	(729)	(713)	(898)	(818)	(894)
SCT-Da336	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNSHSFPFT
	(680)	(729)	(713)	(888)	(818)	(894)
SCT-Da337	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNGHSFPFT
	(680)	(729)	(713)	(888)	(818)	(889)
SCT-Da338	GYTFTDYA	INTYSGNT	ARRRGSHRDAYFDY	QSISDY	YAS	QNSHSFPFT
	(680)	(729)	(713)	(888)	(818)	(894)
SCT-Da339	GYTFTDYV	IYPGGNR	ARFNDWAMDY	QSLVHSNGITY	KVS	SQSTHVPWT
	(714)	(737)	(720)	(914)	(907)	(916)
SCT-Da340	GYTFTDYE	IDPETGAT	TARQLGLPFAY	QSVSND	YAS	QQDYTSPPT
	(738)	(739)	(740)	(966)	(818)	(971)
SCT-Da341	GFSLNTSNL	AHIWWDDD	ARKNHYYGHWYFDV	QFVSNF	YAS	QQDYSSPYT
	(741)	(742)	(743)	(963)	(818)	(960)
SCT-Da342	GFSLNTSNM	AHIWWDDD	ARKNHYYGHWYFDV	QFVSNF	YAS	QQDYSSPYT
	(744)	(742)	(743)	(963)	(818)	(960)
SCT-Da343	GFSLSTPGL	AHIWWDDD	ARKNHYYGHWYFDV	QSVNND	YAS	QQDYNSPYA
	(745)	(742)	(743)	(964)	(818)	(965)
SCT-Da344	GFSLSTPNM	AHIWWDDD	ARKIHYYGHWYFDV	QSVIND	YAS	QQDYSSPYT
	(746)	(742)	(747)	(961)	(818)	(960)
SCT-Da345	GFSLSTPSM	AHIWWDDD	ARKNHYSGHWFFDV	QSVIND	YAS	QQDYSSPYT
	(748)	(742)	(749)	(961)	(818)	(960)
SCT-Da346	GFSLSTSGM	AHIWWDDD	ARKNHYYGHWYFDV	QSVSNY	YAS	QQDYSSPYT
	(750)	(742)	(743)	(969)	(818)	(960)
SCT-Da347	GFSLSTSNL	AHIWWDDD	ARKSHYYGHWYFDV	QSVIND	YAS	QQDYSSPYT
	(751)	(742)	(752)	(961)	(818)	(960)
SCT-Da348	GFSLSTSNM	AHIWWDDD	ARKSHYYGHWYFDF	QSVIND	YAS	QQDYNSPFT
	(753)	(742)	(754)	(961)	(818)	(972)
SCT-Da349	GFSLSTSNM	AHIWWDDD	GRKSHYYGHWYFDV	QNVGTD	SAS	QQYNSYPYT
	(753)	(742)	(755)	(904)	(882)	(902)
SCT-Da350	GFSLSTSNM	AHIWWDDD	GRKSHYYGHWYFDV	QNVDNY	YAS	QQDYSSPYT
	(753)	(742)	(755)	(959)	(818)	(960)
SCT-Da351	GFSLSTSNM	AHIWWDDD	GRKSHYYGHWYFDV	QNVDNY	YAS	QQDYSSPYT
	(753)	(742)	(755)	(959)	(818)	(960)
SCT-Da352	GFSLSTSNM	AHIWWDDD	ARKNHYYGHWYFDF	QSVIND	YAS	QQDYNSPYT
	(753)	(742)	(756)	(961)	(818)	(962)
SCT-Da353	GFSLSTSNM	AHIWWDDD	ARKNHYYGHWYFDF	QSVIND	YAS	QQDYNSPYT
	(753)	(742)	(756)	(961)	(818)	(962)
SCT-Da354	GFSLSTSNM	AHIWWDDD	ARKNHYYGHWYFDV	ENIYSN	AAT	QHFWGTPFT
	(753)	(742)	(743)	(790)	(791)	(792)
SCT-Da355	GFSLSTSNM	AHIWWDDD	ARKNHYYGHWYFDV	QDINKY	YTS	LQYDNLWT
	(753)	(742)	(743)	(796)	(771)	(798)
SCT-Da356	GFSLSTSNM	AHIWWDDD	ARKNHYYGHWYFDV	QSVIND	YAS	QQDYSSPYT
	(753)	(742)	(743)	(961)	(818)	(960)
SCT-Da357	GFSLSTSNM	AHIWWDDD	ARKNHYYGHWYFDV	QSVTND	YAS	QQDYNSPYT
	(753)	(742)	(743)	(970)	(818)	(962)
SCT-Da358	GFSLSTSNM	AHIWWDDD	ARKSHYYGHWYFDV	QSVSND	YAS	QQDYNSPYT
	(753)	(742)	(752)	(966)	(818)	(962)
SCT-Da359	GFSLSTSNM	AHIWWDDD	GRKSHYYGHWYFDV	QSVIND	YAS	QQDYSSPYT
	(753)	(742)	(755)	(961)	(818)	(960)
SCT-Da360	GFSLSTSNM	AHIWWDDD	ARKNHYYGHWYFDV	QTVTND	YAS	QQDYISPYT
	(753)	(742)	(743)	(942)	(818)	(943)
SCT-Da361	GFSLSTYGI	AHIWWNDN	ARIDYWFAY	QGIINY	YTS	QQYSKLPYT
	(757)	(758)	(759)	(809)	(771)	(810)
SCT-Da362	GFSLSTYGI	AHIWWNDN	ARIDYWFAY	SSVSY	LTS	QQWSSNPLT
	(757)	(758)	(759)	(944)	(957)	(947)
SCT-Da363	GFTFSSFY	IYAGPGYT	ARHVGRQRGYFDV	QDVSTA	SAS	QQHYSTPWT
	(634)	(652)	(653)	(884)	(882)	(885)
SCT-Da364	GFTFSSFY	IYAGPGYT	ARHVGRQRGYFDV	QDVSTA	SAS	QQHYSTPWT
	(634)	(652)	(653)	(884)	(882)	(885)
SCT-Da365	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da366	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da367	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da368	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da369	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da370	GYTFTEYT	INPNNGGT	ARPHSLLRLRREFDY	SSVSY	LTS	QQWSSNPLT
	(582)	(552)	(589)	(944)	(957)	(947)
SCT-Da371	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da372	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da373	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)
SCT-Da374	GVNIKDTY	IDPANGNR	ARDGYYAPGY	QNVGTD	SAS	QQYNSYPYT
	(574)	(560)	(546)	(904)	(882)	(902)

TABLE 6
		SEQ		SEQ
mAb		ID		ID
AA ID	VH Amino Acid Sequence	NO:	VL Amino Acid Sequence	NO:
SCT-Da001	AVQLQESGPDLVKPSQSLSLTCTVTGYSITSNY	4	DIKMTQSPSSMYASLGERVTITCKASQDINSYL	247
	NWHWIRQFPGNKLEWMGYIHYSDDTNYNPSLKS		SWFQQKTGKSPKTLIYRANRLVDGVPSRFSGSG
	RISITRDPSKNQFFLQLNSVTTEDTATYYCARW		SGQDYSLTISSLEYEDMGIYYCLQYDEFPPTFG
	SYYYGGPYYYSMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da002	DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGY	5	DIKMTQSPSSMYASLGERVTITCKASQDINTYL	248
	NWHWIRQFPGNKLEWMGYIHYSGGTNYNPSLKS		SWFQQKPGKSPKTLIYRANILVDGVPSRFSGSG
	RISITRDASKNQFFLQLNSVTTEDTATYYCGRW		SGQDYSLTISSLEYEDMGIYYCLQYDEFPPTFG
	SYYYGSPYYYSMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da003	DVQLQESGPGLVKPSQSLSLTCSVTGFSITSGY	6	DIVLTQSPASLAVSLGQRVTISCKASQSVDYDG	249
	YWNWIRQFPGNKLEWMGYISYDGSNNYNPSLKN		DSYMNWYQQKPGQPPKVLIYAASNLESGIPARF
	RISITRDTSKNQFFLNLNSVTTEDTATYYCARD		SGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDP
	YYGYPAWFTYWGQGTLVTVSA		RTFGGGTKLEIK
SCT-Da004	DVQLQESGPGLVKPSQSLSLTCSVTGYSITDGY	7	DIQMTQSTSSLSASLGDRVTISCRASQDISNYL	250
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RLSITRDTSENQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISSLEQEDIATYFCQQGNALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da005	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	8	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	251
	FWNWFRQFPGNKLEWLGFINYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTTEDTATYYCARR		SGTAYSLTISNLEEEDIATYFCQQGKSLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da006	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	9	DIQMTQPTSSLSASLGDRVTISCRASQDISNYL	252
	FWNWFRQFPGNKLEWMGYINFDGSSNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTSEDTATYFCARR		SGTDYSLTISNLDQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSITVSS		GGTKLEIK
SCT-Da007	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	9	DIQMTQPTSSLSASLGDRVTISCRASQDISNYL	253
	FWNWFRQFPGNKLEWMGYINFDGSSNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTSEDTATYFCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSITVSS		GGTKLEIK
SCT-Da008	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	9	DIQMTQTTSSLSASLGDRVTISCRASQDINNYL	254
	FWNWFRQFPGNKLEWMGYINFDGSSNYNPSLKN		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTSEDTATYFCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSITVSS		GGTKLEIK
SCT-Da009	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	9	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	255
	FWNWFRQFPGNKLEWMGYINFDGSSNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTSEDTATYFCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSITVSS		GGTKLEIK
SCT-Da010	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	10	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	256
	FWNWFRQFPGNRLEWLGFINYDGTNTYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTTEDTATYYCARR		SGTAYSLTISNLEEADIATYFCQQGKSLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da011	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	11	DIQMTQTTSSLSASLGDRVTISCRASQDINNYL	254
	FWNWFRQFPGNRLEWMGFINYDGTNTYNPSLKN		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da012	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSAY	11	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	256
	FWNWFRQFPGNRLEWMGFINYDGTNTYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTTEDTATYYCARR		SGTAYSLTISNLEEADIATYFCQQGKSLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da013	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSDS	12	DIQMTQTTSSLSASLGDRVTISCRASQDINNYL	254
	FWNWIRQVPGNKLEWMGFISYDGSNNYNPSLKN		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLKLNSVTTEDTATYYCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da014	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSDY	13	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	257
	FWNWIRQFPGNKLEWMGFISYDGSNNYNPSLKN		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLKLNSVTSEDTATYFCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da015	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSDY	14	DIQMTQTTSSLSASLGDRVTISCRASQDISNFL	258
	FWNWIRQFPGNKLEWMGFISYDGSNYCNPSLKN		NWFQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLKLNSVTTEDTATYYCARR		SGTDYSLTISNLEQEDIASYFCQQGKTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da016	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	15	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	259
	FWNWFRQFPGDKLEWMGYINYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RVSISRDTSKNQFFLRLSSVTAEDTATYYCARR		SGTDYSLTISNLEQEDLATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da017	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	16	DIQMTQPTSSLSASLGDRVTISCRASQDINNYL	260
	FWNWFRQFPGNKLEWMGFINYDGSDNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDSWGQGTSVTVSS		GGTKLEIK
SCT-Da018	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	16	DIQMTQTTSSLSASLGDRVTISCRASHDIHNYL	261
	FWNWFRQFPGNKLEWMGFINYDGSDNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDSWGQGTSVTVSS		GGTKLEIK
SCT-Da019	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	17	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	257
	FWNWFRQFPGNKLEWMGFINYDGSNNYNPSLKN		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTSEDTATYYCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da020	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	18	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	262
	FWNWFRQFPGNKLEWMGFINYDGSSNYNPSLKN		LHWYQQKPGFSPKLLIYRTSNLASGVPARFSGS
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	KGWLYAMDYWGQGTSVTVSS		GSGTKLEIK
SCT-Da021	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	19	DIQMTQSTSSLSASLGDRVTISCRASQDISNYL	250
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRFNSVTTEDTATYYCARR		SGTDYSLTISSLEQEDIATYFCQQGNALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da022	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	19	DIQMTQSTSSLSASLGDRVTISCRASQDISNYL	250
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRFNSVTTEDTATYYCARR		SGTDYSLTISSLEQEDIATYFCQQGNALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da023	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	21	DIQMTQSTSSLSASLGDRVTISCRASQDISNYL	263
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRLSSVTTEDTATYFCARR		SGTDYSLTISSLEQEDIATYFCQQGIALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da024	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	22	DIQMTQSTSSLSASLGDRVTISCRASQDISNYL	263
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISSLEQEDIATYFCQQGIALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da025	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	22	DIQMTQSTSSLSASLGDRVTISCRASQDISNYL	250
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISSLEQEDIATYFCQQGNALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da026	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	22	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	264
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	KGWLYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da027	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	22	SIVMTQTPKFLLVSAGDRVTITCRASQSVTNDV	265
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		YGTDFTFTISTVQAEDLAVYFCQQDYNSPYTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da028	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	23	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	266
	FWNWFRQFPGNKLEWMGFLNYDGSNNYNPSLKN		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISSLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLESK
SCT-Da029	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	24	DIQMTQSTSSLSASLGDRVSISCRASQDISNYL	267
	FWNWFRQFPGNKLEWMGFLNYDGSSNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSENQFFLRLSSVTTEDTATYYCARR		SGTDYSLTISSLEQEDVATYFCQQGNALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da030	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	25	DIQMTQTTSSLSASLGDRVTISCRTSQDISNYL	268
	FWNWIRQFPGNKLEWMGFINYDGSNNYNPSLKN		NWYQQKPDGWKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLKLNSVTTEDTATYYCARR		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da031	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	26	DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAV	269
	YWNWIRQFPGNKLEWMGYISYDGSNNYNPSLKN		AWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSG
	RISITRDTSKNQFFLKLNSVTTEDTATYYCARE		SGTDFTLTISNVQSEDLADYFCQQYSSYPYTFG
	GDYGSYWGQGTLVTVSA		GGTKLEIK
SCT-Da032	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGY	27	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	270
	YWNWIRQFPGNKLEWMGYISYDGSNNYNPSLKN		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	RISITRDTSKNQFFLKLTSVTTEDTATYYCTRR		SGTDYSLTISNLEQEDIATYFCQQGNALPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da033	DVQLQESGPGLVKPSQSLSLTCTVTGYSITSDY	28	DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAV	271
	AWNWIRQFPGNKLEWMGYISYSGSTNYNPSLKS		AWYQQRPGQSPKLLIYSASYRFIGVPDRFTGSG
	RISITRDTSKNQFFLQLNSVTTEDTATYYCASG		SGTDFTFTISTVQAEDLAVYYCQQHYSTPFTFG
	YYGIHYYAMDYWGQGTSVTVSS		SGTKLEIK
SCT-Da034	DVQLQESGPGLVKSSQSLSLTCSVTGYSITSGY	29	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	266
	FWNWIRQFPGNKLEWMGFINYDGSSNYNPSLKN		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	RISITRDTSKNQFFLKLNSVTTEDTATYYCARR		SGTDYSLTISSLEQEDIATYFCQQGNTLPWTFG
	KGWLYAMDYWGQGTSVTVSS		GGTKLESK
SCT-Da035	EIHLQQTGPELVKPGASVKISCKASGYSFTAYI	30	DVLMTQTPLSLPVSLGDHASISCRSSQSIVHTN	272
	MLWVKQSHGKSLEWIGNINPYYGSTSYNLKFKG		GNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDR
	KATLTVDQSSSTAYMQLNSLTSDDSAVYYCARG		FSGSGSGTDFTLKISRVEAEDLGLYYCFQGSHV
	PPYYYGSSRDYALDYWGQGTSVTVSS		PYTFGGGTKLEIK
SCT-Da036	EIQLQQTGPELVKPGASVKISCKASGYSFTDYI	31	DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSN	273
	MLWVKQSHGKSLEWIGNINPYYDTTAYNLKFKG		GNTYLHWYLQKPGQSPNLLIYKVSNRFSGVPDR
	KATLTVDKSSSTAYMLLNSLTSEDSAVYYCATY		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHG
	DGFAYWGQGTLVTVSA		PWTFGGGTKLEIK
SCT-Da037	EIQLQQTGPELVKPGASVKISCKASGYSFTDYI	32	DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSY	274
	MLWVKQSHGKSLEWIGNINPYYGTTSYNLKFKG		GNTYLHWHLQKPGQSPKLLIYKVSNRFSGVPDR
	KATLTVDKSSSTAYMQLNSLTSEDSAVYYCATY		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHG
	DGFAYWGQGTLVTVSA		PWTFGGGTKLEIK
SCT-Da038	EIQLQQTGPELVKPGASVKISCKASGYSFTDYI	33	DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSN	275
	MLWVKQSHGKSLEWIGNINPYYYTTSYNLKFKG		GNTYLHWHLQKPGQSPKLLIYKVSNRFSGVPDR
	KATLTVDKSSSTAYMQLNSLTSEDSAVYYCATY		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHG
	DGFAYWGQGTLVTVSA		PWTFGGGTKLEIK
SCT-Da039	EVHLQQSGAELVRPGALVKLSCKASGFNIKDYY	34	EIVLTQSPTPMAASPGEKITITCSASSSISSNY	276
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LHWYRQKPGFSPKLLIYRTSNLASGVPPRFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCTIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSLPRTF
	VRRDYFDYWGQGTTLTVSS		GSGTKLEIK
SCT-Da040	EVKLEESGGGLVQPGGSMRLSCVASGFTFSNYW	35	QIVLTQSPAIMSASPGEKVTITCSASSSVNYMH	277
	MNWVRQSPEKGLEWVAEIRLKFNNYTTHYAESV		WFQQKPGTSPKLWIYSTSNLASGVPARFSGSGS
	KGRFTISRDDSKSSVYLQMNNLRTEDTGIYYCI		GTSYSLTISRMEAEDAATYYCQQRSTYPRTFGG
	KFGGMDYWGPGTSVTVSS		GTKLEIK
SCT-Da041	EVKLVESGGGLVKPGGSLKLSCAASGFAFNSYD	36	DILMTQSPSSMSVSLGDTVSITCHASQGISSNI	278
	MSWVRQTPEKRLEWVATISDGGSFTYYPDSVKG		GWLQRKPGKSFKGLIYHGTNLEDGLPSRFSGSG
	RFTISRDNARNTLYLHMSSLRSEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	QITTLRMDYWGQGTSVTVSS		GGTKLELK
SCT-Da042	EVKLVESGGGLVKPGGSLKLSCAASGFAFSSYD	37	DILMTQSPSSMSVSLGDTVSITCHASQGISSNI	279
	MSWVRQTPEKRLEWVAAISDGGSYTYYPDSVKG		GWLQQKPGKSFKGLIYHGTNLEDGLPSRFSGSG
	RFTISRDNAGNTLYLQMSSLRSEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	RVTTVRMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da043	EVKLVESGGGLVKPGGSLKLSCAASGFAFSSYD	38	DILMTQSPSSMSVSLGDTVSITCHASQGISSNI	280
	MSWVRQTPEKRLEWVATISDGGSYTYYPDSVKG		GWLQQKPGKSFKGLIYHGTNLEDGLPSRFSGSG
	RFTISRDNAGKTLYLQMSSLRPEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	RVTTVRMDYWGQGTSVTVSS		GGTKLEIL
SCT-Da044	EVKLVESGGGLVKPGGTLKLSCAASGFAFSDYD	39	DILMTQSPSSMSVSLGDSVSITCHASQGISSNI	281
	MSWVRQTPEKRLEWVATISDGGSYTYYPDSVKG		GWLQQKAGKSFKGLIYHGTNLEDGVPSRFSGSG
	RFTISRDNARNTLYLQMSSLRSEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	LITTLRMDYWGQGASVTVSS		GGTKVEIK
SCT-Da045	EVKLVESGGGLVKPGGTLKLSCAASGFAFSDYD	39	DILMTQSPSSMSVSLGDTVTITCHASQGISSNI	282
	MSWVRQTPEKRLEWVATISDGGSYTYYPDSVKG		GWLQQKPGKSFKGLIYHGTNLEDGVPSKFGGSG
	RFTISRDNARNTLYLQMSSLRSEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	LITTLRMDYWGQGASVTVSS		GGTKLEIK
SCT-Da046	EVKLVESGGGLVKPGGTLKLSCAASGFAFSDYD	40	DILMTQSPSSMSVSLGDSVSITCHASQGISSNI	283
	MSWVRQTPEKRLEWVATISDGGSYTYYPDSVKG		GWLQQKAGKSFKGLIYHGTNLEDGVPSRFSGSG
	RFTVSRDNARNTLYLQMSSLRSEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	LITTLRMDYWGQGASVTVSS		GGTTLEIK
SCT-Da047	EVKLVESGGGLVKPGGTLKLSCAASGFAFSDYD	41	DILMTQSPSSMSVSLGDSVSITCHASQGISSNM	284
	MSWVRQTPEKRLEWVATISNDGSYTYYPDSVKG		GWLQQKAGKSFKGLIYHGTNLEDGVPSRFSGSG
	RFTISRDNARNTLYLQMSSLRSEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	LITTLRMDYWGQGASVTVSS		GGTKLEIK
SCT-Da048	EVKLVESGGGLVKPGGTLKLSCAASGFAFSDYD	41	DILMTQSPSSMSVSLGDSVSITCHASQGISSNM	285
	MSWVRQTPEKRLEWVATISNDGSYTYYPDSVKG		GWLQQKTGKSFKGLIYHGTNLEDGVPSRFSGSG
	RFTISRDNARNTLYLQMSSLRSEDTALYYCARH		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	LITTLRMDYWGQGASVTVSS		GGTKLEIK
SCT-Da049	EVMLVASGGGLVKPGGSLKLSCAASGFTFSSYT	42	DIVLTQSPASLTVSLGQRATISCRASKSVSTSA	286
	VSWVRQTPEKRLEWVASIISGGGDIYYPDSVRG		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	RFTISRDNARNNLYLQMSSLRSEDTALYYCARW		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELL
	YSAGYFDVWGAGTTVTVSS		TFGSGTKLEIK
SCT-Da050	EVMLVASGGGLVKPGGSLKLSCAASGFTFSSYT	43	DIVLTQSPPSLAVSLGQRATISCRASKSVSTSA	287
	VSWVRQTPEKRLEWVATISGGGVTYYPDSVRGR		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	FTISRDNAKNNLYLQMRSLRSEDTALYYCARWY		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELL
	SVGYFDVWGAGTTVTVSS		TFGSGTKLEIK
SCT-Da051	EVMLVASGGGLVKPGGSLKLSCAASGFTFSSYT	44	DIVLTQSPASLTVSLGQRATISCRASKSVSTSA	288
	VSWVRQTPEKRLEWVATITGGGDTYYPDSVRGR		YSYMHWYQQKLGQPPKLLIYLASNLESGVPARF
	FTISRDNAKNNLYLQMSSLRSEDTALYYCARWY		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELL
	SVGYFDVWGAGTTVTVSS		TFGSGTKLEIK
SCT-Da052	EVMLVASGGGLVKPGGSLKLSCAASGFTFSSYT	45	DIVLTQSPASLAVSLGQRATISCRASKSVSTSA	289
	VSWVRQTPEKRLEWVATITSGGGDTYYPDSVRG		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	RFTISRDNAKNNLYLEMSSLRSEDTALYYCARW		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELL
	YSAGYFDVWGAGTTVTVSS		TFGSGTKLEIK
SCT-Da053	EVMLVASGGGLVKPGGSLNLSCAASGFTFSSYT	46	DIVLTQSPPSLAVSLGQRATISCRASKSVSTSA	287
	VSWVRQTPEKRLEWVATISGGGVTYYPDTVRGR		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	FTISRDNAKNNLYLQMRSLRSEDTALYYCARWY		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELL
	SVGYFDVWGAGTTVTVSS		TFGSGTKLEIK
SCT-Da054	EVMLVESGGGLVKPGGSLKLSCAASGFTFSSYA	47	DIVLTQSPASLAVSLGQRATISCRASKSVSTSN	290
	MSWVRQTPEKRLEWVATIFFGSSVTYFPASVKG		YSYMHWYQQKPGQPPKLLLYLASNLESGVPARF
	RFTISRDNANNTLFLQLSSLRSEDTAMYYCARQ		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELP
	GTSPWFAYWGQGTLVTVSA		TFGGGTKLEIK
SCT-Da055	EVMLVESGGGLVKPGGSLKLSCAASGFTFSSYT	48	DIVLTQSPASLAVSLGQRATISCRASKSVSTSG	291
	MSWVRQTPEKRLEWVATIISGGGNTYYPDSVKG		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	RFTISRDNAKNNLYLQMSSLRSEDTALYYCARW		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELL
	YSAGYFDVWGAGTTVTVSS		TFGSGTKLEIK
SCT-Da056	EVMLVESGGGLVKPGGSLKLSCAASGFTFSSYT	49	DIVLTQSPASLAVSLGQRATISCRASKSVSTSG	292
	MSWVRQTPEKRLEWVATISGGVGDTYYPDSVKG		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	RFTISRDNAKNNLYLQMSSLRSEDTALYYCARQ		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELP
	GGFPWFAYWGQGTLVTVSA		YTFGGGTKLEIK
SCT-Da057	EVQLQPSGAELVKPGASVKLSCTASGFNIEDTY	50	DIVMTQFQKFMSTSVGDRVSVTCKASQNVDTNV	293
	IHWMKQRPEQGLEWIGRIDPANGNTISDPKFQG		AWYQQKPGQSPKLLIYSGSYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNTYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da058	EVQLQPSGAELVKPGASVKLSCTASGFNIEDTY	51	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	294
	IHWMKQRPEQGLEWIGRIDPANGNTISDPKFRG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da059	EVQLQPSGSELVKPGASVKLSCTASGFNIEDTY	52	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	294
	IHWMKQRPEQGLEWIGRIDPANGYTTYDPKFQD		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da060	EVQLQQFGAELVKPGASMKISCKASGYTFTDYN	53	DIVLTQSPVSLVVSLGQRATISCRANETVDSYG	295
	MAWVKQSHGKSLEWIGDINPNYDSTSYNQKFKG		SSFMHWYQQKPGHPPKLLIYRASNLESGIPARF
	KATLTVDKSSSTAYMELRSLTSEDAALYYCARS		SGSGSRTDFTLTINPVEADDVATYFCQQSNEDP
	GFDGYYYAMDYWGQGTSVTVSS		FTFGSGTKLEIK
SCT-Da061	EVQLQQFGAELVKPGASVKISCKASDYTFTDYN	54	DIQMTQTTSSLSASLGDRVTISCSASQGISNYL	296
	MDWVKQSHGKSLEWIGDINPNNGGTIYNLKFKG		NWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSG
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGTDYSLTISNLEPEDIATYYCQQYSKLPLTFG
	HYGNYFYAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da062	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	55	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	297
	IDWVKQSHGKSLEWIGDINPNGDFTTYNLKFKG		NSFMHWYQQKPGQPPKLLVYIASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAAAYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da063	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	56	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	264
	MDWVKQNHGKSLEWIGDINPNNGGTIYNLKFKG		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da064	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	57	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	298
	MDWVKQSHGKSLEWIGDINPNDDSTKYNLKFKG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGKDYTLSITSLQTEDVATYYCQQYWSTPTFGG
	HYGNYFYAMDYWGQGTSVTVSS		GTKLEIK
SCT-Da065	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	57	DIVLTQSPASLAVSLGQRATISCRASESVDSFG	299
	MDWVKQSHGKSLEWIGDINPNDDSTKYNLKFKG		HSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDGATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da066	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	58	DIVLTQSPASLAVSLGQRATISCRASESVDSFG	300
	MDWVKQSHGKSLEWIGDINPNDDSTSYNLKFKG		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIGPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEII
SCT-Da067	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	59	DIVLTQSPASLAVSLGQRATISCRASESVDNFG	301
	MDWVKQSHGKSLEWIGDINPNNGGTIYNLKFKG		NSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da068	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	59	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	264
	MDWVKQSHGKSLEWIGDINPNNGGTIYNLKFKG		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da069	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	60	DIVLTQSPASLAVSLGQRATISCRASESVDSFG	302
	MDWVKQSHGKSLEWIGDINPNNGGTIYNQKFKG		NSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da070	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	60	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	303
	MDWVKQSHGKSLEWIGDINPNNGGTIYNQKFKG		NSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da071	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	60	DIVLTQSPASLAVSLGQRVTISCKASQSVDYDG	249
	MDWVKQSHGKSLEWIGDINPNNGGTIYNQKFKG		DSYMNWYQQKPGQPPKVLIYAASNLESGIPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da072	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	60	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	304
	MDWVKQSHGKSLEWIGDINPNNGGTIYNQKFKG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	HYGNYFYAMDYWGQGTSVTVSS		GGAKLEIK
SCT-Da073	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	61	DIVLTQSPASLAVSLGQRVTISCKASQSVDYDG	249
	MDWVKQSHGKSLEWIGDINPNNGGTLYNLKFKG		DSYMNWYQQKPGQPPKVLIYAASNLESGIPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da074	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	62	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	305
	MDWVKQSHGKSLEWIGDINPNYDSTNYNLKFKG		GWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGKDYTLSITSLQTEDVATYYCQQYWSIPYTFG
	HYGNYFYAMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da075	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	62	DIVLTQSPASLAVSLGQRATISCRASESVDSFG	306
	MDWVKQSHGKSLEWIGDINPNYDSTNYNLKFKG		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTRLEIK
SCT-Da076	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	62	DIVLTQSPASLAVSLGQRVTISCKASQSVDYDG	249
	MDWVKQSHGKSLEWIGDINPNYDSTNYNLKFKG		DSYMNWYQQKPGQPPKVLIYAASNLESGIPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da077	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	63	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	264
	MDWVKQSHGKSLEWIGDISPNYESTNYSLKFKG		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da078	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	63	DIVLTQSPDSLAVSLGQRATISCRASESVDSFG	307
	MDWVKQSHGKSLEWIGDISPNYESTNYSLKFKG		HSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da079	EVQLQQFGAELVKPGASVKISCKASGYTFTDYN	64	DIVLTQSPASLAVSLGQRATISCRAGESVDSFG	308
	VDWVKQSHGKSLEWIGDINPNDDSTSYNLKFKG		NSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTVDKSSSTAYMELRSLTSEDTAVYYCARR		SGSGSRTDFTLTIDPVEADDAAAYYCQQSNEDP
	HYGNYFYAMDYWGQGTSVTVSS		RTFGGGTKLEIK
SCT-Da080	EVQLQQFGTELVKPGASVKISCKASGYTFTDYN	65	DIQMTQTTSSLSASLGDRVTISCRASQDISNYL	257
	INWVKQSHGRSLEWIGDINPNYDSTSYNQNFKG		NWYQQKPDGIVKLLIYYTSRLNSGVPSRFSGSG
	KATLTVDKSSSTSYMELRSLTSEDTAVYYCARG		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	GFYGNFFDYWGQGTTLTVSS		GGTKLEIK
SCT-Da081	EVQLQQFGTELVKPGASVKISCKASGYTFTDYN	66	DIVLTQSPASLAVSLGQRATISCRASESVDSSG	309
	INWVKQSHGRSLEWIGDINPNYDSTSYNQNFKG		NSFMHWYQQKPGQPPKLLIYRASNLESGIPARF
	KATLTVDKSSSTSYMELRSLTSEDTAVYYGARG		SGSGSRTDFTLTINPVEADDVATYYCQQSNEDP
	GFYGNFFDYWGQGTTLTVSS		FTFGSGTKLEIK
SCT-Da082	EVQLQQSGADLVRPGALVKLSCKTSGFNIKDYY	67	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	310
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LNWYQQKPEFSPKLLIYRTSNLASGVPARFSGS
	KASITADTSSSTAYLQLSSLTSEDTAVYYCSIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSLPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da083	EVQLQQSGAEFVRPGALVKLSCKTSGFNIKDYY	68	DILMTQSPSSMSVSLGDSVSITCHASQGISSNI	283
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		GWLQQKAGKSFKGLIYHGTNLEDGVPSRFSGSG
	KASITADTSSNTAYLQLSSLTSEDTAVYYCTIG		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	VRRDYFDYWGQGTTLTVSS		GGTTLEIK
SCT-Da084	EVQLQQSGAEFVRPGALVKLSCKTSGFNIKDYY	68	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	311
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LHWYQQKPGFSPKLFIYRTSNLASGVPARFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCTIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFDYWGQGTTLTVSS		GSGTKLEIK
SCT-Da085	EVQLQQSGAELVKPGASVKLSCTASGFNIEDTY	69	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	312
	IHWMKQRPEQGLEWIGRIDPANGNPIYDPKFQG		LNWYQQKPEFSPKLLIYRTSNLASGVPARFSGS
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	GYYAPGYWGQGTTLTVSS		GSGTKLEIK
SCT-Da086	EVQLQQSGAELVKPGASVKLSCTASGFNIEDTY	70	DIVMTQFQKFMSTSVGDRVSVTCKASQNVDTNV	293
	IHWMKQRPEQGLEWIGRIDPANGNPKSDPRFQG		AWYQQKPGQSPKLLIYSGSYRFSGVPDRFTGSG
	KATITADSSSNTAYLQFSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNTYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da087	EVQLQQSGAELVKPGASVKLSCTASGFNIEDTY	71	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	313
	IHWMKQRPEQGLEWIGRIDPANGNRKYDPRFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da088	EVQLQQSGAELVKPGASVKLSCTASGFNIEDTY	72	DIQMTQSPSSLSASLGGKVTITCKASQDINKYI	314
	IHWMKQRPEQGLEWIGRIDPANGNTISDPRFRG		AWYQHKPVKGPRLLIHYTSTLQPGIPSRFSGSG
	KATITADTSSNTAYLQFSSLTSEDTAVYYCARD		SGRDYSFSISNLEPEDIATYYCLQYDNLRTFGG
	GYYAPGYWGQGTTLTVSS		GTKLEIK
SCT-Da089	EVQLQQSGAELVKPGASVKLSCTASGFNIEDTY	72	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	305
	IHWMKQRPEQGLEWIGRIDPANGNTISDPRFRG		GWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KATITADTSSNTAYLQFSSLTSEDTAVYYCARD		SGKDYTLSITSLQTEDVATYYCQQYWSIPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da090	EVQLQQSGAELVKPGASVKLSCTASGFNIEDTY	72	DIVMTQFQKFMSTSVGDRVSVTCKASQNVDTNV	293
	IHWMKQRPEQGLEWIGRIDPANGNTISDPRFRG		AWYQQKPGQSPKLLIYSGSYRFSGVPDRFTGSG
	KATITADTSSNTAYLQFSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNTYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da091	EVQLQQSGAELVKPGASVKLSCTASGFNIEDTY	73	DIVMTQAAPSIPVTPGESVSISCRSSKSLLHSN	315
	MHWVKERPEQGLEWIGRNDPANGNTEYDPKFQG		GNTFLYWFLLRPGQSPHLLIYRMSNLASGVPDR
	KATITSDTSSNTAYLQLSTLTSEDTAVYYCASL		FSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEF
	WVDYWGQGTSVTVSS		PYTFGGGTKLEIK
SCT-Da092	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	74	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	316
	IHWMKQRPEQGLEWIGRIDPANANTQYDPKFQG		AWYQQRPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNNYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da093	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	75	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	317
	IHWMKQRPEQGLEWIGRIDPANGNTIYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNIYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da094	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	75	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWMKQRPEQGLEWIGRIDPANGNTIYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da095	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	75	ETTVTQSPASLSMAIGEKVTIRCITSTDIDDDM	319
	IHWMKQRPEQGLEWIGRIDPANGNTIYDPKFQG		NWYQQKPGEPPKLLISEGNTLRPGVPSRFSSSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		YGTDFVFTIENMLSEDVADYYCLQSDNLPFTFG
	GYYAPGYWGQGTTLTVSS		SGTKLEIK
SCT-Da096	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	76	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	320
	IHWMKQRPEQGLEWIGRIDPANGNTKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da097	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	77	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	321
	IHWMKQRPIQGLEWIGRIDPANGNSHYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYSCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da098	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	77	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	322
	IHWMKQRPIQGLEWIGRIDPANGNSHYDPKFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da099	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	77	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	323
	IHWMKQRPIQGLEWIGRIDPANGNSHYDPKFQG		AWYQQKSGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da100	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	77	DNVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	324
	IHWMKQRPIQGLEWIGRIDPANGMSHYDPKFQG		AWYQQKSGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da101	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	78	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWMMQRPEQGLEWIGRIDPANGNTIYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLHLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da102	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	79	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	321
	IHWMMQRPEQGLEWIGRIDPANGNTIYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYSCQQYNSYPYTFG
	GYYAPGNWGQGTTLTVSS		GGTKLEIK
SCT-Da103	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	80	DIQMTQTTSSLSASLGDRVTISCSASQGISNYL	325
	IHWMMQRPEQGLEWIGRIDPANGNTIYDPKFQG		NWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDYSLTISNLEPEDIATYYCQQYSKLPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da104	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	80	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	326
	IHWMMQRPEQGLEWIGRIDPANGNTIYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da105	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	80	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWMMQRPEQGLEWIGRIDPANGNTIYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da106	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	81	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWMMQRPEQGLEWIGRIDPANGNTNYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da107	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	82	DILMTQSPSSMSVSLGDTVSITCHASQGISSNI	327
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		GWLQRKPGKSFKGLIYHGTNLEDGLPSRFSGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYFCARD		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da108	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	82	DIVLTQSPASLAVSLGQRATISCKASQSVDYDG	328
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		DNYMNWYQQKPGQPPKLLIYAASNLESGIPARF
	KATITADSSSNTAYLQLSSLTSEDTAVYFCARD		SGSGSGTDFTLNIHPVEEEDAATYYCQQSYEDP
	GYYAPGYWGQGTTLTVSS		WTFGGGTKLEIK
SCT-Da109	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	82	DIVMTQSQKFMSTSVGDGVSVTCKASQNVDSNV	329
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		AWYHQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYFCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEVK
SCT-Da110	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	82	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNI	330
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFSGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYFCARD		SGTDFTLAISNVQSEDLAEYFCQQYNTYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da111	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	83	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	331
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		HWYQQKSHESPRLLIKYVSQSISGIPSRFSGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	GYYAPGYWGQGTTLTVSS		SGTKLEIK
SCT-Da112	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	83	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da113	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	83	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	332
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da114	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	83	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	IHWVKQRPEQGLEWIGRIDPANGNRIYDPKFQG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	GYYAPGYWGQGTTLTVSS		GTKLELK
SCT-Da115	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	84	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	334
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQA		AWYQQKPGQSPKLLIYSASYRFSGVPDRFAGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLADYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEMK
SCT-Da116	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	85	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	304
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGHWGQGTTLTVSS		GGAKLEIK
SCT-Da117	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	85	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	326
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGHWGQGTTLTVSS		GGTKLEIK
SCT-Da118	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	85	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGHWGQGTTLTVSS		GGTKLEIK
SCT-Da119	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	85	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	332
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGHWGQGTTLTVSS		GGTKLEIK
SCT-Da120	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	86	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	335
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYWFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLASEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYSAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da121	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	DIVLTQSPASLAVSLGQRATISCRASESVESNG	336
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		NSFMHWYQQKPGQSPKLLIYRASNLESGIPARF
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGSGSRTDFTLTIYPVEADDVATYYCQQTDEDP
	GYYAPGYWGQGTTLTVSS		FTFGSGTKLGIK
SCT-Da122	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	DIVMTQSPATLSVTPGDRVSLSCRASQRISDYL	337
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGSDFTLSINSVEPEDVGMYYCQNGHSFPFTFG
	GYYAPGYWGQGTTLTVSS		SGTKLEIK
SCT-Da123	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	326
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da124	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	338
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKVEIK
SCT-Da125	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	339
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRYNGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da126	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	340
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRYNGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNTYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da127	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	DVQITQSPSYLAASPGETITINCRASKSISKYL	341
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQEKPGKTNKLLIYSGSTLQSGIPSRFSGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISSLEPEDFAMYYCQQHNEYPLTFG
	GYYAPGYWGQGTTLTVSS		AGTKLELK
SCT-Da128	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	87	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	GYYAPGYWGQGTTLTVSS		GTKLELK
SCT-Da129	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	88	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	TATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da130	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	89	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	342
	MHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTQLEIK
SCT-Da131	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	89	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	313
	MHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da132	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	90	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	342
	MHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYWARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTQLEIK
SCT-Da133	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	91	DIVMTQSQKFMSTSVGDGVSVTCKASQNVDSNV	329
	MHWVKQRPEQGLEWIGRIDPANGNTGYDPKFQG		AWYHQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEVK
SCT-Da134	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	91	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	294
	MHWVKQRPEQGLEWIGRIDPANGNTGYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da135	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	91	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQRPEQGLEWIGRIDPANGNTGYDPKFQG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	GYYAPGYWGQGTTLTVSS		GTKLELK
SCT-Da136	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	91	SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDV	343
	MHWVKQRPEQGLEWIGRIDPANGNTGYDPKFQG		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		YGTDFTFTISTVQAEDLAVYFCQQDYSSPWTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da137	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	92	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	344
	MHWVKQRPEQGLEWIGRIDPANGNTHYDPKFQV		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCTHD		SGTDFTLTISNVQSEDLAEYFCQQYNIYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da138	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	92	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	345
	MHWVKQRPEQGLEWIGRIDPANGNTHYDPKFQV		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCTHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da139	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	92	DIVMTQTPLSLPVSLGDQASISCRSSQSLVHSN	346
	MHWVKQRPEQGLEWIGRIDPANGNTHYDPKFQV		GNTYLHWHLQKPGQSPKLLIYKVSNRFSGVPDR
	KATITADTSSNTAYLQLSSLTSEDTAVYYCTHD		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHA
	GYYAPGYWGQGTTLTVSS		PWTFGGGTKLEIK
SCT-Da140	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	93	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	316
	MHWVKQRPEQGLEWIGRIDPANGNTIYDPKFQA		AWYQQRPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNNYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da141	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	94	DIVMTQSQEFMSTSVGDRVSVTCKASQNVGTNV	347
	MHWVKQRPEQGLEWIGRIDPANGNTIYDPNFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNNYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da142	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	95	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	348
	MHWVKQRPEQGLEWIGRIDPANGNTNYDPKFQG		AWYQQKPGQSPELLIYSASYRYSGVPDRFTGSG
	KATITTDTSSNTAYLQLSSLTSEDTAVYYCAHD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPFTFG
	GYYAPGFWGQGTTLTVSS		GGTKLEIK
SCT-Da143	EVQLQQSGAELVKPGASVKLSCTASGFNIKDTY	96	EIVLTQSPTTMATSPGEKITITCSASSSIISNY	349
	MNWVKQRPEQGLEWIGRIDPANGNTKYDPKFQG		LHWYQQKPGFSPKLLIYRTSNLASGVPARFSGS
	KATITADTSSNTAYLQLSSLTSEDTAVYYCAPF		GSGTSYSLTIGTMETEDVATYYCQQGSSLPRTF
	SYGTLAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da144	EVQLQQSGAELVKPGASVKLSCTASGLNIKDTY	97	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	342
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTQLEIK
SCT-Da145	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	98	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	304
	IHWVKQRPEQGLEWIGRIDPANGNRKSDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGAKLEIK
SCT-Da146	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DILMTQSPSSMSVSLGDSVSITCHASQGISSNM	284
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		GWLQQKAGKSFKGLIYHGTNLEDGVPSRFSGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da147	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DIQMTQTTSSLSASLGDRVTISCSASQGISNYL	296
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		NWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDYSLTISNLEPEDIATYYCQQYSKLPLTFG
	GYYAPGYWGQGTTLTVSS		AGTKLELK
SCT-Da148	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	304
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGAKLEIK
SCT-Da149	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	350
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da150	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	351
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGAKLEIK
SCT-Da151	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da152	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	352
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da153	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	353
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da154	EVQLQQSGAELVKPGASVKLSCTASGVNIKDTY	99	SIVMTQTPKFLLVSAGDRFTITCKASQNVDNYV	354
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	KATITADSSSNTAYLQLSSLTSEDTAVYYCARD		YGTDFTFTITTVQAEDLAVYFCQQDYSSPYTFG
	GYYAPGYWGQGTTLTVSS		GGTKLEIK
SCT-Da155	EVQLQQSGAELVKPGASVKLSCTVSGFNIKDTY	100	DIVMTQAAPSVPVTPGESVSISCRSNKSLLHSN	355
	MHWVKQRPEQGLEWIGMIDPANFNTKYDPKFQG		GNTFLYWFLQRPGQSPQVLIYRHSNLASGVPDR
	KATVTADTSSNTAYLQLSSLTSEDTAVYYCASL		FSGSGSGTAFTLRISRVESEDVGVYYCMQHLEY
	WVDYWGQGTSVTVSS		PYTFGGGTKLEIK
SCT-Da156	EVQLQQSGAELVKPGASVKVSCTASGFNIKDTY	101	DIQMTQSPSSLSASLGGKVTITCKASQDINKYI	314
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQHKPVKGPRLLIHYTSTLQPGIPSRFSGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGRDYSFSISNLEPEDIATYYCLQYDNLRTFGG
	GYYAPGHWGQGTTLSVSS		GTKLEIK
SCT-Da157	EVQLQQSGAELVKPGASVKVSCTASGFNIKDTY	101	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	304
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGHWGQGTTLSVSS		GGAKLEIK
SCT-Da158	EVQLQQSGAELVKPGASVKVSCTASGFNIKDTY	101	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	332
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLAISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGHWGQGTTLSVSS		GGTKLEIK
SCT-Da159	EVQLQQSGAELVKPGASVKVSCTASGFNIKDTY	101	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	322
	IHWVKQRPEQGLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRYSGVPDRFTGSG
	KATITADSLSNTAYLQLSSLTSEDTAVYYCARD		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	GYYAPGHWGQGTTLSVSS		GGTKLEIK
SCT-Da160	EVQLQQSGAELVRPGALVKLSCKASGCNIKDYY	102	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	356
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQA		LNWYQQKPEFSPKLLIYRTSYLASGVPARFSGS
	KASITADTSSNTAYLQFSSLTSEDTAVYYCTIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da161	EVQLQQSGAELVRPGALVKLSCKASGCNIKDYY	103	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	356
	MHWVKQRPEQGLEWIGWIDPENGNTIYDSKFQA		LNWYQQKPEFSPKLLIYRTSYLASGVPARFSGS
	KASITADTSSNTAYLQFSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da162	EVQLQQSGAELVRPGALVKLSCKASGFNIKDFY	104	EIVLTQSPTTMAASPGEKITITCSATSIISSNY	357
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LHWYQQKPGFSPKLLIYRTSNLASGVPARFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFGYWGQGTTLTVSS		GSGTKLDIK
SCT-Da163	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	105	DIQMTQSTSSLSASLGDRVSISCRASQDISNYL	267
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	KARITADTSSNTAYLQLSSLTSEDTAVYYCAIG		SGTDYSLTISSLEQEDVATYFCQQGNALPWTFG
	VRRDYFAYWGQGTTLTVSS		GGTKLEIK
SCT-Da164	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	105	DIQMTQTTSSLSASLGDRVTISCRASHDIHNYL	261
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	KARITADTSSNTAYLQLSSLTSEDTAVYYCAIG		SGTDYSLTISNLEQEDIATYFCQQGNTLPWTFG
	VRRDYFAYWGQGTTLTVSS		GGTKLEIK
SCT-Da165	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	105	EIVLTQSPTTMAASPGEKITIICNASSSISSNY	358
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		FNWYQQKPEFSPKLLIYRTSNLASGVPARFSGS
	KARITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSLPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da166	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	105	EIVLTQSPTTMAASPGEKITITCSANSNISSNY	359
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LNWYQQKPVFSPKLLIYRTSNLASGVPTRFSGS
	KARITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da167	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	DIKMTQSPSSMYASLGERVTITCKASQDIKSYL	360
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		SWYQQKPWKSPKTLIYYATSLADGVPSRFSGSG
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		SGQDYSLTISSLESDDTATYYCLQHGESPFTFG
	VRRDYFAYWGQGTTLTVSS		SGTKLEIK
SCT-Da168	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	DIVLTQSPASLAVSLGQRATISCRASKSVSSSG	361
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		YNYLHWYQQKPGQPPKLLIYLASNLESGVPARF
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		SGSGSGTDFTLNIHPVEEEDAATYYCQHSGELP
	VRRDYFAYWGQGTTLTVSS		LTFGAGTKLELK
SCT-Da169	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	362
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		SGSDFTLSINSVEPEDVGVYYCQNGHSFPPFTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da170	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	DIVMTQTPLSLPVSLGDQASISCRSSQSLVHSD	363
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		GNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDR
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		FSGSGSGTDFTLMISRVEAEDLGVYFCSQSTHV
	VRRDYFAYWGQGTTLTVSS		PWTFGGGTKLEIK
SCT-Da171	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	EIVLTQSPTTMAASPGEKITITCSASSSINSNY	364
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LNWYQQKPEFSPKLLIYRTSNLASGVPTRFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da172	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	312
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LNWYQQKPEFSPKLLIYRTSNLASGVPARFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da173	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	365
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LNWYQQKPEFSPKLLIYRTSNLASGVPGRFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da174	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	106	QIVLTQSPALMAASPGEKVTITCSVSSSISYMY	366
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		WYQQKSETSPKPWIYGTSNLASGVPVRFSGSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GTSYSLTISSMEAEDAATYYCQQWSSYPLTFGA
	VRRDYFAYWGQGTTLTVSS		GTKLELK
SCT-Da175	EVQLQQSGAELVRPGALVKLSCKASGFNIKDYY	107	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	262
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LHWYQQKPGFSPKLLIYRTSNLASGVPARFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFDYWGQGTTLTVSS		GSGTKLEIK
SCT-Da176	EVQLQQSGAELVRPGALVKLSCKTSGFNIKDYY	108	DILMTQSPSSMSVSLGDSVSITCHASQGISSNI	283
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQD		GWLQQKAGKSFKGLIYHGTNLEDGVPSRFSGSG
	KAGITADTSSNTAYLQLSSLTSEDSAVYYCAIG		SGADYSLTISSLESEDFADYYCVQYAQFPYTFG
	VRRDYFAYWGQGTTLTVSS		GGTTLEIK
SCT-Da177	EVQLQQSGAELVRPGALVKLSCKTSGFNIKDYY	108	EIVLTQSPTTMAASPGEKITITCSANSNISSNY	359
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQD		LNWYQQKPVFSPKLLIYRTSNLASGVPTRFSGS
	KAGITADTSSNTAYLQLSSLTSEDSAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da178	EVQLQQSGAELVRPGALVKLSCKTSGFNIKDYY	108	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	367
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQD		LNWYQQKPVFSPKLLIYRTSNLASGVPTRFSGS
	KAGITADTSSNTAYLQLSSLTSEDSAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFAYWGQGTTLTVSS		GSGTKLEIK
SCT-Da179	EVQLQQSGAELVRPGALVKLSCKTSGFNIKDYY	109	EIVLTQSPTTVAASPGEKITITCSASSSISSNH	368
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LNWYQQKPGFSPKLLIYRTSNLASGVPARFSGS
	KASITADTSSNTAYLQLNSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFDYWGQGTTLTVSS		GSGTKLEIK
SCT-Da180	EVQLQQSGAELVRPGALVKLSCKTSGFNIKDYY	110	EIVLTQSPTTVAASPGEKITITCSASSSISSNH	368
	MHWVKQRPEQGLEWIGWIDPENGNTIYDPKFQG		LNWYQQKPGFSPKLLIYRTSNLASGVPARFSGS
	KASITADTSSNTAYLQLSSLTSEDTAVYYCAIG		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	VRRDYFDYWGQGTTLTVSS		GSGTKLEIK
SCT-Da181	EVQLQQSGPELLKPGASVKISCKTSGYTFTEYT	111	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	LHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKD		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSSSAYMELRSLTSEDSAVYYCTRP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da182	EVQLQQSGPELVKPGASMKISCKVSGFSFTGYT	112	DIVLTQSPASLAVSLGQRATISCKASQSVDYNG	369
	MNWVKQSHGKNLEWIGLINTYNGGTFYNQKFKA		YSYLNWYQQKPGQPPKLLIYPASNLESGIPARF
	KATLTVDKSSSTAHMELLSLTSEDSAVYYCARS		SGSGSGTDFTLNIHPVEEEDAATYYCQQSKEDP
	PGRYSMDYWGQGTSVTVSS		YTFGGGTKLEIK
SCT-Da183	EVQLQQSGPELVKPGASMQISCKTSGYTFTEYT	113	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	VHWVKQSHGKSLEWIGVINPSTGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da184	EVQLQQSGPELVKPGASVKISCKTSGYTFAEYT	114	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	370
	MHWVKQSHGKSLEWIGVINPNNGGTTYNQQFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCTRP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGT
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da185	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYP	115	QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMH	371
	MHWVKQSHGKSLEWIGGINPNNGGTTYNQKFKG		WYQQKSGTSPKRWIYDTSKLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCALY		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	GNYWYFDVWGAGTTVTVSS		GTKLELK
SCT-Da186	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	116	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	372
	IHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDHSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISTMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da187	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	117	QIVLTQSPALMSASPGEKVTMTCSATSSVSYMY	373
	IHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da188	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	118	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHLVKQSHGKSLEWIGVINPNNGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da189	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	119	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGAVNPNTGGTTYNQKFKD		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTIDKSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da190	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	120	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	374
	MHWVKQSHGKSLEWIGGINPNNGGTSYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCHQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da191	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	121	DIVMTQSQKFMSTSVGDGVSVTCKASQNVDSNV	329
	MHWVKQSHGKSLEWIGVINPNNGGTTYNQKFKG		AWYHQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCARP		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	HSLLRLRREFDYWGQGTTLTVSS		GGTKLEVK
SCT-Da192	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	121	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGVINPNNGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da193	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	122	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	375
	MHWVKQSHGKSLEWIGVINPNNGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFNGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCTRP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da194	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	123	QIVLTQSPALMSVSPGEKVTMTCSASSSVSYMY	376
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKD		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCTRP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da195	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	124	QIVLTQSPALMSASPGEKVTMTCSASSSVSYIY	377
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da196	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	124	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	378
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSSLASGVPARFSGSGS
	KATLTVDKSSSTAYMELRSLTSEDSAVYYCARP		GTSFSLTISNMEAEDAATYYCHQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da197	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	125	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	379
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSSTAYMELLSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELN
SCT-Da198	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	126	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	294
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTVDQSSSTAYMELRSLTSEDSAVYYCARP		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	HSLLRLRREFDYWGQGTTLTVSS		GGTKLEIK
SCT-Da199	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	126	QIVLTQSPALMSASPGEKVTMTCSASSSVSYIY	377
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da200	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	126	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da201	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	127	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSSTAYMELRSLTYEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da202	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	128	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	294
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTVDQSSTTAYMELRSLTSEDSAVYYCARP		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	HSLLRLRREFDYWGQGTTLTVSS		GGTKLEIK
SCT-Da203	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	128	EIVLTQSPTTMAASPGEKITITCSANSNISSNY	359
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		LNWYQQKPVFSPKLLIYRTSNLASGVPTRFSGS
	KATLTVDQSSTTAYMELRSLTSEDSAVYYCARP		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	HSLLRLRREFDYWGQGTTLTVSS		GSGTKLEIK
SCT-Da204	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	128	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMH	380
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPGSSPKPWIYATSNLASGVPARFSGSGS
	KATLTVDQSSTTAYMELRSLTSEDSAVYYCARP		GTSYSLTISRVEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da205	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	128	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSTTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da206	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	129	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGVINPNTGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSTTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da207	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	130	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGVINPNTGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSTTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da208	EVQLQQSGPELVKPGASVKISCKTSGYTFTEYT	131	QIVLTQSPALMSASPGEKVTMTCSASSSVSYIY	381
	MHWVKQSQGKSLEWIGAVNLNTGGTTYNQKFKD		WYQQKPGSSPKPWIYLTSNLASGVPPRFSGSGS
	KATLTIDKSSSTAYMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAASYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da209	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYV	132	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	317
	IHWVKQKPGQGLEWIGYINPYHDGTKYNEKFKG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTSDKSSSTAYMELSSLTSEDSAVYYCARS		SGTDFTLTISNVQSEDLAEYFCQQYNIYPYTFG
	RTVIGFDYWGQGTTLTVSS		GGTKLEIK
SCT-Da210	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYV	133	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	382
	MHWVKQKPGQGLEWIGYINPYHDGTKYNEKFIG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATLTSDKSSSTAYMELSSLTSEDSAVYYCARS		SGTDFTLSINSVEPEDVGVYYCQSGHSFPLTFG
	RTVIGFDYWGQGTTLTVSS		AGTKLEVK
SCT-Da211	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYV	134	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	317
	MHWVKQKPGQGLEWIGYINPYHDGTKYNEKFKG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTSDKSSSTAYMELSSLTSEDSAVYYCARS		SGTDFTLTISNVQSEDLAEYFCQQYNIYPYTFG
	RTVIGFDYWGQGTTLTVSS		GGTKLEIK
SCT-Da212	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYV	135	DIQMTQSPASLSASVGETVTITCRASENIYSYL	383
	MHWVKQKPGQGLEWIGYINPYNDATKNNEKFKV		AWHKQKQGKSPQFLVYNAKTLAEGVPSRFSGSG
	KATLTSDKSSNTAYMELSSLTSEDSAVYYCARG		SGTQFSLKINGLQPEDFGSYYCQHHYVIPPTFG
	VRLLDYWGQGTTLTVSS		GGTKLEIK
SCT-Da213	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYV	136	DIVMTQSPATLSVTPGDRVSLSCRASQNISDYL	384
	MHWVKQKPGQGLEWIGYINPYTDGTKYNEKFKG		HWYQQRSHESPRLLIKYASLSISGIPSRFSGSG
	KATLTSDKSSSTAYMELSSLTSEDSAVYYCAKS		SGSDFTLSINSVEPEDVGLYYCQNGHSFPLTFG
	RTVIGFDYWGQGTTLTVSS		AGTKLELK
SCT-Da214	EVQLQQSGPELVKPGASVKMSCKASGYTFTSYV	137	DIVMTQSPATLSVTPGDRVSLSCRASQNISDYL	385
	MHWVRQKPGQGLEWIGYINPYNDGTKYNEKFKG		HWYQQRSHESPRLLIKYASLSISGIPSRFSGSG
	KATLTSDKSSSTANMELSSLTSEDSAVYYCARS		SGSDFTLSINSVEPEDVGVYYCQNAHSFPLTFG
	RTVVGFDYWGQGTTLTVSS		AGTKLELK
SCT-Da215	EVQLQQSGPELVKPGASVKMSCKASGYTFTTYV	138	QNVLTQSPALMSASPGEKVTMTCSASSSVSYMY	386
	MHWVKQKPGQGLEWICYINPYNDGSNYNEKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTSDKSSTTAYMELSSLTSEDSAVYYCARW		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	VYYDFGGSMDYWGQGTSVTVSS		GTKLELK
SCT-Da216	EVQLQQSGPELVKPGASVKMSCKASGYTFTTYV	139	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQKPGQGLEWIGYINPYNDGSNYNEKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTSDKSSTTAYMELSSLTSEDSAVYYCARW		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	VYYDFGGSMDYWGQGTSVTVSS		GTKLELK
SCT-Da217	EVQLQQSGPELVKPGASVKMSCKASGYTFTTYV	139	QNVLTQSPALMSASPGEKVTMTCSASSSVSYMY	386
	MHWVKQKPGQGLEWIGYINPYNDGSNYNEKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTSDKSSTTAYMELSSLTSEDSAVYYCARW		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	VYYDFGGSMDYWGQGTSVTVSS		GTKLELK
SCT-Da218	EVQLQQSGPELVKPGTSVKISCKTSGYTFTEYT	140	QIVLTQSPALMSASPGEKVTMTCSASSSVSYIY	387
	MHWVKQSHGKSLEWIGAVNPNTGGTTYNQKFKD		WYQQKPRSSPKPLIYLTSNLASGVPARFSGSGS
	KATLTIDKSSSTAYMQLRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAASYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da219	EVQLQQSGPELVKPGTSVKMSCKASGYTFTSYV	141	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	388
	MHWVKQKPGQGLEWIGYINPYHDGTQYNEKFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATLTSDKSSSTAYMELSSLTSEDSAVYYCARS		SGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFG
	RTVIGFDYWGQGTTLTVSS		AGTKLELK
SCT-Da220	EVQLQQSGPELVKSGASVKISCKTSGYTFTEYT	142	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVKQSHGKSLEWIGVINPNSGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDQSSSTAYMELRSLTSEESAVYYCTRP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da221	EVQLQQSGPELVTPGASVNISCKTSGYTFTEYT	143	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	389
	MHWVRQSHGKSLEWIGVINPNSGGTTYNQKFKD		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSTTAFMELRSLTSEDSAVYYCARP		GTSYSLTISNMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da222	EVQLQQYGPELVKPGASVKISCKTSGYTFTEYT	144	DIVMTQSQKFMSTSVGDGVSVTCKASQNVDSNV	329
	MHWVRQSHGKSLEWIGVINPNNGGTTYNQKFKG		AWYHQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTVDKSSTTAFMELRSLTSEDSAVYYCARP		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	HSLLRLRREFDYWGQGTTLTVSS		GGTKLEVK
SCT-Da223	EVQLQQYGPELVKPGASVKISCKTSGYTFTEYT	144	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MHWVRQSHGKSLEWIGVINPNNGGTTYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTVDKSSTTAFMELRSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	HSLLRLRREFDYWGQGTTLTVSS		GTKLELK
SCT-Da224	EVQLVESGGDLAKPGGSLKLSCAASGFTLSRYG	145	DIQMTQSPAFLSASVGESVTITCRASENIYSYL	390
	MSWVRQTPDKRLEWVATSSGGGIYTYYPDSVKG		AWYQQKQGKSPQLLVYNAKTLAEGVPSRFSGSG
	RFTISRDNAKNTLYLQMSSLKSEDTAMYYCARH		SGTHFSLKINSLQPEDFGGYYCQHHYGIPPWTF
	DGVPMDYWGQGTSVTVSS		GGGTKLEIK
SCT-Da225	EVQLVESGGDLVKPGGSLKLSCAASGFTFSSYG	146	DIVLTQSPASLAVSLGQRATFSCRASKSVSTSG	391
	MSWVRQTPDKRLEWVATIFSGDSNTYYLDSVKG		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	RFIISRDNAKNTLYLQMSSLKSEDTAMYYCSRQ		SGSGSGTDFTLNIHPVEEEDAAAYYCQHSRELP
	GHRSWFAYWGQGTLVTVSA		YTFGGGTKLEIK
SCT-Da226	EVQLVESGGDLVKPGGSLKLSCAASGFTFSTYG	147	EIVLTQSPTTMATSPGEKITITCSASSSIISNY	349
	MSWVRQTPDKRLEWVATISGGGIYTYYPDSVKG		LHWYQQKPGFSPKLLIYRTSNLASGVPARFSGS
	RFTISSDNAKNTLYLQMSSLKSEDTAMYYCVRM		GSGTSYSLTIGTMETEDVATYYCQQGSSLPRTF
	ITTYFDHWGQGTTLTVSS		GSGTKLEIK
SCT-Da227	EVQLVESGGDLVKPGGSLKVSCAASGFTFSSYG	148	DIVLTQSPASLVVSLGQRATISCRASKSVSTSG	392
	MSWVRQTPDKRLEWVATIFSGDSYTYYSDSVKG		YSYMHWYQQKPGQPPKLLIYLASNLESGVPARF
	RFTISRDNAKNTLYLQMSSLKSEDTAMYYCARQ		SGSGSGTDFTLNIHPVEEEDAATYYCQHSRELP
	GHRSWFAYWGQGTLVTVSA		STFGGGTKLEIK
SCT-Da228	EVQLVESGGGLVKPGGSLKLSCAASGFTFSSYA	149	DIQMTQSPASLSASVGETVTITCRASENIYSYL	393
	MSWVRQTPEKRLEWVATISSGGSYTYYPDSVKG		VWYQQKQGKSPQLLVYYAKTLAEGVPSRFSGSG
	RFTISRDIAENTLFLQMSSLRSEDTAMYYCARH		SGTQFSLKINSMQPEDFGSYYCQHHYGTPLTFG
	EDTTYYYAMDYWGQGTSVTVSS		VGTKVELK
SCT-Da229	EVQLVESGGGLVLPKGSLKLSCAASGFTFNTYA	150	QIVLTQSPAIMSASPGEKVTLTCSASSSVSSSH	394
	MNWVRQAPGKGLEWVARIRIKSNNYATSYADSV		MYWYQQKPGSSPKLWIYSTSNLASGVPARFSGS
	KDRFTISRDDSQSMLYLQMNNLKTEDTAVYYCV		GSGTSYSLTISSMEAEDAASYFCHQWSSYPYTF
	RQAYGNSYFFAMDYWGQGTSVTVSS		GGGTKLEIK
SCT-Da230	EVQLVETGGGLVQPKGSLKLSCAASGFTFNTNA	151	DVVMTQTPLSLPVSLGDQASISCSSSQSLVYSN	395
	MNWVRQAPGKGLEWVARIRSKSNNYATNYVDSV		GNTYLHWYLQKPGQSPKLLIYKVSNRFPGVPDR
	KDRFTISRDDSQSILYLQMNNLKTEDTAMYYCT		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV
	AMDYWGQGTSVTVSS		PYTFGGGTKLEIK
SCT-Da231	HVQLQQSGPELVRPGASVKLSCKASGYIFITYW	152	QIVLTQSPAIMSASPGEKVTISCSASSSVSYMY	396
	MTWVKQRPGQGLEWIGQIFPASGSTTYNEMFEG		WYQQKPGSSPKPWIYRTSNLASGVPARFSGSGS
	KATLTVDTSSSTAYMQLSSLTSEDSAVYYCASY		GTSYSLTISSMEAEDAATYYCQQYHSFPRTFGG
	DGYYSWFAYWGQGTLVTVSA		GTKLEIK
SCT-Da232	QGQMQQSGAELVKPGASVKLSCKTSGFTFSHSY	153	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	397
	ISWLKQKPGQSLEWIAWIYAGTGGTTYNQKFTG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARH		SGKDYTLSITSLQIEDVATYSCQQYWSIPYTFG
	ETYGSSPDYWGQGTTLTVSS		GGTKLEIK
SCT-Da233	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSFY	154	DIVMTQSHKFMSTSVGDRVNITCKASQDVNTAV	398
	ISWLKQKPGQSLEWIAWIDAGTGGTSYNQKFTG		AWYQQKPGQSPKLLFYSTSYRYTGVPDRFTGSG
	KAQLTVDTFSSTAYMQFSSLTTEDSAIYYCARH		SGTDFTFTISSVQAEDLAVYYCQQHYSSPWTFG
	VGRLRGYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da234	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSNY	155	DIVLTQSPAALSVTPGDSVSLSCRASQSISSTL	399
	ISWLKQKPGQSLEWIAWIYAGTGSTGYNQKFTG		HWYQQKSHESPRLLIRYASQSISGIPSRFSGSG
	KAQLTVDTFSSTAYMQFSSLTTEDSAIYYCASH		SGTDFTLSINSVETEDFGMYFCHQSYSWPHTFG
	DGHDAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da235	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSNY	156	DIVMTQSHKFMSTSVGDRVSITCRASQDVSTAV	400
	ISWLNQKPGQSLEWIAWIDAGTGGSSYNQKFTG		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTVSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARH		SGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFG
	VGRLRGYFDVWGAGTRVTVSS		GGTKLEIK
SCT-Da236	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSRY	157	DIVLTQSPAALSVTPGDSVSLSCRASQSISNTL	401
	ISWLKQKPGQSLEWIAWIYAGTGGTGYNQKFTG		HWYQQKSHESPRLLIRYASQSISGIPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAMYYCASH		SGTDFTLSINSVETEDFGMYFCQQSNDWPHTFG
	DGHDAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da237	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSRY	157	DIVLTQSPAALSVTPGDSVSLSCRASQSISNTL	402
	ISWLKQKPGQSLEWIAWIYAGTGGTGYNQKFTG		HWYQQKSHESPRLLIRYASQSISGIPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAMYYCASH		SGTDFTLSINSVETEDFGMYFCQQSYDWPHTFG
	DGHDAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da238	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSRY	158	DIVLTQSPAALSVTPGDSVSLSCRASQSISNTL	403
	ISWLKQYPGQSLEWIAWIYAGTGGSGYNQKFTG		HWYQQKSHESPRLLIRYASQSISGIPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAMYYCASH		SGTDFTLSINSVETEDFGMYFCQQSYNWPHTFG
	DGHDAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da239	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	159	DIQMTQSPASLSGSVGETVTITCRASENIYSFL	404
	ISWLKQKPGQSLEWIAWIYAGTGDTSYNQKFTG		AWYQQKQGKSPQLLIYNARTLAGGVPSRFSGSR
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCASP		SGTQFSLRINSLQPEDFGTYFCQHHYGPPFTFG
	TGINWYFDVWGAGTTVTVSS		GGTNLEIK
SCT-Da240	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	160	DIQMTQSPASLSASVGETVTITCRASENIYSFL	405
	ISWLKQKPGQSLEWIAWIYAGTGDTSYNQKFTG		AWYQQKQGKSPQLLIYNARALAEGVTSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCASP		SGTQFSLRINSLQPEDFGTYFCQHHYGPPFTFG
	TGVNWYFDVWGAGTTVTVSS		GGTNLEIK
SCT-Da241	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	161	DIQMTQSSSYLSVSLGGRVTITCKASDHISNWL	406
	ISWLKQKPGQSLEWIAWIYAGTGGTSYNQKFTG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARP		SGKDYTLSITSLQTEDVATYYCQQYWSLPYTFG
	NGYGYGMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da242	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	162	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	407
	ISWLKQKPGQSLEWIAWIYAGTGGTSYNQKFTG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARQ		SGKDYTLSITSLQTEDVATYFCQQYWTIPYTFG
	DSYGRGPDCWGQGTTLTVSS		GGTKLEIK
SCT-Da243	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	163	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	408
	ISWLKQKPGQSLEWIAWIYAGTGGTSYNQKFTG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARQ		SGKDYTLSITSLQTEDVATYYCQQYWSIPYTFG
	DSYGRSPDYWGQGTTLTVSS		GGTKLEIK
SCT-Da244	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	164	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	397
	ISWLKQKPGQSLEWIAWIYAGTGGTTYNQKFTG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARH		SGKDYTLSITSLQIEDVATYSCQQYWSIPYTFG
	ETYGSGPDYWGQGTTLTVSS		GGTKLEIK
SCT-Da245	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	165	DIQMTQSPASLSASVGETVTITCRASGNIHNYL	409
	ISWLKQKPGQSLEWIAWIYAGTGGTTYNQKFTG		AWYQQKQGKSPQLLVYNAKTLADGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARH		SGTQYSLKINSLQPEDFGSYYCQHFWSTPWTFG
	ETYGSSPDYWGQGTTLTVSS		GGTKLEIK
SCT-Da246	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	165	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	397
	ISWLKQKPGQSLEWIAWIYAGTGGTTYNQKFTG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARH		SGKDYTLSITSLQIEDVATYSCQQYWSIPYTFG
	ETYGSSPDYWGQGTTLTVSS		GGTKLEIK
SCT-Da247	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	166	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	305
	ISWLKQKPGQSLEWIAWIYAGTGGTTYNQKFTG		GWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARQ		SGKDYTLSITSLQTEDVATYYCQQYWSIPYTFG
	DSYGRSPDYWGQGTTLTVSS		GGTKLEIK
SCT-Da248	QGQMQQSGAELVKPGASVKLSCKTSGFTFSSSY	167	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	397
	ISWLKQKPGQSLEWIAWIYAGTGGTTYNQKFTG		AWYQQKPGNAPRLLISGATSLETGVPSRFSGSG
	RAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARQ		SGKDYTLSITSLQIEDVATYSCQQYWSIPYTFG
	DSYGRSPDYWGQGTTLTVSS		GGTKLEIK
SCT-Da249	QGQMQQSGAELVKPGASVKLSCRTSGFTFSSRY	168	DIVLTQSPATLSVTPGDRVSLSCRASQSINNYL	410
	ISWLKQKPGQSLEWIAWIYAGTGGTSYNQKFTG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCASH		SGTDFTLSINSVETEDFGVYFCQQSNSWPLTFG
	DGLDAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da250	QGQMQQSGAELVKPGASVRLSCKTSGFTFSSFY	169	DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAV	411
	ISWLKQKPGQSLEWIAWIYAGPGYTSYNQKFTG		AWYQQKPGQSPKLLIYSASYRYTGVPDHFTVSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARH		SGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFG
	VGRQRGYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da251	QGQMQQSGAELVKSGASVKLSCKTSGFTFSSSY	170	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	412
	ISWLKQKPGQSLEWIAWIYAGTGGTTYNEKFTG		AWYQQKPGNAPRLLISGATSLEPGVPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCGRH		SGKDYTLTITSLQTEDVATYYCQQYWSLPYMFG
	NGYGIGMDYWGQGTSVTVSS		GGTKLEIK
SCT-Da252	QGQMQQSGGELVKPGASVKLSCKTSGLTFSSSY	171	DIVMTQSHKFMSTSVGDRVSITCKASQDVTTAV	413
	ISWLKQKPGQSLEWIAWIDAGTGGTSYNQKFTG		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTVSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCARH		SGTDFTLTISSVQAEDLAVYYCQQHYSAPWTFG
	VGRLRGYFDVWGAGTTVTVSS		GGTKLKIT
SCT-Da253	QGQMQQSGPELVKPGASVKLSCKTSGFTFSSNY	172	DIVLTQSPAALSVTPGDSVSLSCRASQSISNTL	414
	ISWLKQKPGQSLEWIAWIYAGTGGTGYNQKFTG		HWYQQKSHESPRLLIRYASQSISGIPSRFSGSG
	KAQLTVDTSSSTAYMQFSSLTTEDSAIYYCASH		SGTDFTLSINSVETEDFGMYFCQQSNSWPHTFG
	DGHDAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da254	QIQLQQSGAELVRPGVSVKISCKGSGYTFTDYP	173	DIVLTQSPASLAVSLGQRATISCRASKSVSTSG	415
	IHWVKQSHTTSLEWIGVIITYYGDATYNQKFKG		YSYMHWYQQKPGQAPKLLIYLASNLESGVPARF
	KATMTVDKSSSTAYMELARLTSDDSAIYYCASH		SGSGSGTDFTLNIQPVEEEDAATYYCQHSRELY
	RGKGYFDVWGAGTTVTVSS		TFGGGTKLEIK
SCT-Da255	QIQLQQSGAELVRPGVSVKISCKGSGYTFTDYP	173	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	IHWVKQSHTTSLEWIGVIITYYGDATYNQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATMTVDKSSSTAYMELARLTSDDSAIYYCASH		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	RGKGYFDVWGAGTTVTVSS		GTKLELK
SCT-Da256	QIQLQQSGPELVKPGASVKISCKASGYTFTDYF	174	DIVLTQSPATLSVTPGDRVSLSCRASQSISNYL	416
	INWVKQKPGQGLEWIGWIYPGNINTNYNENFKG		HWYQQKSRESPRLLIKYASQSISGIPSRFSGSG
	KATLTVDTSSSTAYMQLSSLTSEDTAVYFCAGG		SGTDFTLSINSVETEDFGMYFCQQSNSWPLTFG
	NYALDYWGQGTSVTVSS		AGTKLELK
SCT-Da257	QIQLQQSGPELVKPGASVKISCKASGYTFTDYY	175	DIVLTQSPATLSVTPGDRVSLSCRASQSISNYL	417
	INWVKQKPGQGLEWIGCIYPGNDNSNYNEKFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATLTVDTSSSTAYMQLSSLTSEDTAVYFCAGG		SGTDFTLSINSVETEDFGMYFCQQSNSWPLTFG
	NYAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da258	QIQLQQSGPELVNPGASVMISCKASGYTFTAYY	176	DIVLTQSPATLSVTPGDRVSLSCRASQSISNYL	418
	MNWVKQKPGQGLEWIGWIYPGNDNTNYNEKFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATLTVDTSSSTAFMQLSSLTSEDTAVYFCAGG		SGTDFTLSISSVETEDFGMYFCQQSNSWPLTFG
	NYAMDYWGLGTSVTVSS		AGTKLELK
SCT-Da259	QIQLVQSGPELKKPGETVKISCKASGYTFTNSG	177	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMH	419
	MNWVKQAPGKGLKWMGWINTYTGEPTYVDDFKG		WYQQKPGSSPKPWIFATSNLAYGVPDRFSGSGS
	RFAFSLETSASTAYLQINNLKNEDTATYFCAPT		GTSYSLTISRMEAEDAATYYCQQWSSTPPTFGG
	IQVRRLFDYWGQGTTLTVSS		GTKLEIK
SCT-Da260	QIQLVQSGPELKKPGETVKISCKASGYTFTNSG	178	QIVLSQSPAILSASPGEKVTMTCRASSSVSYMH	419
	MNWVKQAPGKGLKWMGWINTYTGEPTYVDDFKG		WYQQKPGSSPKPWIFATSNLAYGVPDRFSGSGS
	RFAFSLETSASTAYLQINNLKNEDTATYFCAPT		GTSYSLTISRMEAEDAATYYCQQWSSTPPTFGG
	IQVRRLVDYWGQGTTLTVSS		GTKLEIK
SCT-Da261	QIQLVQSGPELKKPGETVKISCKASGYTFTNYG	179	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	420
	MNWVKQAPGKGLKWMGWINTNTGEPTYAEEFKG		NSFMHWYQQKPGQPPKLLIYRASNLESGIPARF
	RFAFSLETSASTAYLQINNLKNEDTATYFCARR		SGSGSRTDFTLTINPVEADDVATYYCQQSNEDP
	GYYGRGDYWGQGTTLTVSS		YTFGGGTKLEIK
SCT-Da262	QVQLKESGPGLVAPSQSLSITCTVSGFSLTSYD	180	SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDV	421
	ISWIRQPPGKGLEWLGVIWTGGGTNYNSAFMSR		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	LSISKDNSKSQVFLKMNSLQTDDTAIYYCVRWG		YGTDFTFTISTVQAEDLAVYFCQQDYSSPPTFG
	DDYDWFAYWGQGTLVTVSA		GGTKLEIK
SCT-Da263	QVQLKQSGPSLVQPAQSLSITCTVSGFSLTTYG	181	DIVMSQSPSSLAVSVGEKVTMSCKSSLSLLYSS	422
	VHWLRQSPGKGLEWLGVIWRGGGTDYNAPFMSR		NQKNYLAWYQQKPGQSPKLLIYWASTRESGVPD
	LSITKDDSKSQLFFKMNSLHADDTAIYYCAIYS		RFTGSGSGTGFTLTISSVKAEDLAVYYCQQYYS
	DHDTYALDYWGQGTSVTVSS		YPLTFGAGTKLELK
SCT-Da264	QVQLQHSGAELVRPGVSVKISCKGSGYTFTDYA	182	DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAV	423
	MHWVKQSHAKSLEWIGVISNYNGDVTYNQKFKG		AWYQQKPGQSPKLLIYRASTRHTGVPDRFTGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGTDFILTISNVQSEDLADYFCQQYSTYYTFGG
	HGNRAMDYWGQGTSVTVSS		GTKLEIK
SCT-Da265	QVQLQQPGAELVKPGASVKLSCKASGYSFTSYY	183	DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAV	424
	MYWVKQRPGHGLEWIGEINPSNGGTYFNVKFQS		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSG
	KATLTVDKSSTTAYMQLSSLTSEDSAVYFCTRE		SGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFG
	GNYGYSWYAYWGQGTLVTVSA		GGTKLEIK
SCT-Da266	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYW	184	DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSD	425
	MHWVKQRPGQGLEWIGEIDPSDSYTNYNQKFKG		GKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDR
	KATLTVDKSSSTAYMQLSSLTSEDSAVYYCAGG		FTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHF
	IHFDYWGQGTTLTVSS		PFTFGSGTKLEIK
SCT-Da267	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYN	185	DIVLTQSPASLAVSQGQRATISCRASESVDSYG	426
	LHWLKLTPGQGLEWIGIIYPGKDDTSYNQKFKG		YSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTADTSSSTAYMQLSSLTSEDSAVYYCARV		SGSGSRTDFTLTIDPVEADDAATYYCQQNNEDP
	YYGNYGGFDYWGQGTLVTVSA		FTFGSGTKLEIK
SCT-Da268	QVQLQQPGSELVRPGASVKLSCKASGYTFTSYW	186	DIVMTQTPLSLPVSLGDQASISCRSSQSLVHSN	427
	MYWVKQRPGQGLEWIGNIYPGSGSVNYDEKFKS		GNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDR
	KATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRG		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV
	GIGVRSPFDVWGAGTTVTVSS		WTFGGGTKLEIK
SCT-Da269	QVQLQQPGSVLVRPGASVKLSCKASGYTFTSSW	187	DIQMTQSSSYLSVSLGGRVTITCKASDHINNWL	428
	MHWAKQRPGQGLEWIGEIHPNSGNTNYNEKFKG		AWYQQKPGNAPRLLISGATSLETGIPSRFSGSG
	KATLTIDTSSSTAYVDLSSLASEDSAVYYCVRL		SGKDYSLSITSLQIEDVATYSCQQYWSIPYTFG
	GLFDFWGQGTTLTVSS		GGTKLEIK
SCT-Da270	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	188	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	429
	MHWIKQRPGQGLEWIGYISPRTGNTEYNQKFKD		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSASG
	KATLTADKSSSIVYMQLSSLTSEDSAVYYCTRG		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da271	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	188	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	430
	MHWIKQRPGQGLEWIGYISPRTGNTEYNQKFKD		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSIVYMQLSSLTSEDSAVYYCTRG		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da272	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	189	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	431
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKD		AWFQLKQGKSPQLLIYNANTLEDGVPSRFSASG
	KATLTADKSSSIVYIQLSSLTSEDSAVYYCTRG		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da273	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	190	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	429
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKD		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSASG
	KATLTADKSSSIVYMQLSSLTSEDSALYYCTRG		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da274	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	190	QIVLTQSPALMSASPGEKVTMTCSASSSVSYIY	387
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKD		WYQQKPRSSPKPLIYLTSNLASGVPARFSGSGS
	KATLTADKSSSIVYMQLSSLTSEDSALYYCTRG		GTSYSLTISSMEAEDAASYYCQQWSSNPLTFGA
	EAYWGQGTLVTVSA		GTKLELK
SCT-Da275	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	191	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	430
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKD		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSIVYMQLSSLTSEDSAVYYCARG		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da276	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	192	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	432
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKD		AWFQLKQGKSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSIVYMQLSSLTSEDSAVYYCTRG		SGTQFSMKIKSMQPEDSATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da277	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	193	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	433
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKD		AWFQQKQGKSPQLLIYNAKSLEDGVPSRFSASG
	KATLTADKSSSIVYMQLSSLTSEDSAVYYCTRG		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da278	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	194	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	434
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKG		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSIVYMHLSSLTSEDSAVYYCARG		SGTQFSMKIKSMQPEDTATYFCKQAYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da279	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	194	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	434
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFKG		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSIVYMHLSSLTSEDSAVYYCARG		SGTQFSMKIKSMQPEDTATYFCKQAYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da280	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	196	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	429
	MHWVKQRPGQGLEWIGYISPRTGNTEYNQKFRD		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSASG
	KATLTADKSSSIVYMQLSSLTSEDSAVYYCTRG		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da281	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	197	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	434
	MHWVKQRPGQGLEWIGYISPRTGNTNYNQRFKD		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSIVYMQLSSLTSEDSAVYYCARG		SGTQFSMKIKSMQPEDTATYFCKQAYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da282	QVQLQQSGAELAKPGASVKMSCKASGYTFTNYW	198	DIQMTQSPASLAASVGETVTITCRASENIYYTL	435
	MHWVKQRPGQGLEWIGYISPRTTYTEYNQKFKD		AWFQQKQGNSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSTAFLQLSSLTSEDSAVYYCTRG		SGTQYSMKINSMQPEDTATYFCKQAYDVPYTFG
	EAYWGQGTLVTVSA		GGTKLEIK
SCT-Da283	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	DIQMTQPTSSLSASLGDRVTISCRASQDISNYL	252
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		NWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGTDYSLTISNLDQEDIATYFCQQGNTLPWTFG
	YGTSQAWFAYWGQGTLVTVSA		GGTKLEIK
SCT-Da284	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	DIVLTQSPASLAVSLGQRATISCRASESVDNFG	301
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		NSFMHWYQQKPGQPPKLLIYLASNLESGVPARF
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	YGTSQAWFAYWGQGTLVTVSA		RTFGGGTKLEIK
SCT-Da285	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	264
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	YGTSQAWFAYWGQGTLVTVSA		RTFGGGTKLEIK
SCT-Da286	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	DIVMTQFQKFMSTSVGDRVSVTCKASQNVDTNV	293
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		AWYQQKPGQSPKLLIYSGSYRFSGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGTDFTLTISNVQSEDLAEYFCQQYNTYPYTFG
	YGTSQAWFAYWGQGTLVTVSA		GGTKLEIK
SCT-Da287	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	DIVMTQSPATLSVTPGDRVSLSCRASQRISDYL	337
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGSDFTLSINSVEPEDVGMYYCQNGHSFPFTFG
	YGTSQAWFAYWGQGTLVTVSA		SGTKLEIK
SCT-Da288	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNV	294
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	YGTSQAWFAYWGQGTLVTVSA		GGTKLEIK
SCT-Da289	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	YGTSQAWFAYWGQGTLVTVSA		GGTKLEIK
SCT-Da290	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	EIVLTQSPTTMAASPGEKITIICNASSSISSNY	358
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		FNWYQQKPEFSPKLLIYRTSNLASGVPARFSGS
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		GSGTSYSLTIGTMEAEDVATYYCQQGSSLPRTF
	YGTSQAWFAYWGQGTLVTVSA		GSGTKLEIK
SCT-Da291	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	EIVLTQSPTTMAASPGEKITITCSASSSISSNY	312
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		LNWYQQKPEFSPKLLIYRTSNLASGVPARFSGS
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		GSGTSYSLTIGTMEAEDVATYYCQQGSSIPRTF
	YGTSQAWFAYWGQGTLVTVSA		GSGTKLEIK
SCT-Da292	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMH	371
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		WYQQKSGTSPKRWIYDTSKLASGVPARFSGSGS
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	YGTSQAWFAYWGQGTLVTVSA		GTKLELK
SCT-Da293	QVQLQQSGAELAKPGASVKMSCKASGYTFTTYW	199	QIVLTQSPALMAASPGEKVTITCSVSSSISYMY	366
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		WYQQKSETSPKPWIYGTSNLASGVPVRFSGSGS
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		GTSYSLTISSMEAEDAATYYCQQWSSYPLTFGA
	YGTSQAWFAYWGQGTLVTVSA		GTKLELK
SCT-Da294	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	430
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSGSG
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	EADDLWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da295	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DIVLTQSPASLAVSLGQRATISCKASQSVDYDG	328
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		DNYMNWYQQKPGQPPKLLIYAASNLESGIPARF
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGSGSGTDFTLNIHPVEEEDAATYYCQQSYEDP
	EADDLWYFDVWGAGTTVTVSS		WTFGGGTKLEIK
SCT-Da296	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DIVLTQSPASLAVSLGQRATISCRASESVDSYG	264
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		NSFMHWYQQKPGQPPKLLIYIASNLESGVPARF
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGSGSRTDFTLTIDPVEADDAATYYCQQSNEDP
	EADDLWYFDVWGAGTTVTVSS		RTFGGGTKLEIK
SCT-Da297	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAV	411
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		AWYQQKPGQSPKLLIYSASYRYTGVPDHFTVSG
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFG
	EADDLWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da298	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DIVMTQSHKFMSTSVGDRVSITCKASQDVTTAV	413
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTVSG
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGTDFTLTISSVQAEDLAVYYCQQHYSAPWTFG
	EADDLWYFDVWGAGTTVTVSS		GGTKLKIT
SCT-Da299	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	304
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	EADDLWYFDVWGAGTTVTVSS		GGAKLEIK
SCT-Da300	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	318
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	EADDLWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da301	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	DNVMTQSQKFMSTSVGDRVSVTCKASQNVGTNV	324
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		AWYQQKSGQSPKLLIYSASYRFSGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		SGTDFTLTISNVQSEDLAEYFCQQYNSYPYTFG
	EADDLWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da302	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	EADDLWYFDVWGAGTTVTVSS		GTKLELK
SCT-Da303	QVQLQQSGAELARPGASVKLSCKASGYTFTSYW	200	SIVMTQTPKFLLVSAGDRVTITCRASQSVTNDV	265
	MQWIKQRPGQGLEWIGAIYPGDGDTRYTQKFKG		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLASEDSAVYYCARV		YGTDFTFTISTVQAEDLAVYFCQQDYNSPYTFG
	EADDLWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da304	QVQLQQSGAELSKPGASVKMSCKASGYTFTTYW	201	DIQMTQSPASLAASVGETVTITCRTSENIYYSL	429
	MHWVKQRPGQGLEWIGYINPSTGYTYYNQKFKD		AWFQQKQGKSPQLLIYNANSLEDGVPSRFSASG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCASY		SGTQFSMKIKSMQPEDTATYFCKQSYDVPYTFG
	YGTSQAWFAYWGQGTLVTVSA		GGTKLEIK
SCT-Da305	QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYL	202	DIQMTQSPSSLSASLGERVSLTCRASQEISGYL	436
	IEWVKQRPGQGLEWIGVINPGSGGPNYNEKFKG		TWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSR
	KATLTADKSSSTAYMQLSSLTSDDSAVYFCASD		SESDYSLTISSLESEDFADYYCLQSASYPPTFG
	NYGNYDVLDYWGQGTSVTVSS		GGTKLEIK
SCT-Da306	QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYL	203	DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSN	437
	IEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKG		GNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDR
	KATLTADKSSSTAYMQLSSLTSDDSAVYFCDRE		FSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEY
	DAYWGQGTLVTVSA		PYTFGGGTKLEIK
SCT-Da307	QVQLQQSGPDLVRPGVSVKISCKGSGYTFTDYA	204	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	438
	LHWVKQSHAKSLEWIGVINTYSSNTYYNQNFEG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSNTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da308	QVQLQQSGPDLVRPGVSVKISCKGSGYTFTDYA	204	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	439
	LHWVKQSHAKSLEWIGVINTYSSNTYYNQNFEG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSNTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTRLEIK
SCT-Da309	QVQLQQSGPDLVRPGVSVKISCKGSGYTFTDYA	205	DIVMTQSPATLSVTLGDRVSLSCRASQSISDYL	440
	LHWVKQSHAKSLEWIGVINTYSSNTYYNQNFEG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da310	QVQLQQSGPDLVRPGVSVKISCKGSGYTFTDYA	205	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	438
	LHWVKQSHAKSLEWIGVINTYSSNTYYNQNFEG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da311	QVQLQQSGPELVKPGASVKMSCKASGYTFTDYV	206	DVVMTQTPLSLPVSLGDQASISCRSRQSLVHSN	441
	MSWVKQRTGQGLEWIGEIYPGGNRTYYSEKFKG		GITYLHWYLQKPGQSPKLLIDKVFNRFSGVPDR
	KATLTADKSSNTAYMQVSSLTAEDSAVYFCARF		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV
	NDWAMDHWGQGTSVTVSS		PWTFGGGTKLEIK
SCT-Da312	QVQLQQSGPELVKPGASVKMSCKASGYTFTDYV	207	DVVMTQTPLSLPVSLGDQASISCRSRQSLVHSN	442
	MSWVKQRTGQGLEWIGEIYPGGNSTYYNEKFKG		GITYLHWYLQKPGQSPKLLIYKVSNRFSGVPDR
	KATLTADKSSNTAYMQLSSLTSEDSAVYFCARF		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV
	NDWSMDYWGQGTSVTVSS		PWTFGGGTKLEIK
SCT-Da313	QVQLQQSGPELVKPGASVKMSCKASGYTFTDYV	208	DVVMTQTPLSLPVSLGDQASISCRSRQSLVHSN	443
	MSWVTQRTGQGLEWIGEIYPGGSSIHYNEKFKD		GITYLHWYLQKPGQSPKLLIYKVSNRFSGVPDR
	KATLTADKSSNTAYMQLSSLTSEDSAVYFCARF		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHF
	NDWAMDYWGQGTSVTVSS		PWTFGGGTKLEIK
SCT-Da314	QVQLQQSGPELVKPGASVKMSCKASGYTFTDYV	209	DVVMTQTPLSLPVSLGDQASISCRSRQSLVHSN	443
	MSWVTQRTGQGLEWIGEIYPGGSSIYYNEKFKD		GITYLHWYLQKPGQSPKLLIYKVSNRFSGVPDR
	KATLTADKSSNTAYMQLSSLTSEDSAVYFCARF		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHF
	NDWAMDYWGQGTSVTVSS		PWTFGGGTKLEIK
SCT-Da315	QVQLQQSGPELVKPGASVRISCKASGYTFTSYF	210	DIVLTQSPATLSVTPGDRVSLSCRASQSINNYL	444
	IHWVKQRPGQGLEWIGWIYPGNVNTNYNERFKG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCARD		SGTDFTLSINSVETEDFGMYFCQQSSTWPLTFG
	YAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da316	QVQLQQSGPELVKPGASVRISCKASGYTFTTYF	211	DIVLIQSPATLSVTPGDRVSLSCRASQGINNYL	445
	IHWVKQRPGQGLEWIGWIYPGNVNVNYNEKFKG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KATLTADKSSSTAYMHLSSLTSEDSAVYFCSRD		SGTDFTLSINSVETEDFGMYFCQQSNSWPLTFG
	YAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da317	QVQLQQSGPELVKPGASVRISCKASGYTFTTYY	212	DIVLTQSPATLSVTPGDRVSLSCRASQSINNYL	446
	IHWVKQRPGQGLEWIGWIYPGNVNTNYNEKFKG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCTRD		SGTDFTLSINSVESEDFGKYFCQQSNSWPLTFG
	YAMDYWGQGTSVTVSS		AGTQLELK
SCT-Da318	QVQLQQSGPELVKPGASVRISCKASGYTFTTYY	213	DIVLIQSPATLSVTPGDRVSLSCRASQSINNYL	447
	IHWVKQRPGQGLEWIGWIYPGNVNVNYNEKFKG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCTRD		SGTDFTLSINSVETEDFGMYFCQQSNSWPLTFG
	YAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da319	QVQLQQSGPELVKPGASVRISCKASGYTFTTYY	214	DIVLTQSPATLSVTPGDRVSLSCRASQSINNYL	410
	IHWVKQRPGQGLEWIGWIYPGNVNVNYNERFKG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCTRD		SGTDFTLSINSVETEDFGVYFCQQSNSWPLTFG
	YAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da320	QVQLQQSGPELVKPGASVRISCTASGYTFTTYY	215	DIVLTQSPATLSVTPGDRVSLSCRASQSINNYL	448
	IHWVKQRPGQGLEWIGWIYPGNVNTNYNEKFKG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCARD		SGTDFTLSINSVETEDFGMYFCQQSNSWPLTFG
	YAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da321	QVQLQQSGPELVKPGASVRISCTASGYTFTTYY	215	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	IHWVKQRPGQGLEWIGWIYPGNVNTNYNEKFKG		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	KATLTADKSSSTAYMQLSSLTSEDSAVYFCARD		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	YAMDYWGQGTSVTVSS		GTKLELK
SCT-Da322	QVQLQQSGPELVKPWASVRISCKASGYTFTTYY	216	DIVLTQSPATLSVTPGDRVSLSCRASQRINSYL	449
	IHWVKQRPGQGLEWIGWIYPGNVNVNYNERFKG		HWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
	KATLTADKPSSTAYMQLSSLTSEDSAVYFCSRD		SGTDFTLSINSVETEDFGMYFCQQSNSWPLTFG
	YAMDYWGQGTSVTVSS		AGTKLELK
SCT-Da323	QVQLQQSGPELVRPGVSVKISCKGFGYTFTDYA	217	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	450
	MHWVKQSHAKSLEWIGVINTYSGNTYYNQKFKD		HWYQQKSHESPRLLIKSASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTPLTVSS		SGTKLEIE
SCT-Da324	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	218	DVVMAPTPLTLSVTIGQPASISCKSSQSLLDSD	451
	IHWVKQSHAKSLEWIGVINTHSDNTNYFQRFKG		GETYLNWLLQRPGQSPKRLIYLVSKLDSGVPDR
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARP		FTGSGSGTDFTLKISRVEAEDLGVYYCWEGTHF
	NYDGHWYFDVWGAGTTVTVSS		WPFGGGTKLEIK
SCT-Da325	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	219	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	452
	IHWVKQSHAKSLEWIGVINTYSGNTNYNQNFKV		YWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSNTAYMELARLTSEDSAIYYCARR		SGSDFTLSISSVEPEDVGVYYCQNGHSFPFTFG
	RGIHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da326	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	220	ENVLTQSPVIMSASPGEKVTMTCRASSSVSSSY	453
	MHWVKQSHAKSLEWIGIINSYSGNTNYNQKFKG		LHWYQQKSGASPKLWIYSTSNLASGVPARFSGS
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARW		GSGTSYSLTISSVEAEDAATYYCQQYSGYPLTF
	AITTGVYYAMDYWGQGTSVTVSS		GSGTKLEIK
SCT-Da327	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	221	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	331
	MHWVKQSHAKSLEWIGVINTYSANTNYNQKFKG		HWYQQKSHESPRLLIKYVSQSISGIPSRFSGSG
	KATMTVDKSSSTAYLELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da328	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	222	DIVLTQSPASLAVSLGQRATISCRASESVDNYG	454
	MHWVKQSHAKSLEWIGVINTYSGNTNYNQNFKV		ISFMNWFQQKPGQPPKLLIYAASNQGSGVPARF
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVP
	RGSHRDAYFDYWGQGTTLTVSS		TFGGGTKLEIK
SCT-Da329	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	222	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	455
	MHWVKQSHAKSLEWIGVINTYSGNTNYNQNFKV		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLSISSVEPEDVGVYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da330	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	222	QIVLTQSPALMAASPGEKVTITCSVSSSISYMY	366
	MHWVKQSHAKSLEWIGVTNTYSGNTNYNQNFKV		WYQQKSETSPKPWIYGTSNLASGVPVRFSGSGS
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		GTSYSLTISSMEAEDAATYYCQQWSSYPLTFGA
	RGSHRDAYFDYWGQGTTLTVSS		GTKLELK
SCT-Da331	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	223	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	438
	MHWVKQSHVKSLEWIGVINTYSGNTNYNQKFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFG
	RGSHQDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da332	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	224	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	456
	VHWMKQSHAKSLEWIGVINTYSGNTYYNLHFKD		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELATLTSEDSAIYYCARR		SGSDFTLSIMMVEPEDVGVYYCQNSHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da333	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	225	DIVMTQSHKFMSTSVGDRVSITCRASQDVSTAV	400
	VHWVKQSHAKSLEWIGVINTYSGNTYYNLHFKG		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTVSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGTDFTFTISSVQAEDLAVYYCQQHYSTPWTFG
	RGSHRDAYFDYWGQGTTLTVSS		GGTKLEIK
SCT-Da334	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	225	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	457
	VHWVKQSHAKSLEWIGVINTYSGNTYYMLHFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVDPEDVGMYYCQNSHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da335	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	225	DIVMTQSPATLSVTPGDSVSLSCRASQTISDYL	458
	VHWVKQSHAKSLEWIGVINTYSGNTYYNLHFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLSINSVEPEDVGVYYCQNSHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da336	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	226	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	456
	VHWVKQSHAKSLEWIGVINTYSGNTYYNLHFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELATLTSEDSAIYYCARR		SGSDFTLSINNVEPEDVGVYYCQNSHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da337	QVQLQQSGPELVRPGVSVKISCKGSGYTFTDYA	227	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	459
	VHWVKQSHAKSLEWIGVINTYSGNTYYNLNFTG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELARLTSEDSAIYYCARR		SGSDFTLTINSVEPEDIGLYYCQNGHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da338	QVQLQQSGPELVSPGVSVKISCKGSGYTFTDYA	228	DIVMTQSPATLSVTPGDRVSLSCRASQSISDYL	457
	VHWVKQSHAKSLEWIGVINTYSGNTYFNLHFKG		HWYQQKSHESPRLLIKYASQSISGIPSRFSGSG
	KATMTVDKSSSTAYMELASLTSEDSAIYYCARR		SGSDFTLSINSVDPEDVGMYYCQNSHSFPFTFG
	RGSHRDAYFDYWGQGTTLTVSS		SGTKLEIK
SCT-Da339	QVQLQQSGPEVVKPGASVKMSCKASGYTFTDYV	229	DVVMTQTPLSLPVSLGDQASISCRSRQSLVHSN	460
	MTWVKQRTGQGLEWIGEIYPGGNRTYYKEKFKG		GITYLHWYLQKPGQSPKLLIFKVSNRFSGVPDR
	KATLTADKSSNTAYMQLSSLTSEDSAVYFGARF		FSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHV
	NDWAMDYWGQGTSVTVSS		PWTFGGGTKLEIK
SCT-Da340	QVQLQQSGTELVRPGASVTLSCKTSGYTFTDYE	230	SIVVTQTPKFLLVSAGDRVTITCKASQSVSNDV	461
	MHWVKQTPVHGLEWIGGIDPETGATAYNQKFKG		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	KATLTADKSSSTAYMELRSLTSEDSAVYYCTAR		YGTDFTFTISTVQAEDLAVYFCQQDYTSPPTFG
	QLGLPFAYWGQGTLVTVSA		GGTKLEIK
SCT-Da341	QVTLKESGPGILQPSQTLSLTCSFSGFSLNTSN	231	SIVMTQTPKFLLVSAGDRVTITCKANQFVSNFV	462
	LGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDSSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTITAVQAEDLAVYFCQQDYSSPYTFG
	KNHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da342	QVTLKESGPGILQPSQTLSLTCSFSGFSLNTSN	232	SIVMTQTPKFLLVSAGDRVTITCKASQFVSNFV	463
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDSSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTITTVQAEDLAVYFCQQDYSSPYTFG
	KNHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da343	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTPG	233	SIVMTQTPKFLLVSAGDRVTITCKASQSVNNDV	464
	LGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTISTVQAEDLAVYFCQQDYNSPYAFG
	KNHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da344	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTPN	234	SIVMTQTPKFLLVSAGDRVTITCKASQSVINDV	465
	MGVGWIRQPSGKGLEWLAHIWWDDDKRQNAALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKETSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTISSVQAEDLAVYFCQQDYSSPYTFG
	KIHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da345	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTPS	235	SIVMTQTPKFLLVSAGDRVTITCKASQSVINDV	466
	MGVGWIRQPSGKGLEWLAHIWWDDDKRSDPALK		AWFQQKPGQSPNLLIYYASNRYTGVPARFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTGTYYCAR		YGTDFTFTISTVQAEDLAVYFCQQDYSSPYTFG
	KNHYSGHWFFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da346	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSG	236	SIVMTQTPKFLLVSAGDRVTITCKASQSVSNYV	467
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDSSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTITTVQAEDLAVYFCQQDYSSPYTFG
	KNHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da347	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	237	SIVMTQTPKFLLVSAGDRVTITCKASQSVINDV	468
	LGVGWIRQPSGKGLEWLAHIWWDDDKRYNPDLE		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTISTVQAEDLAVYFCQQDYSSPYTFG
	KSHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da348	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	238	SVVMTQTPKFLLVSAGDRITITCKASQSVINDV	469
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYHPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTISTVQAEDLAVYFCQQDYNSPFTFG
	KSHYYGHWYFDFWGAGTTVTVSS		GGTKLEIK
SCT-Da349	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	239	DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTDV	304
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYSASYRFSGVPDRFTGSG
	SRLTISKDSSNNQVFLKIASVDTSDTAIYYCGR		SGTDFSLAISNVQSEDLAEYFCQQYNSYPYTFG
	KSHYYGHWYFDVWGAGTTVTVSS		GGAKLEIK
SCT-Da350	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	239	SIVMTQTPKFLLVSAGDRFTITCKASQNVDNYV	354
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDSSNNQVFLKIASVDTSDTAIYYCGR		YGTDFTFTITTVQAEDLAVYFCQQDYSSPYTFG
	KSHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da351	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	239	SIVMTQTPKFLLVSTGDRFTITCKASQNVDNYV	470
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDSSNNQVFLKIASVDTSDTAIYYCGR		YGTDFTFTITTVQAEDLAVYFCQQDYSSPYTFG
	KSHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da352	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	240	SLVMTQTPKFLLVSPGDRITITCKASQSVINDV	471
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLIYYASNRNTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADSATYYCAR		YGTDFTLTISTVQAEDLAVYFCQQDYNSPYTFG
	KNHYYGHWYFDFWGAGTTVTVSS		GGTKLEIK
SCT-Da353	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	241	SIVMTQTPKFLLVSAGDRITITCKASQSVINDV	472
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPALK		AWYQQKPGQSPKLLMYYASNRNTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		YGTDFTLTISTVQAEDLAVYFCQQDYNSPYTFG
	KNHYYGHWYFDFWGAGTTVTVSS		GGTKLEIK
SCT-Da354	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	242	DIQMTQSPASLSVSVGETVTITCRASENIYSNL	473
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPDLK		AWYQQKQGKSPQLLVYAATNLADGVPSRFSGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		SGTQYSLKINSLQSEDFGSYYCQHFWGTPFTFG
	KNHYYGHWYFDVWGAGTTVTVSS		SGTKLEIK
SCT-Da355	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	242	DIQMTQSPSSLSASLGGKVTITCKASQDINKYI	474
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPDLK		SWYQHKPGKGPRLLIHYTSTLQPGIPSRFSGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		SGRDYSFSISNLEPEDIATYYCLQYDNLWTFGG
	KNHYYGHWYFDVWGAGTTVTVSS		GTKLEIK
SCT-Da356	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	242	SIVMTQTPKFLLVSAGDRVTITCKASQSVINDV	475
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPDLK		AWFQQQPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTISTVQAEDLAVYFCQQDYSSPYTFG
	KNHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da357	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	242	SIVMTQTPKFLLVSAGDRVTITCRASQSVTNDV	265
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPDLK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTISTVQAEDLAVYFCQQDYNSPYTFG
	KNHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da358	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	243	SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDV	476
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPDLK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCAR		YGTDFTFTISTVQAEDLAVYFCQQDYNSPYTFG
	KSHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da359	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	244	SIVMTQTPKFLLVSAGDRVTITCKASQSVINDV	468
	MGVGWIRQPSGKGLEWLAHIWWDDDKRYNPDLK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYYCGR		YGTDFTFTISTVQAEDLAVYFCQQDYSSPYTFG
	KSHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da360	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSN	245	NIVMTQTPRFLLVSAGDRVTITCKASQTVTNDV	477
	MGVGWIRQPSGKGLEWLAHIWWDDDTRYKPALK		AWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSG
	SRLTISKDTSSNQVFLKIASVDTADTATYFCAR		YGTDFTFTISTVQAEDLAVYFCQQDYISPYTFG
	KNHYYGHWYFDVWGAGTTVTVSS		GGTKLEIK
SCT-Da361	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYG	246	DIQMTQTTSSLSASLGDRVTINCSASQGIINYL	478
	IGVGWIRQPSGKGLEWLAHIWWNDNKYYNTALK		NWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSG
	SRLTISKDTSNNQVFLKIASVDTADTATYYCAR		SGTDYSLTISNLEPEDIASYYCQQYSKLPYTFG
	IDYWFAYWGQGTLVTVSA		GGTKVEIK
SCT-Da362	QVTLKESGPGILQPSQTLSLTCSFSGFSLSTYG	246	QIVLTQSPALMSASPGEKVTMTCSASSSVSYMY	333
	IGVGWIRQPSGKGLEWLAHIWWNDNKYYNTALK		WYQQKPRSSPKPWIYLTSNLASGVPARFSGSGS
	SRLTISKDTSNNQVFLKIASVDTADTATYYCAR		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	IDYWFAYWGQGTLVTVSA		GTKLELK
SCT-Da363	EVQLVESGGDLVQPGGSLRLSCKTSGFTFSSFY	973	DIQMTQSPSSLSASVGDRVTITCRASQDVSTAV	974
	ISWVRQAPGKGLEWIAWIYAGPGYTSYADSVKG		AWYQQKPGKAPKLLIYSASYRYSGVPSRFSGSG
	RFTISRDNSRNTLYLQMNSLRAEDTAVYYCARH		SGTDFTLTISSLQPEDFATYYCQQHYSTPWTFG
	VGRQRGYFDVWGQGTLVTVSS		QGTKVEIK
SCT-Da364	EVQLVESGGDLVQPGGSLRLSCKTSGFTFSSFY	973	DIVMTQSQRFMSTTVGDRVSITCKASQDVSTAV	975
	ISWVRQAPGKGLEWIAWIYAGPGYTSYADSVKG		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSG
	RFTISRDNSRNTLYLQMNSLRAEDTAVYYCARH		SGTDFTLTISNMQSEDLADFFCQQHYSTPWTFG
	VGRQRGYFDVWGQGTLVTVSS		GGTKLEIK
SCT-Da365	EVQLQQSGPELEKPGASVKLSCKASGYTFTEYT	976	DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIH	977
	MHWVKQSHGKSLEWIGVINPNNGGTTYNQKFRG		WFQQKPGKAPKPWIYLTSNLASGVPVRFSGSGS
	KATLTVDKSSSTAYMQLKSLTSEDSAVYYCARP		GTDYTFTISSLQPEDIATYYCQQWSSNPLTFGG
	HSLLRLRREFDYWGAGTTVTVSS		GTKLEIK
SCT-Da366	EVQLQQSGPELEKPGASVKLSCKASGYTFTEYT	976	QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMY	978
	MHWVKQSHGKSLEWIGVINPNNGGTTYNQKFRG		WYQQKPGSSPRLLIYLTSNLASGVPVRFSGSGS
	KATLTVDKSSSTAYMQLKSLTSEDSAVYYCARP		GTSYSLTISRMEAEDAATYYCQQWSSNPLTFGG
	HSLLRLRREFDYWGAGTTVTVSS		GTKLEIK
SCT-Da367	EVQLQQSGPELEKPGASVKLSCKASGYTFTEYT	976	QIVSTQSPAIMSASPGEKVTMTCSASSSVSYMQ	979
	MHWVKQSHGKSLEWIGVINPNNGGTTYNQKFRG		WYQQKPGTSPKRWIYLTSKLASGVPARFSGSGS
	KATLTVDKSSSTAYMQLKSLTSEDSAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGG
	HSLLRLRREFDYWGAGTTVTVSS		GTKLEIK
SCT-Da368	EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYT	980	DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIH	977
	MHWVKQAPGQGLEWIGVINPNNGGTTYNQKFQG		WFQQKPGKAPKPWIYLTSNLASGVPVRFSGSGS
	RVTMTRDTSISTAYMELGSLRSDDTAVYYCARP		GTDYTFTISSLQPEDIATYYCQQWSSNPLTFGG
	HSLLRLRREFDYWGQGTMVTVSS		GTKLEIK
SCT-Da369	EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYT	980	QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMY	978
	MHWVKQAPGQGLEWIGVINPNNGGTTYNQKFQG		WYQQKPGSSPRLLIYLTSNLASGVPVRFSGSGS
	RVTMTRDTSISTAYMELGSLRSDDTAVYYCARP		GTSYSLTISRMEAEDAATYYCQQWSSNPLTFGG
	HSLLRLRREFDYWGQGTMVTVSS		GTKLEIK
SCT-Da370	EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYT	980	QIVSTQSPAIMSASPGEKVTMTCSASSSVSYMQ	979
	MHWVKQAPGQGLEWIGVINPNNGGTTYNQKFQG		WYQQKPGTSPKRWIYLTSKLASGVPARFSGSGS
	RVTMTRDTSISTAYMELGSLRSDDTAVYYCARP		GTSYSLTISSMEAEDAATYYCQQWSSNPLTFGG
	HSLLRLRREFDYWGQGTMVTVSS		GTKLEIK
SCT-Da371	QVQLQQPGAELVKPGASVKMSCKASGVNIKDTY	981	DIQMTQSPSSLSASVGDRVTITCKASQNVGTDV	982
	IHWVKQTPGRGLEWIGRIDPANGNRKYNQKFKG		AWYQQKPGKAPKALIYSASYRFSGVPYRFSGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYYCARD		SGTDFTLTISSLQPEDFATYFCQQYNSYPYTFG
	GYYAPGYWGAGTTVTVSA		QGTKVEIK
SCT-Da372	QVQLQQPGAELVKPGASVKMSCKASGVNIKDTY	981	DIVMTQSQRFMSTTVGDRVSITCKASQNVGTDV	983
	IHWVKQTPGRGLEWIGRIDPANGNRKYNQKFKG		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSG
	KATLTADKSSSTAYMQLSSLTSEDSAVYYCARD		SGTDFTLTISNMQSEDLADFFCQQYNSYPYTFG
	GYYAPGYWGAGTTVTVSA		GGTKLEIK
SCT-Da373	EVQLVQSGAEVKKPGASVKVSCKASGVNIKDTY	984	DIQMTQSPSSLSASVGDRVTITCKASQNVGTDV	982
	IHWVRQAPGQRLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGKAPKALIYSASYRFSGVPYRFSGSG
	RVTITADTSASTAYMELSSLRSEDTAVYYCARD		SGTDFTLTISSLQPEDFATYFCQQYNSYPYTFG
	GYYAPGYWGQGTLVTVSS		QGTKVEIK
SCT-Da374	EVQLVQSGAEVKKPGASVKVSCKASGVNIKDTY	984	DIVMTQSQRFMSTTVGDRVSITCKASQNVGTDV	983
	IHWVRQAPGQRLEWIGRIDPANGNRKYDPKFQG		AWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSG
	RVTITADTSASTAYMELSSLRSEDTAVYYCARD		SGTDFTLTISNMQSEDLADFFCQQYNSYPYTFG
	GYYAPGYWGQGTLVTVSS		GGTKLEIK

The preceding merely illustrates the principles of the disclosure. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the disclosure and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the disclosure and the concepts contributed by the inventors to furthering the art and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the disclosure as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present disclosure, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present disclosure is embodied by the appended claims.

REFERENCES CITED

Other References

• Castriconi, R., Dondero, A., Augugliaro, R., Cantoni, C., Carnemolla, B., Sementa, A. R., Negri, F., Conte, R., Corrias, M. V., Moretta, L., et al. (2004). Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc. Natl. Acad. Sci. U.S.A 101, 12640-12645.
• Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001). B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2, 269-274.
• Hashiguchi, M., Kobori, H., Ritprajak, P., Kamimura, Y., Kozono, H., and Azuma, M. (2008). Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. U.S.A 105, 10495-10500.
• Hofmeyer, K. A., Ray, A., and Zang, X. (2008). The contrasting role of B7-H3. Proc. Natl. Acad. Sci. U.S.A 105, 10277-10278.
• Loos, M., Hedderich, D. M., Ottenhausen, M., Giese, N. A., Laschinger, M., Esposito, I., Kleeff, J., and Friess, H. (2009). Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 9, 463.
• Nygren, M. K., Tekle, C., Ingebrigtsen, V. A., and Fodstad, O. (2011). B7-H3 and its relevance in cancer; immunological and non-immunological perspectives. Front. Biosci. Elite Ed. 3, 989-993.
• Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., and Dong, C. (2004). Murine B7-H3 is a negative regulator of T cells. J. Immunol. Baltim. Md. 1950 173, 2500-2506.
• Roth, T. J., Sheinin, Y., Lohse, C. M., Kuntz, S. M., Frigola, X., Inman, B. A., Krambeck, A. E., McKenney, M. E., Karnes, R. J., Blute, M. L., et al. (2007). B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900.
• Saatian, B., Yu, X.-Y., Yu, X., Lane, A. P., Doyle, T., Casolaro, V., and Spannhake, E. W. (2004). Expression of genes for B7-H3 and other T cell ligands by nasal epithelial cells during differentiation and activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L217-225.
• Steinberger, P., Majdic, O., Derdak, S. V., Pfistershammer, K., Kirchberger, S., Klauser, C., Zlabinger, G., Pickl, W. F., Stockl, J., and Knapp, W. (2004). Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol. Baltim. Md. 1950 172, 2352-2359.
• Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003). The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4, 899-906.
• Sun, M., Richards, S., Prasad, D. V. R., Mai, X. M., Rudensky, A., and Dong, C. (2002). Characterization of mouse and human B7-H3 genes. J. Immunol. Baltim. Md. 1950 168, 6294-6297.
• Sun, Y., Wang, Y., Zhao, J., Gu, M., Giscombe, R., Lefvert, A. K., and Wang, X. (2006). B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer Amst. Neth. 53, 143-151.
• Wang, L., Fraser, C. C., Kikly, K., Wells, A. D., Han, R., Coyle, A. J., Chen, L., and Hancock, W. W. (2005). B7-H3 promotes acute and chronic allograft rejection. Eur. J. Immunol. 35, 428-438.
• Wu, C.-P., Jiang, J.-T., Tan, M., Zhu, Y.-B., Ji, M., Xu, K.-F., Zhao, J.-M., Zhang, G.-B., and Zhang, X.-G. (2006). Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. 12, 457-459.
• Yamato, I., Sho, M., Nomi, T., Akahori, T., Shimada, K., Hotta, K., Kanehiro, H., Konishi, N., Yagita, H., and Nakajima, Y. (2009). Clinical importance of B7-H3 expression in human pancreatic cancer. Br. J. Cancer 101, 1709-1716.

Claims

1. An antibody that binds human B7-H3 (SEQ ID NO:1) comprising: a) a HCDR1 having the amino acid sequence of SEQ ID NO:574, a HCDR2 having the amino acid sequence of SEQ ID NO:560, a HCDR3 having the amino acid sequence of SEQ ID NO:546, a LCDR1 having the amino acid sequence of SEQ ID NO:904, a LCDR2 having the amino acid sequence of SEQ ID NO:882, and a LCDR3 having the amino acid sequence of SEQ ID NO:902; orb) a HCDR1 having the amino acid sequence of SEQ ID NO:585, a HCDR2 having the amino acid sequence of SEQ ID NO:586, a HCDR3 having the amino acid sequence of SEQ ID NO:587, a LCDR1 having the amino acid sequence of SEQ ID NO:833, a LCDR2 having the amino acid sequence of SEQ ID NO:834, and a LCDR3 having the amino acid sequence of SEQ ID NO:835; orc) a HCDR1 having the amino acid sequence of SEQ ID NO:582, a HCDR2 having the amino acid sequence of SEQ ID NO:552, a HCDR3 having the amino acid sequence of SEQ ID NO:589, a LCDR1 having the amino acid sequence of SEQ ID NO:944, a LCDR2 having the amino acid sequence of SEQ ID NO:957, and a LCDR3 having the amino acid sequence of SEQ ID NO:947; ord) a HCDR1 having the amino acid sequence of SEQ ID NO:634, a HCDR2 having the amino acid sequence of SEQ ID NO:652, a HCDR3 having the amino acid sequence of SEQ ID NO:653, a LCDR1 having the amino acid sequence of SEQ ID NO:884, a LCDR2 having the amino acid sequence of SEQ ID NO:882, and a LCDR3 having the amino acid sequence of SEQ ID NO:885; ore) a HCDR1 having the amino acid sequence of SEQ ID NO:634, a HCDR2 having the amino acid sequence of SEQ ID NO:652, a HCDR3 having the amino acid sequence of SEQ ID NO:653, a LCDR1 having the amino acid sequence of SEQ ID NO:884, a LCDR2 having the amino acid sequence of SEQ ID NO:882, and a LCDR3 having the amino acid sequence of SEQ ID NO:885; orf) a HCDR1 having the amino acid sequence of SEQ ID NO:582, a HCDR2 having the amino acid sequence of SEQ ID NO:552, a HCDR3 having the amino acid sequence of SEQ ID NO:589, a LCDR1 having the amino acid sequence of SEQ ID NO:944, a LCDR2 having the amino acid sequence of SEQ ID NO:957, and a LCDR3 having the amino acid sequence of SEQ ID NO:947.

2. The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:574, the HCDR2 has the amino acid sequence of SEQ ID NO:560, the HCDR3 has the amino acid sequence of SEQ ID NO:546, the LCDR1 has the amino acid sequence of SEQ ID NO:904, the LCDR2 has the amino acid sequence of SEQ ID NO:882, and the LCDR3 has the amino acid sequence of SEQ ID NO:902.

3. The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:585, the HCDR2 has the amino acid sequence of SEQ ID NO:586, the HCDR3 has the amino acid sequence of SEQ ID NO:587, the LCDR1 has the amino acid sequence of SEQ ID NO:833, the LCDR2 has the amino acid sequence of SEQ ID NO:834, and the LCDR3 has the amino acid sequence of SEQ ID NO:835.

4. The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:582, the HCDR2 has the amino acid sequence of SEQ ID NO:552, the HCDR3 has the amino acid sequence of SEQ ID NO:589, the LCDR1 has the amino acid sequence of SEQ ID NO:944, the LCDR2 has the amino acid sequence of SEQ ID NO:957, and the LCDR3 has the amino acid sequence of SEQ ID NO:947.

5. The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:634, the HCDR2 has the amino acid sequence of SEQ ID NO:652, the HCDR3 has the amino acid sequence of SEQ ID NO:653, the LCDR1 has the amino acid sequence of SEQ ID NO:884, the LCDR2 has the amino acid sequence of SEQ ID NO:882, and the LCDR3 has the amino acid sequence of SEQ ID NO:885.

6. The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:634, the HCDR2 has the amino acid sequence of SEQ ID NO:652, the HCDR3 has the amino acid sequence of SEQ ID NO:653, the LCDR1 has the amino acid sequence of SEQ ID NO:884, the LCDR2 has the amino acid sequence of SEQ ID NO:882, and the LCDR3 has the amino acid sequence of SEQ ID NO:885.

7. The antibody of claim 1, wherein the HCDR1 has the amino acid sequence of SEQ ID NO:582, the HCDR2 has the amino acid sequence of SEQ ID NO:552, the HCDR3 has the amino acid sequence of SEQ ID NO:589, the LCDR1 has the amino acid sequence of SEQ ID NO:944, the LCDR2 has the amino acid sequence of SEQ ID NO:957, and the LCDR3 has the amino acid sequence of SEQ ID NO:947.

8. An antibody that binds human B7-H3 (SEQ ID NO:1) comprising: a) a VH having the amino acid sequence of SEQ ID NO:99, and a VL having the amino acid sequence of SEQ ID NO:304; orb) a VH having the amino acid sequence of SEQ ID NO:112, and a VL having the amino acid sequence of SEQ ID NO:369; orc) a VH having the amino acid sequence of SEQ ID NO:121, and a VL having the amino acid sequence of SEQ ID NO:333; ord) a VH having the amino acid sequence of SEQ ID NO:169, and a VL having the amino acid sequence of SEQ ID NO:411; ore) a VH having the amino acid sequence of SEQ ID NO:973, and a VL having the amino acid sequence of SEQ ID NO:975; orf) a VH having the amino acid sequence of SEQ ID NO:980, and a VL having the amino acid sequence of SEQ ID NO:978.

9. The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:99, and the VL has the amino acid sequence of SEQ ID NO:304.

10. The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:112, and the VL has the amino acid sequence of SEQ ID NO:369.

11. The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:121, and the VL has the amino acid sequence of SEQ ID NO:333.

12. The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:169, and the VL has the amino acid sequence of SEQ ID NO:411.

13. The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:973, and the VL has the amino acid sequence of SEQ ID NO:975.

14. The antibody of claim 8, wherein the VH has the amino acid sequence of SEQ ID NO:980, and the VL has the amino acid sequence of SEQ ID NO:978.

15. An antibody that binds human B7-H3 (SEQ ID NO:1) comprising: a) a heavy-chain comprising the amino acid sequence of SEQ ID NO:99 and a light-chain comprising the amino acid sequence of SEQ ID NO:304; orb) a heavy-chain comprising the amino acid sequence of SEQ ID NO: 112 and a light-chain comprising the amino acid sequence of SEQ ID NO:369; orc) a heavy-chain comprising the amino acid sequence of SEQ ID NO:121 and a light-chain comprising the amino acid sequence of SEQ ID NO:333; ord) a heavy-chain comprising the amino acid sequence of SEQ ID NO:169 and a light-chain comprising the amino acid sequence of SEQ ID NO:411; ore) a heavy-chain comprising the amino acid sequence of SEQ ID NO:973 and a light-chain comprising the amino acid sequence of SEQ ID NO:975; orf) a heavy-chain comprising the amino acid sequence of SEQ ID NO:980 and a light-chain comprising the amino acid sequence of SEQ ID NO:978.

16. The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:99 and the light-chain comprises the amino acid sequence of SEQ ID NO:304.

17. The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:112 and the light-chain comprises the amino acid sequence of SEQ ID NO:369.

18. The antibody of claim 15, wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:121 and the light-chain comprises the amino acid sequence of SEQ ID NO:333; or wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:169 and the light-chain comprises the amino acid sequence of SEQ ID NO:411; or wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:973 and the light-chain comprises the amino acid sequence of SEQ ID NO:975; or wherein the heavy-chain comprises the amino acid sequence of SEQ ID NO:980 and the light-chain comprises the amino acid sequence of SEQ ID NO:978.

19.-21. (canceled)

22. A pharmaceutical composition comprising the antibody of claim 1.

23. A kit comprising the antibody of claim 1.